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Overall thesis abstract (Summary) 
 
Anastomotic leak (AL) following colorectal surgery leads to significant morbidity, 
mortality and poorer oncological outcomes. Diagnosis of AL is frequently delayed 
as current methods of detection are not 100% sensitive or specific. Recent work 
has illustrated that local biomarkers from the perianastomotic environment may 
have the ability to detect AL early. A literature review undertaken as part of this 
project identified lactate and pH as the most promising biomarkers. Advances in 
biosensor technology means that the development of a degradable or removal 
biosensor for AL represents an exciting possibility. With the ultimate aim of 
developing such a sensor, this study aimed to determine the stability of lactate 
and pH in peritoneal fluid, further assess their usefulness as biomarkers of AL 
and other complications after surgery and compare their performance to that of 
commonly used blood biomarkers in detecting AL and other complications 
following colorectal surgery. Peritoneal fluid lactate was found to be stable over 
24 hours, except if the fluid had a high WCC. For pH, clinically significant 
changes were detected after 1 hour. As there were no ALs in the study it was not 
possible to determine the usefulness of lactate and pH in relation to this 
complication. Although the difference was not statistically significant, pH 
generally rose over the first 3 days post-operatively in patients making an 
uncomplicated recovery. Lactate did not appear to be useful in predicting post-
operative complications but it was thought that this was related to the method 
by which lactate was measured and that further study of lactate was merited. 
Blood biomarkers were superior to perianastomotic lactate and pH at predicting 
post-operative complications but they lacked specificity and significant 
differences were only apparent at 5 days following surgery. Overall, the work 
has contributed to our understanding of the stability of lactate and pH in 
peritoneal fluid, highlighted trends in pH in post-operative patients that merit 
further investigation and has illustrated the limitations of blood biomarkers. In 
addition, it has provided insight into how further studies in the area should be 
conducted and which questions need to be addressed next in order to pursue the 
eventual aim of developing a biosensor for the early detection of AL.
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PPV   Positive predictive value  
RAH   Royal Alexandra Hospital  
RBCs   Red blood cells  
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RCT   Randomised controlled trial   
RT-PCR  Real-time polymerase chain reaction  
SBO  Small bowel obstruction 
SBP   Spontaneous bacterial peritonitis  
SDD   Selective decontamination of the digestive tract  
SOP   Standard Operating Procedure  
SPSS   Statistical Package for the Social Sciences 
St02  Tissue oxygen saturation  
SVT  Supraventricular tachycardia 
TGF-B  Tissue growth factor B  
TIMPs   Tissue inhibitors of metalloproteinase  
TNFa   Tumour necrosis factor alpha  
TOOS   N-ethyl-N-(2-hydroxy-3-sulphopropyl) m-toluidine 
UC  Ulcerative colitis 
UK  United Kingdom 
UTI  Urinary tract infection 
WCC   White cell count    
μL  Microlitre 
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1 Chapter 1  - General introduction 
 
General surgery is one of the largest surgical specialties, 31% of all United 
Kingdom (UK) surgeons are general surgeons (England). Colorectal surgery is the 
largest sub-specialty within general surgery, in the UK there are 850 colorectal 
surgeons registered with The Association of Coloproctology of Great Britain and 
Ireland (personal communication). Colorectal surgery is required for a variety of 
benign and malignant conditions. Frequently it involves removal of a diseased 
segment of bowel. In this situation surgeons will consider performing an 
anastomosis to re-join the cut ends of bowel in order to optimize the patients’ 
quality of life. This section discusses, in depth, the definition of an anastomosis, 
conditions where an anastomosis may be required, possible complications of an 
anastomosis and the current methods to predict and detect these complications. 
 
1.1 Healing in the gastrointestinal (GI) tract 
1.1.1 The anatomical structure of the gastrointestinal tract 
The intraperitoneal gastrointestinal tract consists of 4 layers: mucosa, 
submucosa, muscularis propria and serosa (see figure 1.3); the extraperitoneal 
areas, e.g. lower third of rectum, lack the serosa.  The mucosa consists of 
epithelium, lamina propria (loose connective tissue containing collagen) and a 
muscularis mucosa (thin layer of smooth muscle cells). Migration and hyperplasia 
of epiltheilal cells can seal a mucosal breach within 3 days.  
 
The submucosa consists of collagenous and elastic fibres together with a 
submucosal plexus of nerve fibres, blood vessels and lymphatics (Thornton and 
Barbul, 1997). The composition of types of collagen is different in the bowel 
compared to other soft tissues. In addition to type I and III collagen, bowel also 
contains type V collagen. The relative proportions of collagen in the submucosa 
are type I 68%, type III  20% and 12% is type V collagen (Thornton and Barbul, 
1997). In 1887 Halsted discovered that most of the tensile strength of the bowel 
comes from the submucosa (Halsted, 1887). This principle of this is still applied 
today as hand sewn bowel anastomoses are generally performed by incorporating 
serosa and submucosa within the anastomotic suture line (a sero-submucosal 
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stitch). Experimental studies have shown that sutures through the mucosal layer 
do not add to the strength of the anastomosis and therefore serosubmucosal 
bites, rather than full-thickness bites, are taken through the bowel wall (Egorov 
et al., 2002, Tera and Aberg, 1976). 
 
The muscularis propria consists mostly of smooth muscle cells and collagen. The 
serosa is a thin layer of connective tissue covering the muscularis propria. Sound 
apposition of the serosa during formation of an anastomosis reduces the risk of 
anastomotic leak (DiZerega, 1989, Getzen, 1966, LaCalle et al., 1982).   
  
 
 
 
FIGURE 1.1 LAYERS OF THE GASTROINTESTINAL TRACT (SCHOOLBAG.INFO, 2016) 
 
 
1.1.2 General wound healing 
Wound healing is a series of steps designed to re-establish an immune barrier 
and then repair the injured tissue. The classic phases of wound healing are 
divided into three phases: the inflammatory or ‘lag’ phase, proliferative phase 
and remodelling phase (see Figure 1.4). 
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FIGURE 1.2 PHASES OF WOUND HEALING (ANDREU ET AL., 2015) 
 
 
The classic phases of wound healing have been studied extensively. In 2006 
Thompson et al provided a succinct overview of the three stages (Thompson et 
al., 2006);  
1. In the inflammatory phase, haemostasis is secured by platelet migration 
to the site of injury to form a fibrin-based clot. Increased vessel 
permeability allows inflammatory cells to migrate into the area. Initially 
the main cell type is neutrophils but they are rapidly superseded by 
macrophages which are the dominant cell type by day 2-3. They 
synthesise and release tissue growth factors essential to the progression 
of tissue repair.  
2. The start of the proliferative phase is marked by the arrival of fibroblasts, 
they are the major cell type by day 4. Fibroblasts replace the provisional 
matrix with collagen-rich granulation tissue. Normal soft tissue is made up 
of 80% type I collagen and 20% type III collagen. The new granulation 
tissue laid down at the outset of healing contains a higher level of type III 
collagen – 30-40%. Ferrous iron, molecular oxygen, alpha-ketoglutarate 
and vitamin C are required as cofactors for hydroxylation necessary for 
collagen synthesis. During this proliferative phase angiogenesis also occurs 
in order to ensure adequate oxygen and nutrient supply to the healing 
tissues.  
3. Remodelling is the final phase in wound healing. This takes place over 
several weeks to months. The granulation tissue laid down initially is 
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remodelled. The number of macrophages and fibroblasts decreases and 
the percentage of type III collagen falls to 20%.  
 
 
1.1.3 Healing of an anastomosis 
Healing of a gastrointestinal anastomosis proceeds via the three phases outlined 
above – inflammatory (lag), proliferative and remodelling phases but there are 
some important differences between healing in the GI tract and skin (see table 
1.6) (Thompson et al., 2006). The appearance of granulation tissue in the 
anastomosis marks the beginning of the proliferative phase. The collagen in the 
wound undergoes both lysis and synthesis. In 1887 Halsted demonstrated that 
the submucosa provides the majority of the strength to the GI tract (Halsted, 
1887). Consequently, the strength of the anastomosis is derived from the 
collagen in the submucosal layer of the bowel wall. Unlike skin, initially 
collagenase activity predominates which results in a reduction in collagen and 
therefore a decrease in anastomotic strength (Martens et al., 1992). For the first 
1 - 3 days (the inflammatory phase) the anastomosis will rely upon the sutures or 
staples used to create it for its strength. This is followed by the proliferative 
phase which is characterized by a switch from collagen degradation to collagen 
deposition. This leads to a rapid increase in anastomotic strength (Thompson et 
al., 2006). This initial dip in wound tensile strength is demonstrated in the 
curves shown in figure 1.5. Any factor which delays or prevents the transition to 
the proliferative phase can result in a failure of the anastomosis to heal.  
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TABLE 1.1 DIFFERENCES BETWEEN HEALING IN SKIN AND THE GI TRACT (THOMPSON ET 
AL., 2006) 
 GI tract Skin 
Collagen 
 Subtypes 1, 3, 5 1, 3 
 Production Smooth muscle cells 
and fibroblasts 
Fibroblasts only 
 Regulation Tissue growth factor B 
(TGF-B) 
TGF-B, dexamethasone, 
interleukin-1B 
Wound strength 
 Rate of healing Rapid (weeks) Prolonged (months) 
 Components Additional strength due 
to serosa 
No serosa equivalent 
Wound environment 
 Shear stress Increased due to 
peristalsis and bulk 
transit 
Minimal 
 Bacteria Aerobic and anaerobic, 
may affect anastomotic 
healing 
Aerobic, rarely causes 
problems 
 Vascular 
perfusion 
Downregulated if 
hypovolaemic 
Constant 
Collagenase activity Increased in the first 3 
days; causes transient 
decrease in anastomotic 
strength 
Not significant 
 
 
Wounds in the GI tract gain strength more rapidly than cutaneous wounds 
(Martens and Hendriks, 1991). In addition, the rate of healing varies within the 
GI tract. Ileum has less collagen degradation and more collagen formation 
compared to colon. Small bowel anastomoses approach the strength of normal 
bowel by 4 weeks but in the colon the anastomosis only approaches 75% strength 
at 4 months (Martens and Hendriks, 1991, Mast, 1997).   
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FIGURE 1.3  WOUND-HEALING IN GASTROINTESTINAL TRACT IS FINE BALANCE DURING 
‘LAG’ PHASE BETWEEN COLLAGEN SYNTHESIS AND COLLAGENOLYSIS. LINE LABELED 
‘RESULTANT CURVE’ SHOWS THIS BALANCE. WEAK TIME PERIOD DEPICTED ON 
GRAPH (ARROW) CAN BE PROLONGED OR EXACERBATED BY LOCAL OR SYSTEMIC 
FACTORS THAT UPSET EQUILIBRIUM (THOMPSON ET AL., 2006) 
  
 
A wound will fail to heal if there is a disruption of one of the 3 phases of wound 
repair. Thompson et al described a range of local and systemic factors that can 
adversely impact on wound healing (see table 1.7). Before surgery, the medical 
team should aim to correct malnutrition. The energy required for wound repair 
necessitates adequate calorific intake. Vitamins and minerals such as vitamins A, 
C and B6, and zinc, iron and copper are required for collagen synthesis (Dubay 
and Franz, 2003). Nutritional deficiencies of these elements will impair 
anastomotic healing.  Glycaemic control should be optimized and other problems 
such as jaundice or infection should be treated. 
  
Intra-operatively, good surgical technique providing sound apposition of the 
bowel and avoiding excess tension is required. Tissue hypoperfusion should be 
avoided. This is dependent upon vascular anatomy, vasomotor control and 
arterial tissue oxygen pressure (pO2). The vascular anatomy local to the 
anastomosis should be disrupted as little as possible to ensure that the area 
receives a good blood supply. Systemic hypotension in the post-operative period 
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must be avoided because in the setting of hypovolaemia the body downregulates 
intestinal perfusion and diverts blood to essential organs such as the brain and 
heart. Mature collagen formation fails if p02 falls below 40mmHg (Shandall et 
al., 1985). 
 
Strict haemostasis should be ensured to minimise the need for blood transfusion 
in the intra or post-operative period. In animal models it has been shown that 
blood transfusion has a negative impact on wound healing. It is thought that 
transfusions impair the migration and function of macrophages in the wound and 
thus delay the first phase of healing – the inflammatory phase (Tadros et al., 
1992). 
 
 
TABLE 1.2 LOCAL AND SYSTEMIC FACTORS WITH ADVERSE EFFECTS ON 
GASTROINTESTINAL HEALING (THOMPSON ET AL., 2006)  
Local Systemic 
Tissue hypoperfusion 
Anastomotic tension 
Poor apposition of wound edges 
Local infection 
Radiation injury 
Distal obstruction 
Malnutrition 
Blood transfusion 
Hypovolaemia 
Medication (e.g. cisplatin) 
Immunodeficiency 
Poorly controlled diabetes 
Jaundice 
Obesity 
 
 
1.2  The colorectal anastomosis 
 
1.2.1 Definition of a colorectal anastomosis 
Formation of a colorectal anastomosis is a procedure to restore continuity, i.e. 
creating a join, between two cut ends of bowel (see Figure 1.1). The indications 
for this procedure are wide-ranging but can be broadly split into two categories; 
procedures where a portion of diseased bowel has been removed or to bypass a 
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diseased segment which cannot be removed. The vast majority of operations fall 
into the first category. Examples of situations where a diseased section of bowel 
is removed include: malignancy, diverticular disease, bowel ischaemia, benign 
polyps, traumatic perforations, complications of inflammatory bowel disease 
(e.g. toxic megacolon, perforation, stricture), infections (e.g. TB causing 
stricturing), complications of radiation enteritis (e.g. stricture, perforation), 
catastrophic lower gastrointestinal bleeding and chronic constipation. Examples 
of situations where diseased bowel may need to be bypassed are: locally 
advanced tumour too large to be resected or metastatic disease causing bowel 
obstruction.  
 
 
FIGURE 1.4 AN EXAMPLE OF A COLORECTAL ANASTOMOSIS – A SEGMENT OF BOWEL 
CONTAINING A TUMOUR IS REMOVED AND CREATING AN ANASTOMOSIS RESTORES 
CONTINUITY OF THE CUT ENDS OF BOWEL (MEDICINE, 2016) 
 
 
1.2.2 Common conditions requiring formation of a colorectal anastomosis 
 
1.2.2.1  Inflammatory bowel disease 
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Inflammatory bowel disease (IBD) is generally the term used to describe the two 
most common chronic inflammatory conditions of the bowel – Crohn’s disease 
and Ulcerative Colitis (UC), which affect more than 300,000 people in the United 
Kingdom (UK, 2016a).  There are other less common types of IBD that can only 
be seen microscopically – collagenous and lymphocytic colitis (Palmer KR, 2006). 
Sometimes it is difficult to differentiate between the types of IBD on histology 
and there can be substantial inter-observer variability between pathological 
reporting. Histopathological features can overlap leading to a diagnosis of 
“indeterminant colitis” in 5-10% of patients with just colonic disease (Thompson-
Fawcett MW, 2014). The clinical picture and evolution of symptoms may 
ultimately support one diagnosis over another, e.g. subsequent small bowel 
involvement favouring a diagnosis of Crohn’s disease. 
 
 Although the incidence of IBD varies throughout the world, it is more common in 
the developed than the developing world. The incidence of IBD increased 
substantially over the 20th century in developed countries with Europe now 
having an annual incidence of UC and Crohn’s of 24.3 per 100,000 and 12.7 per 
100,000 respectively (Ananthakrishnan, 2015). The Asia-Pacific Crohn’s and 
Colitis Study noted an increasing incidence of IBD in so-called emerging nations 
such as Korea and China which have seen a more recent growth of urbanisation 
and development. Although still substantially lower than in Europe, the 
incidence rates of UC and Crohn’s in the study were 0.76 per 100,000 and 0.54 
per 100,000 respectively (Ng et al., 2013). In Africa IBD remains a rare disease 
but case series do suggest an increasing incidence (Archampong and Nkrumah, 
2013). The onset of IBD is usually in early adulthood (Palmer KR, 2006). Crohn’s 
disease and UC typically follow a relapsing and remitting course. Whilst UC only 
involves the colon and rectum, Crohn’s disease can affect any part of the 
gastrointestinal tract from the mouth to the anus. 
 
The pathogenesis of IBD appears to be a response to an environmental trigger in 
a genetically susceptible individual, this may explain the variation in incidence 
in the developing versus developed world. There also seems to be a “north – 
south gradient” with studies in both the USA (Schultz and Butt, 2012) and Europe 
(Shivananda et al., 1996) noting higher incidence at more northern latitudes. 
One hypothesis is that increased exposure to vitamin D at southern latitudes is 
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protective. Table 1.1 illustrates a range of known genetic and environmental risk 
factors for IBD. 
 
 
TABLE 1.3 GENETIC AND ENVIRONMENTAL FACTORS ASSOCIATED WITH IBD (PALMER 
KR, 2006) 
Genetic factors 
 Ashkenazi Jewish descent 
 Affected first degree relative 
 Associated with autoimmune thyroiditis and systemic lupus 
erythematosus (SLE) 
 Linkage with mutations in CARD 15/NOD-2 gene on chromosome 16 
(IBD-1 locus) 
 HLA-DR103 associated with severe UC 
 UC and Crohn’s patients with HLA-B27 commonly develop ankylosing 
spondylitis 
Environmental factors 
 UC more common in non-smokers and ex-smokers 
 Associated with low residue, high refined sugar diet 
 Appendicectomy is potentially protective against UC 
 
Crohn’s disease tends to present with abdominal pain, diarrhoea and weight 
loss. Other features such as fever and malaise may also be present. If the colon 
is predominately affected, then the presentation may be with bloody diarrhoea. 
UC presents with diarrhoea that frequently contains blood and/or mucus. 
Although there are many similarities in the presentation and symptoms of 
Crohn’s and UC there are some key differences in the pattern of disease, 
macroscopic and microscopic features, risk of colorectal cancer and histological 
features. Table 1.2 provides a comparison of the two conditions. 
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TABLE 1.4 FEATURES OF CROHN’S DISEASE AND UC (MG, 2007) 
 Crohn’s disease Ulcerative colitis 
Incidence 5-7/100,000 and rising 10/100,000 and stable 
Extent May involve entire 
gastrointestinal tract 
Limited to large bowel 
Rectal involvement Variable Almost invariable 
Disease continuity Discontinuous (skip 
lesions) 
Continuous 
Depth of inflammation Transmural Mucosal 
Macroscopic 
appearance of mucosa 
Cobblestone, discrete 
deep ulcers and fissures 
Multiple small ulcers, 
pseudopolyps 
Histological features Transmural 
inflammation, 
granulomas (50%) 
Crypt abscesses, 
submucosal chronic 
inflammatory cell 
infiltrate, crypt 
architectural distortion, 
goblet cell depletion, 
no granulomas 
Presence of perianal 
disease 
75% of cases with large 
bowel disease; 25% of 
cases with small bowel 
disease 
25% of cases* 
Frequency of fistula 10-20% of cases Uncommon 
Colorectal cancer risk Elevated risk (relative 
risk = 2.5) in colonic 
disease 
25% risk over 30 years 
in pancolitis 
Relationship with 
smoking 
Increased risk, greater 
disease severity, 
increased risk of 
relapse and need for 
surgery 
Protective, first attack 
may be preceded by 
smoking cessation 
within 6 months 
*This includes haemorrhoids, fissures, skin tags, abscesses and fistulae. The incidence of 
complex perianal disease with fistulae and abscesses in UC is closer to 5% (Zabana et al., 2011) 
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IBD is frequently first managed with medical therapies. Steroids may be used to 
settle an acute flare. In the longer term anti-inflammatory drugs such as 5-
aminosalicylic acid agents (e.g. mesalazine, olsalazine) and immunosuppressants 
such as methotrexate and ciclosporin can be used. Biological drugs such as 
infliximab and adalimumab are now considered for use in in refractory cases 
(Danese et al., 2015).  
 
At some point 80% of people with Crohn’s disease will require surgery, in UC the 
corresponding figure is around 10-30% (Cosnes et al., 2011). In the elective 
setting, surgery may be indicated for: subacute obstructions, strictures, perianal 
sepsis and fistulae, disease refractory to medical management, complications of 
medical management (e.g. osteoporosis), concerns about the long term risks of 
immunosuppression or the onset of malignancy. Emergency surgery is often 
needed for fulminant colitis unresponsive to maximal medical management 
(especially when rescue therapy such as anti-TNFs are failing), toxic megacolon, 
perforation or obstruction (MG, 2007). In Crohn’s disease, bowel resection 
should be as limited as possible in order to maintain gut length as 40% of 
patients go on to require further surgery (Coffey et al., 2016). A study looking at 
resection margins for Crohn’s disease found that extensive resection margins are 
unnecessary (Fazio et al., 1996). The 2017 European Crohn’s and Colitis 
Organisation (ECCO) Consensus on Surgery continue to recommend a limited 
resection when surgery is required (Bemelman et al., 2017). However, in a 
recent study of 64 patients undergoing ileocaecal resection for Crohn’s disease, 
excision of the mesentery along with the affected segment of bowel resulted in 
a lower reoperation rate (2.9% vs. 40%) (Coffey et al., 2018). If these results can 
be replicated in larger cohorts then it may lead to a change in practice.  In UC 
removal of the colon and rectum is essentially curative. In the acute setting in 
patients with fulminant colitis; the operation of choice is a subtotal colectomy 
with a long rectal stump, this can provide options for future restorative surgery 
(Carter et al., 2004). This also provides an opportunity for histopathological 
analysis to confirm the diagnosis. Up to 13% of patients having an emergency 
resection for colitis may be found to have either indeterminate colitis or Crohn’s 
disease rather than UC (Hyman et al., 2005), meaning further surgery to remove 
the rectum may be avoided. In the elective setting, a proctocolectomy with end 
ileostomy represents a cure and patients will not require on going disease 
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surveillance. However, there is considerable stoma-associated morbidity such as 
stenosis, herniation and skin excoriation. Requirement for stoma revision surgery 
can be as high as 24% (Carlstedt et al., 1987). As a consequence, a restorative 
proctocolectomy with ileal pouch-anal anastomosis (IPAA) has gained in 
popularity. Despite the need for on going disease surveillance at the resection 
margin in the anal transition zone and the fact that 24-48% experience pouchitis 
(Fazio et al., 1995, Meagher et al., 1998), patients report an improved quality of 
life and 98% would have the surgery again or recommend it to someone else with 
UC (Delaney et al., 2003). 
 
 
1.2.2.2  Colorectal cancer 
Colorectal cancer is the 4th most common cancer in the UK after breast, lung and 
prostate. Around 41,900 cases are diagnosed in the UK each year (UK, 2016c). 
Two thirds of cancers occur in the colon and one third in the rectum (Steele, 
2014). Risk factors for colorectal cancer include: increasing age, male gender, 
family history, ‘Westernised diet’, inflammatory bowel disease, genetic factors, 
and pre-existing adenomatous polyps. 
 
The majority of colorectal cancers occur sporadically but genetic susceptibility 
contributes about 15-20% (Lynch and De la Chapelle, 1999) to the overall 
incidence of colorectal cancer. Mostly this relates to individuals with an ill-
defined increased risk due to a strong family history of colorectal cancer, 
however 5-10% are due to detectable genetic abnormalities (Lynch and De la 
Chapelle, 1999). The three main categories of genetic susceptibility are: 
hereditary nonpolyposis colorectal cancer (HNPCC), dominant polyposis 
syndromes (familial adenomatous polyposis, (FAP); Peutz-Jeghers Syndrome, 
(PJS); juvenile polyposis syndrome, (JPS)) and recessive inheritance syndromes 
such as metaplastic hyperplastic polyposis (MHP). 
 
HNPCC (Lynch syndrome) is the most common autosomal dominant syndrome and 
accounts for 3-5% of all colorectal cancers. The underlying genetic defect is a 
mutation in one of the mismatch repair (MMR) genes MLH1, MSH2, MSH6 or PMS2 
(Vasen et al., 2013). It is characterized by a small number of adenomas but with 
increased potential for transformation into malignancy, with 70% of males and 
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35% of females developing colorectal cancer over their lifetime. There is also an 
increased risk of other cancers: endometrial, gastric, upper urinary tract and 
small intestinal cancers. New guidelines released by the National Institute for 
Clinical Excellence (NICE) in 2017 recommend that all patients diagnosed with a 
colorectal cancer should be offered testing for Lynch syndrome at the time of 
their diagnosis (NICE, 2017). This can be done using immunohistochemistry for 
mismatch repair proteins or microsatellite instability testing to identify tumours 
with deficient DNA mismatch repair. The results of these tests guide further 
sequential testing for Lynch syndrome. 
 
FAP is another autosomal dominant disorder that confers increased risk of CRC. 
The mutation is in the APC gene on the long arm of chromosome 5. The 
incidence of FAP is 1 in 6670 live births and the population prevalence is 1 in 
13528 (Dunlop, 2007). The syndrome is characterized by the presence of > 100 
adenomatous polyps within the colon. These usually develop in the teenage 
years/early adulthood and affected individuals will almost certainly develop 
colorectal cancer by the third or fourth decade. In such cases, prophylactic 
colectomy is performed whilst the patients are young and therefore FAP now 
accounts for less than 0.2% of colorectal cancers in the UK (Dunlop, 2007). Those 
with FAP also have widespread duodenal polyps and there is a risk of malignant 
change peri-ampullary polyps becoming malignant. Patients are also at risk of 
intra-abdominal desmoid tumours and females < 35 years have an increased risk 
of papillary thyroid cancer. 
 
Whether sporadic or genetic, CRC can present with a wide range of symptoms 
including intermittent rectal bleeding, blood and mucus mixed with stool, 
altered bowel habit, abdominal pain, iron deficiency anaemia and in the case of 
low rectal cancers, tenesmus. Around 15% of patients present with obstruction 
and 3% have a perforation at presentation (Dunlop, 2007). In the fourth UK 
National Emergency Laparotomy Audit (NELA), the operative finding was listed 
as “colorectal cancer” in 8.1% of cases (Team, 2018). This will include those 
operated on as an emergency for a perforated or obstructed colorectal cancer. 
 
With the advent of the national bowel screening programme some cancers are 
now picked up in asymptomatic individuals – in England 1778 cancers were 
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picked up from the first 1 million bowel screening tests that were returned 
(Logan et al., 2012). In Scotland screening started in 2007. All individuals 
between 50 – 74 years receive a stool testing kit testing kit every 2 years. 
Around 2% have an abnormal test (Mackay et al., 2014) and are invited for 
colonoscopy. Of these, 50% do not have a polyp or a cancer, 40% have a polyp 
and 10% have a cancer (UK, 2016b). Results from a single centre in Scotland 
showed that over a 4 year period, following the introduction of bowel screening, 
17% of the cancers they treated were identified via the bowel screening 
programme. These cancers were diagnosed in younger people (median 65.5 years 
for screen-detected vs. 71.6 years “other referrals”), were at a less advanced 
stage and had significantly better survival outcomes (Mackay et al., 2014). 
Between 2007 – 2017 participants received a faecal occult blood (FOB) testing 
kit. In 2017 there was a transition to the faecal immunochemical test (FIT) 
(Scotland, 2017). The FIT test requires only one stool sample which makes it 
simpler and more user friendly than the old FOB test which required samples 
over 3 days. This makes the test more acceptable and has been shown to 
increase participation in the bowel screening programme (Chambers et al., 
2016). 
 
The management and prognosis of a CRC is determined by the stage of the 
cancer and whether it is in the colon or rectum. Following detection of a cancer, 
all patients will undergo a staging computed tomography (CT) scan of the chest, 
abdomen and pelvis. In the absence of widespread metastatic disease surgery is 
the main treatment for colon cancer. In rectal cancer, a key determinant of 
staging is the assessment of the extramural tumour spread in relation to the 
mesorectal fascia and sphincter complex. Magnetic resonance imaging (MRI) 
provides the most accurate imaging of soft tissues in this area (Jhaveri and 
Hosseini-Nik, 2015), therefore all patients with a rectal cancer have an MRI 
pelvis in addition to staging CT. In rectal cancer, patients with resectable 
disease and no metastases will be offered surgery. Those patients with a rectal 
cancer that is margin-threatening (tumour on MRI is ≤ 1mm from the 
circumferential resection margin) or low in the rectum (< 5cm from anal verge) 
will be considered for neoadjuvant chemo-radiotherapy prior to potentially 
curative surgery as this has been shown to reduce local recurrence and increase 
long term survival (Poston et al., 2011, Glimelius et al., 2013). Following 
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chemoradiotherapy some patients are judged to have had a clinical complete 
response with no evidence of residual tumour on MRI or clinical examination. In 
such patients a “watch and wait approach” may be adopted. A recent systematic 
review found that at 2 years 15.7% of patients had evidence of local tumour 
regrowth, of these patients 95.4% were able to go on to have salvage therapies 
such as surgery or further oncological treatment (Dossa et al., 2017). In the 
future, this may mean that fewer patients require major complex surgery for 
rectal cancer thus reducing the number of patients having a colorectal 
anastomosis and therefore reducing the number of patients exposed to the risk 
of AL and its deleterious consequences. However, this approach has still only 
been studied in a relatively small number of patients and prospective studies are 
on-going to confirm the long-term safety of a “watch and wait approach”. 
 
Surgery for a CRC involves resection of the affected segment of bowel along with 
excision of the colonic mesentery, ligation of the arterial supply at its origin and 
excision of loco-regional lymph nodes. For tumours of the colon a 5cm disease 
free margin is recommended, and in the rectum, a 2cm margin but if the tumour 
is < 5cm from the anal verge then a 1cm is considered acceptable (Nelson et al., 
2001). The cut ends of bowel then have to be re-joined (formation of an 
anastomosis) or if they are not anastomosed then a stoma is brought out onto 
the skin. For rectal cancers, the mesorectum (which carries blood vessels and 
lymph nodes) is excised along with the diseased segment of rectum. Figure 1.2 
shows the operations carried out depending on the site of the tumour.  
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FIGURE 1.5 COMMON COLORECTAL RESECTIONS (FRY RD, 2012). THE SHADED AREA 
INDICATES THE SEGMENT OF BOWEL REMOVED WITH EACH PROCEDURE. 
 
 
Once the cancer has been removed it can be accurately staged. In the UK this is 
done using either the TNM staging system shown in table 1.3 or the Duke’s 
staging system shown in table 1.4. 
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TABLE 1.5 TNM STAGING OF COLORECTAL CANCER (UICC TNM STAGING 8TH 
EDITION) (GOSPODAROWICZ ET AL., 2017) 
T (Tumour) 
 Tx  Primary tumour cannot be assessed 
 T0 No evidence of primary tumour 
 Tis  Carcinoma in situ: invasion of the lamina propria 
 T1  Cancer invades the submucosa 
 T2  Cancer invades into muscularis propria 
 T3  Cancer invades through muscularis propria and into subserosa or 
adjacent non-peritonealised tissues 
 T4  Cancer perforates the visceral peritoneum or directly invades 
adjacent organs 
 T4a Tumour perforates visceral peritoneum 
 T4b Tumour directly invades other organs or structures 
N (Nodes) 
 Nx  The regional lymph nodes cannot be assessed 
 N0  No regional lymph nodes involved 
 N1  Metastases in 1-3 pericolic or perirectal lymph nodes 
 N1a Metastasis in 1 regional lymph node 
 N1b Metastasis in 2 -3 regional lymph nodes 
 N1c Tumour deposits (s), i.e. satellites, in the subserosa, or in non-
peritonealised pericolic or perirectal soft tissue without regional 
lymph node metastasis 
 N2  Metastasis in 4 or more pericolic or perirectal lymph nodes 
 N2a Metastasis on 4 – 6 regional lymph nodes 
 N2b Metastasis in 7 or more regional lymph nodes 
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M (Metastases) 
 Mx  The presence of distal metastases cannot be assessed 
 Mo  No distant metastases 
 M1  Distant metastases 
 M1a Metastasis confined to one organ (liver, lung, ovary, non-regional 
lymph node(s) without peritoneal metastasis 
 M1b Metastasis in more than one organ 
 M1c Metastasis to the peritoneum with or without other organ 
involvement 
 
 
TABLE 1.6 DUKE’S STAGING FOR COLORECTAL CANCER 
Duke’s stage Description 
A Spread into, but not beyond, muscularis propria 
B Spread through full thickness of the bowel wall 
C Spread to involve lymph nodes 
D Distant metastases 
 
 
The TNM classification is used to group CRCs into numerical stages. These stages 
guide decisions regarding adjuvant therapy and serve as a guide to prognosis 
(table 1.5). The NICE guidelines state that those with stage 1 disease do not 
require adjuvant therapy. Chemotherapy should be offered to those with stage 3 
CRC who are fit enough to receive it. In stage 2 disease adjuvant chemotherapy 
may be offered if the tumour has high risk features (e.g. poorly differentiated, 
high grade, presence of venous invasion). Patients who present with stage 4 
disease should have the resectability of their primary and metastatic disease 
assessed by site-specific multi-disciplinary teams (MDTs), e.g. liver metastases 
by a hepato-biliary MDT or lung metastases by a lung MDT. Such cases are 
considered by the MDTs on an individual basis with consideration given to 
chemotherapy, hepatic or lung surgery and colorectal surgery; the order of these 
interventions will be decided upon by the individual MDT. In the case of 
irresectable disease, palliative chemotherapy or radiotherapy can be considered 
but the main focus in these patients is symptom control and quality of life 
(Poston et al., 2011). 
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TABLE 1.7 NUMERICAL STAGING OF CRC AND PROGNOSIS (UK, 2016D) 
Stage Description Prognosis (% 5 year 
survival) 
0 (carcinoma in situ) Cancer cells contained 
within the inner lining of 
the bowel 
 
Men: 95% 
Women: almost 100% 
1 T1 N0 M0 or T2 N0 M0 
2a T3 N0 M0 Men: 80% 
Women: 90% 2b T4 N0 M0 
3a T1 N1 M0 or T2 N1 M0  
Men & women: 65% 3b T3 N1 M0 or T4 N0 M0 
3c Any T N2 M0 
4 Any T Any N M1 Men: 5% 
Women: 10% 
(but if resection of 
liver metastases 
possible then can be 
25-40%) 
 
 
1.2.2.3 Diverticular disease 
Diverticular disease (DD) is a benign acquired condition of the large bowel that is 
very common in developed countries with more than 60% of those over 70 years 
having features of DD on imaging or colonoscopy (Dunlop, 2007). It is associated 
with a low fibre diet and DD is rare in populations with a high fibre diet (Winter, 
2014). The sigmoid colon is the most commonly affected site in the western 
world, likely due to the increased intraluminal pressures generated here when a 
low-fibre diet is consumed. Pulsion diverticulae develop between the mesenteric 
and antimesenteric taeniae and are due to herniation of mucosa through the 
circular muscle at the sites of penetration of blood vessels (Dunlop, 2007). DD is 
frequently asymptomatic and picked up as an incidental finding but it can cause 
lower abdominal/left iliac fossa pain, altered bowel habit (usually constipation) 
and colonic bleeding.  
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The exact pathogenesis of acute diverticulitis is unclear. Classically it was 
thought that diverticulitis was caused by local trauma to the mucosa due to 
impaction of inspissated faeces in a diverticulum which then produced stasis and 
a local inflammatory response. More recently an “ischaemic hypothesis” has 
been proposed. It has been suggested that  prolonged or recurrent contractile 
spikes due to alterations in the muscle of the diverticular segment result in 
compression of vascular structures in the neck of the diverticulum. This causes 
localised ischaemia and subsequent micro-perforation of the diverticulum which 
in turn sets up a localised inflammatory response (Zullo, 2018). Further work is 
required to determine which of these hypotheses, or indeed whether a 
combination of the two, cause acute diverticulitis.  
 
Patients with acute diverticulitis often present with left iliac fossa pain and a 
low grade pyrexia. Diverticulitis can range in severity from uncomplicated 
inflammatory diverticulitis to complicated diverticulitis (with abscess formation 
or perforation). For decades the Hinchey classification, based on surgical 
findings, has been used to classify the severity of diverticulitis into 4 grades: 
stage 1, pericolic abscess confined by the mesocolon; stage 2, pelvic abscess 
distant from the area of inflammation; stage 3, generalised peritonitis resulting 
from abscess rupture; stage 4, faecal peritonitis resulting from the perforation 
of colonic diverticulum (Hinchey et al., 1978). With the increased availability of 
CT scanning this has now become the investigation of choice in cases of 
suspected diverticulitis (Ambrosetti et al., 2000). In 2016 the World Society of 
Emergency Surgery Consensus Conference created guidelines for the 
management of acute diverticulitis (Sartelli et al., 2016). They suggest that 
cases of mild inflammation, not complicated by systemic upset or localised 
complication (e.g. abscess or perforation), can managed symptomatically 
without antibiotics. If systemic upset is present then antibiotics should be give. 
In cases of diverticulitis complicated by a localised abscess, IV antibiotics may 
be sufficient but if the abscess is > 4-5cm then percutaneous drainage should be 
performed. For patients with perforated diverticulitis and generalised peritonitis 
they recommend surgery. Depending on the clinical condition of the patient and 
the expertise of the operating surgeon, either resection of the affected segment 
with primary anastomosis or a Hartmann’s procedure (resection of the affected 
segment with the proximal end of bowel being brought to the surface and over-
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sewing of the rectal stump) can be performed. They do not recommend 
laparoscopic lavage and drainage in patients with generalised peritonitis. Where 
a Hartmann’s procedure is performed only 30% of these colostomies are reversed 
(MG, 2007). The reversal procedure itself is often challenging and post operative 
complications are common with one study finding that patients undergoing a 
reversal of Hartmann’s procedure were 2.1 times more likely to experience a 
complication than those undergoing  an elective resection and primary 
anastomosis (Aydin et al., 2005). 
 
 
1.2.3 Creation of an anastomosis 
As described below anastomoses can be formed in a variety of ways, however, 
some general principles apply to all methods: the cut ends of bowel should be 
handled carefully, the size discrepancy between the ends should be minimised 
to allow good apposition and excess tension at the anastomosis must be avoided.  
 
Traditionally anastomoses were hand-sewn. This can be either a single or double 
layer technique. Although more time consuming to perform, the double layer 
technique was thought to offer a more secure anastomosis, however randomized 
controlled trials and meta-analyses have failed to demonstrate a significant 
difference in outcome between single and double layer techniques (Burch et al., 
2000, Shikata et al., 2006). A recent multi-centre randomised control trial of 
single vs. double layer anastomotic techniques for colonic anastomoses closed 
early due to poor recruitment. However, of the 252 patients recruited (129 
single layer anastomosis; 123 double layer anastomosis) there was no significant 
difference in the anastomotic leak (AL) rate but the single layer technique was 
significantly quicker to perform (Herrle et al., 2016). A systematic review also 
failed to show superiority of one technique over the other but also commented 
that the single layer technique was quicker and easier to perform (Slieker et al., 
2013).   With the advent of reliable stapling devices in the 1970s and 1980s 
stapled anastomoses have grown in popularity. They are easy to use and less 
time-consuming than hand-sewn anastomoses. A plethora of studies have 
compared hand-sewn versus stapled anastomoses and these have been the 
subject of recent systematic Cochrane reviews. In the first Nuetzling et al 
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(Neutzling et al., 2012) looked at 1233 patients across 9 studies. Stapled 
colorectal anastomoses were performed in 622 patients and 611 had hand-sewn 
anastomoses, no significant difference in outcome was found between the two 
groups. However, in the case of right-sided ileo-colic anastomoses a Cochrane 
review found there were significantly fewer anastomotic leaks in the stapled 
group (Choy et al., 2011). However, contrasting results were found in an 
international cohort study published in 2017 by the European Society of 
Coloproctology (Battersby et al., 2017). They looked at stapled versus hand sewn 
anastomoses for right hemicolectomy or ileocaecal resection in both the elective 
and emergency setting in 3208 patients. A higher rate of AL was identified in the 
group who underwent a stapled anastomosis.  
 
 
1.3 Complications of colorectal surgery  
 
Potential complications of colorectal surgery can include: anastomotic stricture 
(narrowing of the join), bleeding, prolonged ileus, wound infection and 
anastomotic leak (AL).   
 
 
1.3.1 Anastomotic stricture 
A stricture is a delayed complication that develops over weeks to months after 
the creation of anastomosis. The incidence is approximately 2-5% (Del Gaudio et 
al., 1993, Schaefer et al., 1993, Laxamana et al., 1995, Fingerhut et al., 1995). 
The exact mechanism of stricture formation is unclear but post-operative AL, 
pelvic sepsis, radiotherapy and ischaemia at the anastomosis have all been 
implicated (Orsay et al., 1995, Senagore et al., 1990, Påhlman et al., 1989, 
Chung et al., 1988). It is more common in low, stapled joins e.g. in the rectum. 
It usually presents with difficulty in defecation, partial or sometimes complete 
intestinal obstruction. In the past it was treated surgically but now endoscopic 
dilatation is firmly established as the first line treatment of choice (Belverde et 
al., 2012).  
 
 35 
 
1.3.2 Bleeding 
Significant bleeding from a newly created colorectal anastomosis is uncommon 
but can cause significant morbidity and mortality. In a series of 2181 patients 
undergoing anterior resection for rectal cancer with a stapled anastomosis 6 
patients (0.3%) had bleeding requiring intervention (Lou et al., 2014). All 
required blood transfusion but the bleeding was controlled with colonoscopic 
techniques such as clipping and electrocautery. However, occasionally 
uncontrolled bleeding may necessitate a return to theatre. 
 
 
1.3.3 Prolonged ileus 
Post-operative ileus is a transient impairment of bowel motility and can occur 
after any type of intra-abdominal surgery. It presents with nausea, vomiting, 
stomach cramps, lack of passage of flatus and stool, bowel distension and 
reduced/absent bowel sounds. The aetiology is multifactorial involving inhibitory 
neural reflexes and inflammatory mediators from the site of surgery. The 
duration of ileus is affected by the segment of the gastrointestinal tract that has 
been operated on. The longest duration of ileus is encountered after operations 
on the colon compared to operations on the stomach or small intestine (Holte K, 
2000). Laparoscopic surgery, use of local anaesthetic and thoracic epidurals, 
opioid-sparing analgesia and the use of chewing gum and caffeine (Chan MKY, 
2007) in the post-operative period have previously been shown to reduce the 
duration of ileus. However, a recent systematic review concluded that, although 
interventions such as chewing gum and caffeine were safe many of the trials had 
a high risk of bias. They concluded that, whilst the aetiology of postoperative 
ileus remains unclear, minimally invasive surgery, protocol-driven recovery 
programmes and attempts to avoid major inflammatory events represent the 
best chance of reducing the incidence of ileus (Chapman et al., 2018). 
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1.3.4 Wound infection 
Wound infection, or surgical site infection (SSI), can occur after any surgical 
procedure. They are common, accounting for up to 14 – 16% of all hospital 
acquired infections and increase the length of stay of the patient (Smith et al., 
2004). Superficial wound infections may be managed with removal of sutures or 
clips from the wound to allow pus to drain. Deeper infections often require 
systemic antibiotics and/or negative pressure dressings and occasionally results 
in full thickness wound dehiscence requiring a return to theatre with a potential 
prolonged recovery. 
 
 
1.4 Anastomotic leak 
1.4.1 The clinical definition of an anastomotic leak 
Anastomotic leak (AL) is one of the most challenging complications following 
colorectal surgery. The preferred definition of AL, as outlined by the UK Surgical 
Infection Study Group is, “…a leak of luminal contents from a surgical join 
between two hollow viscera” (Peel and Taylor, 1991). ALs are typically 
diagnosed at around day 6 - 8 post surgery (Kanellos et al., 2004, Alves et al., 
1999). The reported incidence of AL is variable ranging from 1-30% (Kingham and 
Pachter, 2009). Some of this variation is due to the impact of anatomical 
location of the anastomosis - low extraperitoneal joins have a much higher leak 
rate than right-sided colonic anastomoses (Platell et al., 2007).    
 
1.4.2 Patient and clinical consequences of an anastomotic leak 
 
When a leak occurs, bowel contents are able to leak into the normally sterile 
abdominal cavity, this can lead to significant morbidity and mortality. The 
economic burden of AL is estimated to be 1.1 – 3.5 million pounds per year in 
England (Ashraf et al., 2013) and $24,129 per person in the USA (Hammond et 
al., 2014). Mortality can be as high as 33% following a leak due to overwhelming 
sepsis and multiorgan failure in addition to requiring an ITU stay (Moher et al., 
2009). Many patients will require emergency surgery and formation of a stoma. 
It may be possible to subsequently reverse the stoma but in many cases it 
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becomes permanent (Erb et al., 2014) . Even when it is possible to reverse the 
stoma, it has been shown that patients who suffered an AL have impaired long-
term anorectal function (e.g. frequency, urgency and faecal incontinence) 
compared to those who did not suffer a leak (Nesbakken et al., 2001). AL has 
also be shown to lead to poorer long term cancer-specific survival (Mirnezami et 
al., 2011). Early detection of a leak is crucial in attempting to reduce the 
resultant morbidity and mortality.  
 
1.4.3 Clinical and surgical management of an anastomotic leak 
Management of a leak depends on the severity of the leak and the clinical 
condition of the patient. The Association of Coloproctology of Great Britain and 
Ireland (ACGBI) has recently issued guidance regarding the management of AL 
((ACGBI), 2016) (table 1.8). All those with a leak should receive oxygen, 
intravenous fluid, antibiotics and be managed in an environment (e.g. ward, 
high dependency, intensive care) appropriate to their overall condition. A small 
contained leak in a stable patient without radiological evidence of anastomotic 
discontinuity may be amenable to treatment with intravenous antibiotics and/or 
radiological drainage or may necessitate a return to theatre for washout and/or 
defunctioning. Defunctioning can involve bringing out a proximal end or loop of 
bowel whilst leaving the original anastomosis intact or suture repairing the 
anastomotic defect to allow it to heal. This temporary stoma may be able to be 
reversed at a later date but sometimes this is not possible and it becomes a 
permanent stoma with a potential impact on quality of life for that patient. If 
there is radiological evidence of multiple collections or anastomotic 
discontinuity then radiological drainage will not be likely to succeed. Those who 
do not respond to this management or have severe sepsis or septic shock should 
return to theatre for washout, resection of the anastomosis and creation of an 
end stoma.  
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TABLE 1.8 ACGBI RECOMMENDATION FOR MANAGEMENT OF AL ((ACGBI), 2016) 
Grade Description Management Source Control 
1 No sepsis Conservative None 
2 Sepsis/contained 
leak/abscess 
Drainage needed Radiological drainage. If 
unavailable, 
laparoscopy/laparotomy 
washout, drain and 
repair AL with proximal 
defunctioning stoma or 
resect anastomosis and 
create stoma 
3 Sepsis, ileus/ 
Single quadrant 
peritonitis 
Resuscitate and 
operate 
Laparoscopy/laparotomy 
washout, drain and 
proximal defunctioning 
stoma or resect 
anastomosis and create 
stoma 
4 Severe sepsis/ 
more than single 
quadrant 
peritonitis 
Resuscitate and 
operate 
Laparoscopy/laparotomy 
washout, resect 
anastomosis and create 
stoma 
5 Septic shock/ 
generalized 
peritonitis 
Resuscitate and 
operate 
Laparoscopy/laparotomy 
washout, resect 
anastomosis and create 
stoma 
 
 
The recommended time limits for intervention relate to the severity of sepsis 
and recommendations have been made by the Royal College of Surgeons of 
England: 
 Those without evidence of organ dysfunction should have a surgical or 
radiological intervention to achieve source control as soon as possible but 
at least within 18 hours; 
  If organ dysfunction is present intervention should take place within 6 
hours; 
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  In cases of septic shock intervention should be immediate, or at least 
within 3 hours (England, 2011).  
 
 
1.4.4 Difficulties in the standardized reporting of anastomotic leaks and 
implications for research 
 
Research and reporting of anastomotic leaks is hampered by the lack of a single 
universally accepted definition of what constitutes an anastomotic leak. 
Although in 1991 the UK Surgical Infection Study Group proposed the following 
definition, “…a leak of luminal contents from a surgical join between two hollow 
viscera” (Peel and Taylor, 1991), a 2001 review of 97 studies looking at the 
definition and measurement of anastomotic leakage after gastrointestinal 
surgery found 56 different definitions (Bruce et al., 2001). This goes someway to 
explaining the wide variation seen in the reporting of leak rates. It also makes 
comparison of existing research into AL difficult.  
 
In 2010 the International Study Group on Rectal Cancer defined AL as, “a 
communication between the intra- and extraluminal compartments due to a 
defect of the integrity of the intestinal wall at the anastomosis between the 
colon and the rectum or the colon and the anus”. They went onto to classify 3 
grades of anastomotic leakage (A-C). Type A (radiological leakage) is usually 
asymptomatic and requires no active intervention. Type B includes leaks treated 
by percutaneous or transanal drainage and antibiotics. Type C is a leak requiring 
laparotomy (which may involve washout and/or stoma formation) (Rahbari et 
al., 2010). Use of this grading system would allow future research to be 
interpreted and compared with greater clarity.  
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1.5 Methods of predicting anastomotic leakage and their 
limitations 
 
There has been considerable interest in trying to predict which patients may 
develop an AL to minimise the complications listed already. A range of pre-
operative and intra-operative risk factors have been identified which confer an 
increased risk of anastomotic leak. 
 
1.5.1 Pre-operative patient and pathological risk factors 
 
These can be divided into modifiable and non-modifiable risk factors. 
 
a. Non-modifiable risk factors 
 
Gender 
 
Males have been consistently found to have an increased risk of AL (Boccola et 
al., 2011, Lipska et al., 2006). In a study of 956 patients undergoing a TME with 
primary anastomosis for rectal cancer, 10.6% of male patients suffered a leak 
versus only 5.1% in females, the difference was statistically significant (Zhou et 
al., 2018). The reason for the difference between males and females is likely to 
be multifactorial and, as yet, not fully elucidated. The fact that the male pelvis 
is narrower and more technically challenging to operate in may account for some 
of the difference (Law et al., 2000). The effect of hormones on the intestinal 
microcirculation is also of interest. Ba et al found that androgens play an 
inhibitory role in small intestinal epithelial function (Ba et al., 2004), potentially 
impairing healing of the anastomosis. Recent work in animal models of colonic 
anastomoses has also demonstrated a significantly lower level of soluble 
collagen levels on post-operative day 3 in male rats compared to females (Kjaer 
et al., 2018). More work is needed to establish if these findings also apply to 
humans and, if so, to develop strategies to mitigate the effects. Overall, Zhou et 
al recommend that consideration should be given to creation of a temporary 
covering stoma in any male patient having a low anastomosis, especially if there 
is any concern about the anastomosis at the time of surgery (Zhou et al., 2018).  
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Age 
 
The impact of increasing age on rates of AL is not entirely clear. A large study of 
1391 patients undergoing anterior resections found that increasing age was 
associated with a higher rate of AL (Jung et al., 2008). Damhuis et al also found 
that mortality and operative morbidity increased with age in patients undergoing 
surgery for colorectal cancer (Damhuis et al., 1996). In contrast, Matthiessen et 
al looked at 432 anterior resections and found that advanced age was not an 
independent risk factor for AL (Matthiessen et al., 2004). Arenal et al also found 
that age > 70 was not associated with increased risk (Arenal et al., 1999). 
Despite the lack of clear evidence as to whether age is an independent risk 
factor for AL the literature is clear that good operative outcomes can be 
achieved in older patients with colorectal cancer and surgery/primary 
anastomosis should not be denied on the basis of age alone (Edna and Bjerkeset, 
1997, Barrier et al., 2003, Houry et al., 1994). 
 
Fitness/co-morbidities 
 
The American Society of Anaesthesiologists (ASA) grading system is used to 
classify patients’ general fitness prior to surgery (see table 1.9). An ASA score of 
3 or more is associated with increased risk of AL (Buchs et al., 2008, Mäkelä et 
al., 2003, Choi et al., 2006). In addition, co-morbidities such as vascular, 
pulmonary and renal disease increase the risk of AL (McDermott et al., 2015). 
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TABLE 1.9 ASA GRADING SYSTEM 
ASA grade Description 
I Normal healthy person 
II Mild systemic disease 
III Severe systemic disease 
IV Severe systemic disease that is a constant threat to life 
V A moribund person not expected to survive without surgery 
VI A declared brain-dead person whose organs are being removed 
for donor purposes 
 
 
Emergency surgery 
 
Creation of an anastomosis during an emergency operation carries a higher risk 
of AL compared to during an elective procedure (Boccola et al., 2011, Platell et 
al., 2007). However, emergency surgery is not an absolute contraindication to 
creation of an anastomosis. It has been shown in studies, including a randomised 
controlled trial (RCT), that in the case of perforated diverticular disease primary 
anastomosis with covering ileostomy is a safe and successful option 
(Constantinides et al., 2007, Oberkofler et al., 2012). Emergency surgery is 
often challenging with patients being more “unwell” than those operated on 
electively, for example those with a perforation are often septic requiring 
inotropic circulatory support and frequently experience greater blood loss. It is 
the accumulation of these risk factors, rather than just emergency surgery itself, 
that is likely to increase the risk of AL after emergency surgery. It is therefore 
the case that emergency surgery is a relative, rather than absolute, risk for AL.  
 
Features of the tumour 
 
Increasing size of the tumour and TNM stage of the cancer are risk factors for AL 
(Boccola et al., 2011, Eberl et al., 2008, Warschkow et al., 2011). In addition, 
the presence of metastatic disease at the time of surgery increases risk 
(Richards et al., 2012). This may be a consequence of poor nutrition with 
advanced disease but there is also evidence that those with advanced or 
metastatic disease have a cancer-associated systemic inflammatory response 
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which has been shown to result in an increased risk of post-operative infective 
complications (Richards et al., 2012, Moyes et al., 2009). 
 
b. Modifiable risk factors 
 
Smoking  
Current (Bertelsen et al., 2010, Bisgård et al., 2013, Richards et al., 2012) and 
previous heavy smoking (Kruschewski et al., 2007) (greater than 40 pack year 
history) are independent risk factors for AL. The reasons for the association are 
likely to be complex but it is postulated that smoking may alter/impair blood 
flow to the mucosa and therefore have a detrimental effect on the healing of 
the anastomosis (Richards et al., 2012). 
 
Alcohol  
In a study of 333 patients undergoing colonic or rectal resections with 
anastomosis (> 15.3% leak rate), those who consumed excess alcohol (>21 units a 
week) compared with those who abstained had a relative risk of an AL of 7.18 
(Sørensen et al., 1999). 
 
Obesity  
Raised body mass index (BMI) (Benoist et al., 2000, Senagore et al., 2003), and 
in particular increased waist circumference, is an independent risk factor for AL 
(Kartheuser et al., 2013). 
 
Neoadjuvant therapy  
It was previously thought that neoadjuvant radiotherapy +/- chemotherapy 
increased the risk of AL (Warschkow et al., 2011, Park et al., 2013) but recent 
RCTs have not supported this (Sebag-Montefiore et al., 2009, Marijnen et al., 
2002, Chang et al., 2014). However, a history of previous pelvic radiotherapy, 
e.g. for prostate or cervical cancer, is a risk factor for AL (Smith et al., 1985).  
 
Nutrition  
Malnutrition, preoperative weight loss and electrolyte disturbances have been 
shown to increase risk of AL in patients undergoing right hemicolectomies 
(Veyrie et al., 2007) and rectal resections (Kang et al., 2013).  
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Non-steroidal anti-inflammatory drugs (NSAIDs) 
As part of a multi-modal analgesia approach in enhanced recovery programmes 
after colorectal surgery the role of NSAIDs has been controversial. A large study 
by Gorissen et al in 2012 found that use non-selective NSAIDs and non-selective 
cyclo-oxygenase 2 (COX-2) inhibitors was associated with a higher rate of AL  
(Gorissen et al., 2012). However, in a meta-analysis of 6 studies published the 
following year the AL rate was not significantly higher in those who received 
NSAIDs in the post-operative period (Burton et al., 2013). Since then, 3 further 
meta-analyses have been published (Smith et al., 2016, Huang et al., 2018, 
Modasi et al., 2019). All have shown that the use of NSAIDs is associated with an 
increased risk of AL. However, when sub-divided into non-selective NSAIDs (e.g. 
diclofeac) and selective COX-2 inhibitors (e.g. celecoxib) only the non-selective 
NSAIDs are consistently associated with increased risk of AL. Based on the 
current available evidence, the use of a non-selective NSAID is not to be 
recommended in the post-operative period, COX-2 inhibitors may be safe but 
larger RCTs are required to clarify their safety following colorectal surgery.  
 
Immunosuppressant and immune-modulator drugs  
Patients on a prolonged course of corticosteroids have an increased risk of AL 
(Slieker et al., 2012). The monoclonal antibody infliximab has been show to 
delay wound healing but not to increase the risk of AL (Canedo et al., 2011, 
Krane et al., 2013). Mycophenolate (Zeeh et al., 2001), tacrolimus (Schäffer et 
al., 1998) and cyclosporin (Petri et al., 1998) have also been found to increase 
the risk of AL in experimental studies. One of the new chemotherapy agents, 
bevacizumab (a vascular endothelial growth inhibitor), works by reducing 
neovascularization and healing therefore increasing the risk of AL. Consequently 
the manufacturer recommends stopping it 28 days prior to surgery and waiting at 
least 28 days before restarting it (Inc, 2015). 
 
Mechanical bowel preparation (MBP) 
MBP was traditionally used to prepare the bowel for surgery as it was thought 
that clearing the bowel would reduce infection and AL rates. MBP also aids 
insertion of stapling devices and provides better views during intra-operative 
endoscopy. However, MBP is unpleasant with up to 40% of patients taking it 
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reporting discomfort (Bretagnol et al., 2010). The GRECCAR III RCT found that 
whilst in rectal resections MBP reduced the rate of infectious complications it 
did not lower the risk of AL (Bretagnol et al., 2010). Meta-analyses and 
systematic reviews looking at MBP for all types of colorectal resections have 
found that its use does not reduce the risk of AL (Slim et al., 2009, Guenaga et 
al., 2009, Cao et al., 2012). Consequently, the ACGBI advises that MBP is not 
essential for colorectal surgery ((ACGBI), 2016). 
 
Antibiotics 
Perioperative (within 30-60 minutes before surgery) parenteral antibiotics are 
given as standard during elective colorectal surgery (Nelson et al., 2009). 
Recently studies have explored the use of oral antibiotics pre-operatively for 
selective decontamination of the digestive tract (SDD). Different protocols exist 
ranging from single to multiple antibiotics and use of antibiotics for 1 or 2 days 
pre-operatively to continuation of treatment post-operatively. A meta-analysis 
of 8 studies found that SDD combined with parenteral antibiotics reduced rates 
of post-operative infection and AL (Roos et al., 2013). More recently, a large 
trial has shown that the combination of mechanical bowel preparation with pre-
operative antibiotics reduced the rate of post-operative wound infection and AL 
(Scarborough et al., 2015). This finding may mean that over the next few years 
more surgeons return to using MBP but also combine it with antibiotics. 
 
 
1.5.2 Intra-operative risk factors 
 
The fundamental basis of creating a healthy anastomosis that heals without 
complication is good surgical technique with sound apposition of two healthy 
ends of bowel. The ends must not be under excess tension and must have a good 
blood supply. However, there are a myriad other intra-operative variables that 
have been shown to influence the rate of AL. 
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Duration of surgery 
 
Prolonged operating times have been found to be an independent risk factor for 
AL. However, it may be the case that prolonged operating time of over 3-4 hours 
is a surrogate for complex or challenging surgery (Mäkelä et al., 2003, 
McDermott et al., 2015). More extensive dissection may have been required, or 
time taken to control bleeding which may have necessitated blood transfusion or 
brief use of vasopressor or inotropic agents. 
 
Fluid therapy 
 
Several studies have indicated that a policy of restrictive fluid replacement 
reduced general complications after colorectal surgery (rate of AL was not 
specifically addressed) (Brandstrup et al., 2003, Nisanevich et al., 2005). 
However, a systematic review and meta-analysis looking at the effect of 
perioperative fluid restriction on complications after colorectal surgery found no 
significant difference in rates of post-operative complications (Boland et al., 
2013). There has been growing interest in the use of oesophageal Doppler 
monitoring of cardiac output to guide individual goal-directed fluid therapy. Two 
meta-analyses found that the use of oesophageal Doppler monitoring reduced 
complications after major abdominal surgery (Abbas and Hill, 2008, Walsh et al., 
2008). Although the role of oesophageal monitoring has not been studied in 
direct relation to AL, the use of oesophageal Doppler monitoring to guide intra-
operative fluid therapy is now recommend by the NICE guidelines in major 
abdominal surgery (Ghosh et al., 2011). 
 
Inotropes 
 
The use of inotropes increases the risk of AL. Zakrison et al (Zakrison et al., 
2007), found that their use increased the risk 3-fold and the risk was greater if 
multiple agents were used. This increased risk was independent of the general 
fitness and operative morbidity of the patient as judged by the Acute Physiology 
and Chronic Health Evaluation (APACHE) and Physiological and Operative 
Severity Score (POSSUM) scores respectively. The mechanism is thought to be 
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vasoconstriction leading to impaired splanchnic perfusion thus a reduced blood 
supply to the anastomosis. 
 
Blood loss and blood transfusion 
 
Increased perioperative blood loss (Bertelsen et al., 2010), blood loss of > 100ml 
(Leichtle et al., 2012) and the requirement for multiple transfusions (Mäkelä et 
al., 2003) are associated with an increased risk of AL. 
 
Anastomosis technique 
 
Anastomoses are either hand sewn or created using a stapling device. For 
colorectal anastomoses a Cochrane review found no difference in AL rates with 
either method (Neutzling et al., 2012). In the case of right-sided surgery with 
ileocolic anastomoses the Cochrane review favoured stapled anastomoses (Choy 
et al., 2011). 
 
Level of anastomosis 
 
Lower, left sided anastomoses, particularly of the rectum, have a higher risk of 
AL compared to right-sided anastomoses (Lipska et al., 2006, Alves et al., 2002). 
In one series the leak rates were 2.2% for right hemicolectomy and 7.4% for 
anterior resection of the rectum (Lipska et al., 2006). Furthermore, the lower in 
the rectum the anastomosis is the higher the leak rate. Those < 5cm from the 
anal verge are particularly at risk (Rullier et al., 1998). 
 
Diverting stomas 
 
As low colorectal anastomoses are known to be at risk of AL many surgeons 
choose to create a diverting stoma, either end ileostomy, loop ileostomy or loop 
colostomy in an attempt to protect the anastomosis and reduce the impact of 
peritoneal soiling following a leak. Four RCTs (Graffner et al., 1983, Pakkastie et 
al., 1997, Pimentel et al., 2003, Matthiessen et al., 2007a), including one with 
over 200 patients, have demonstrated reduced leaks after formation of a 
diverting stoma. When their results were pooled in a meta-analysis (Hüser et al., 
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2008), creation of a diverting stoma was supported. A Cochrane review in 2010 
(Montedori et al., 2010) added further support to this and added that although 
not all studies have found a significantly reduced rate of AL with diverting 
stoma, patients with one who have a leak have less morbidity and need for 
repeat surgical intervention. It appears that an ileostomy rather than colostomy 
is superior, in part due to reduced infective complications (Chen et al., 2013, 
Rondelli et al., 2009). 
 
Placement of drains 
 
Commonly drains have been left in situ following colorectal anastomotic surgery 
with the aim of reducing the risk of complications and as an aid to identifying 
complications such as AL. Two systemic review and meta-analyses looked at the 
role of drainage following colorectal surgery. Patients had a variety of 
operations from right hemicolectomy to anterior resection. They found that 
insertion of a drain did not significantly decrease the risk of AL (Karliczek et al., 
2006, Petrowsky et al., 2004). Consequently, many surgeons now chose not to 
leave a drain. This is particularly the case in the context of enhanced recovery 
programmes which advocate the omission of drains and the early removal of  IV 
lines and urinary catheters in order to promote mobility and an early return to 
“normal” function (Varadhan et al., 2010). However, in a recent meta-analysis 
Rondelli and colleagues (Rondelli et al., 2014) looked at the role of drains in 
extraperitoneal anastomoses e.g. low anterior resection where the risk of AL is 
known to be greater than in other intraperitoneal anastomoses. There were 8 
studies including 3 RCTs. They found that patients who had a drain where 
significantly less likely to develop an anastomotic leak and less likely to require 
reintervention. Overall it would seem that drains do not have an adverse effect 
on outcome and there is evidence to support their routine usage in low 
colorectal anastomoses. Despite this, placement of a drain following a low pelvic 
anastomosis is still not routine practice in all surgical units and is a the 
discretion of the operating surgeon. 
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Air-leak testing 
 
Performing an air-leak test can highlight deficiencies in the anastomosis at the 
time of surgery and allows the surgeon to take steps to correct this either by 
reinforcing the anastomosis, redoing it or considering creation of a stoma. 
Briefly, one surgeon manually occludes the bowel proximal to the newly created 
anastomosis, saline is poured into the abdominal cavity around the anastomosis 
and an assistant injects air via syringe into the colon via the anus. Bubbles of air 
seen in the fluid indicate a breach in the anastomosis as air is able to move from 
the colon into the saline. This test is relatively simple and does not add 
significantly to the length of the operation. Data from a RCT (Beard et al., 1990) 
and other studies (Ricciardi et al., 2009, Ivanov et al., 2011) have consistently 
found that performing an intra-operative air-leak test reduced the risk of 
clinically apparent anastomotic leaks, in the RCT AL was reduced from 14% to 
4%. 
 
Intra-operative endoscopy 
 
Several studies have shown that the use of intra-operative endoscopy (Li et al., 
2009, Shamiyeh et al., 2012, Carlo and Valerio Corazza, 2012) to assess the 
anastomosis may be useful in reducing the risk of anastomotic complications. 
However, there have yet to be any RCTs in this area and many surgeons remain 
wary of inserting a sigmoidoscope or colonscope through newly anastomosed 
bowel for fear of physically damaging the new join. 
 
Laparoscopic versus open surgery 
 
A multi-centre randomized controlled trial (the CLASICC trial) found no 
significant difference in the rate of AL in open versus laparoscopic surgery for 
colorectal cancer. Leak rates were 3% and 4% respectively for open and 
laparoscopic colonic resections and in rectal resections the rates were 7% and 8% 
respectively (Guillou et al., 2005). The COLOR trial also found no difference in 
AL in open versus laparoscopic colonic resections and found that laparoscopic 
resections required less analgesics and were discharged home earlier than those 
having open resections (Group, 2005).  
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Interest is now growing in the use of robotic surgery for colorectal cancer 
resections, in particular for rectal resections. The ROLARR trial found no 
difference in the rate of conversion to open surgery between robotic and 
laparoscopic colorectal surgery (Jayne et al., 2017). However, many of the 
surgeons in the trial were still on the “learning-curve” for robotic surgery and 
this may have impacted the results (Corrigan et al., 2018). A more recent 
systematic review and meta-analysis of 5 RCTs in robotic vs. minimally invasive 
surgery for rectal cancer concluded that robotic surgery resulted in fewer 
conversions to open surgery (Prete et al., 2018). The experience and availability 
of robotic surgery is likely to increase in the years to come and it will be 
possible to determine if it can impact on the incidence of AL. 
 
1.6 Current methods of detecting of an anastomotic leak 
following surgery and their limitations 
 
Currently detection of an anastomotic leak in the post-operative period requires 
a high index of suspicion taking into account known pre- and intra-operative risk 
factors and is aided by clinical assessment, measurement of objective clinical 
signs and blood tests. When a leak is strongly suspected radiological studies, 
most often CT scans, are performed in an attempt to confirm the diagnosis.  
 
 
1.6.1 Clinical assessment and objective clinical signs 
 
Heart rate, blood pressure, respiratory rate, oxygen saturation level, 
temperature and white cell count (WCC) are objective parameters measured 
routinely in all post-operative patients. Any deviation of these parameters from 
normal values can indicate the development of complications such as sepsis. 
Given the heterogeneity of presentation of AL any clinical deterioration in a 
patient may serve as an early indication of the development of AL. Erb et al (Erb 
et al., 2014) carried out a study looking at 452 patients undergoing colorectal 
surgery with formation of an anastomosis in a single centre over a 2 year period. 
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A total of 271 complications occurred in 141 patients, including 19 anastomotic 
leaks (4.2%). Over half the patients with an uncomplicated recovery (311 
patients) experienced tachycardia and tachypnoea at least once a day during 
their post-operative stay. Hypotension, pyrexia and a leucocytosis were also 
common. The positive predictive value (PPV) for any abnormal sign or WCC 
ranged from only 4-11%. Therefore, the development of abnormal vital signs 
following colorectal surgery with formation of an anastomosis can almost be 
considered routine and therefore alone they are poor predictors of AL.  
 
 
1.6.2 Blood tests 
 
C-reactive protein (CRP)  
 
CRP is an acute phase reactant produced in the liver in response to pro-
inflammatory cytokines such as interluekin-6. It actives the complement 
pathway and acts as a stimulus to phagocytosis of foreign and damaged cells 
(Pepys and Hirschfield, 2003, Mold et al., 1999). It has a half-life of 19 hours and 
is known to be a good marker of acute inflammation and is used post-operatively 
as a marker to help predict/identify infective complications (Bianchi et al., 
2004, Warschkow et al., 2012).  It has been extensively investigated in the 
context of AL and there have been 2 recent meta-analyses. In the first a cut-off 
CRP of 135 on post-operative day 4 had a negative predictive value of 89% for 
infective complications (Warschkow et al., 2012). In the second meta-analysis of 
2483 patients across 7 studies (including 3 RCTs) cut-off CRP levels of 172, 124 
and 144 on post-operative days 3, 4, and 5 respectively had a negative 
predictive value of 97% for anastomotic leak. However, PPV was 21-23% (Singh et 
al., 2014). It therefore seems that CRP has limited power to predict AL but may 
have a role as a “rule out test” providing reassurance to the surgeon that AL is 
unlikely. 
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Procalcitonin 
 
Procalcitonin (PCT) is produced by C cells in the thyroid gland and is involved in 
activation of neutrophils (Garcia-Granero et al., 2013). PCT is elevated in 
bacterial, fungal and parasitical infection but not in viral infection or non-
specific inflammation (Meisner et al., 2001). It has also been validated as an 
early marker of sepsis (Assicot et al., 1993). This makes it a particularly 
attractive marker of AL as it is more specific for bacterial infection and sepsis 
than CRP. In a study of 205 patients Garcia-Granero et al (Garcia-Granero et al., 
2013) had 17 patients who had an AL, of these 11 were classified as a “major 
leak” meaning they required either radiological or surgical intervention.  Serum 
PCT was not predictive of AL in general but an elevated PCT at post-operative 
days 3-5 was predictive of “major leak”. Performance on POD 5 was best with 
reported sensitivity of 100%, 72% specificity, 100% negative predictive value 
(NPV) but only 17% PPV.  
 
Komen et al (Komen et al., 2014a) looked at levels of CRP, PCT and 
lipopolysaccharide binding protein (LPS) in drain fluid of 243 patients. Whilst 
PCT was significantly higher in patients who developed a leak it was not found to 
be an independent predictor during subsequent multivariate analysis.  
 
In another smaller study of 84 patients (Reisinger et al., 2014) with 8 
anastomotic leaks on median day 6 (range 3-10) PCT appeared to be an earlier 
predictor of AL than CRP. Mean PCT was higher in those with AL on post-
operative days 2-4 whereas mean CRP only reached statistical significance on 
POD 4. They found that using a formula to create a combined score using PCT 
and CRP yielded the best results with sensitivity and specificity on POD 3 of 100% 
and 89% respectively. However, this was a relatively small study and values for 
PPV and NPV are not quoted. Clearly PCT may have some utility as a marker of 
AL but there are only a few studies with small numbers and heterogeneity of 
definitions of AL and there has yet to be a meta-analysis performed. 
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1.6.3 Imaging 
 
In cases where there is diagnostic doubt regarding the integrity of an 
anastomosis most clinicians will undertake imaging in an attempt to confirm or 
refute the presence of a leak.  Currently the most commonly used modality is 
CT. Where oral or rectal contrast has been used extravasation of contrast out 
with the bowel indicates a leak. Collections of air and fluid around the 
anastomosis also indicate a high probability of a leak especially if the surgery 
was performed more than 5 days previously. Reports on the sensitivity and 
specificity are variable but there is a consensus of opinion that CT alone is not a 
reliable test for AL (Hirst et al., 2014, McDermott et al., 2015). A 2013 meta-
analysis of 8 studies involving 2715 patients where 221 CT scans were performed 
found that the sensitivity of CT was only 68% (Kornmann et al., 2013) . The 
addition of oral or rectal contrast may be beneficial. Three of the studies just 
looked at rectal resections and all used rectal contrast, the sensitivity of CT 
across these studies was 92%. (Nesbakken et al., 2005, Eckmann et al., 2004, 
Kanellos et al., 2004). In the first few postoperative days interpretation of CT is 
particularly challenging as patients with and without AL may have similar 
features such as air-fluid collections (DuBrow et al., 1995, Matthiessen et al., 
2008).  
One study has explored the possibility of using Positron emission tomography 
(PET) scanning to detect a leak. Teeuwen et al showed that in normal 
uncomplicated recovery following colorectal surgery there is low uptake of F-18 
fluorodeoxyglucose (Teeuwen et al., 2012). Therefore, PET scanning may be of 
use in detecting deviations from the normal post-operative course possibly 
indicative of a leak but more work needs to be done to determine its usefulness 
in the detection of AL. 
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1.7 New/novel technologies to prevent or detect anastomotic 
leaks 
1.7.1 Intra-operative assessment of perfusion at the anastomosis 
Several studies have looked at assessment of the microperfusion of the 
anastomosis via measurement of blood flow or tissue perfusion. A recent 
systematic review by Nachiappan et al has assessed the current advances in this 
area (Nachiappan et al., 2014). Doppler assessment of blood flow has found an 
association between reduced blood flow and increased risk of AL (Ambrosetti et 
al., 1994, Hallböök et al., 1996, Vignali et al., 2000, Seike et al., 2007, Boyle et 
al., 2000). Two studies have measured tissue oxygen tension at the 
perianastomotic region. Measurements were made before and after creation of 
the anastomosis. In a study of 50 patients, Sheridan et al found a significant 
association between reduced oxygen tension and risk of anastomotic leak 
(Sheridan et al., 1987). Hall et al found an association between reduced oxygen 
tension and AL but it was not statistically significant (Hall et al., 1995). These 
studies illustrated that there may be some potential benefit in the technique but 
it is not readily available which may explain why no studies have looked at this 
again since 1995.  
 
Visible light oxygen spectroscopy has also shown good potential. Karliczek et al 
used a hand held probe to measure tissue oxygen saturation (St02) at the 
proposed site of anastomosis and again at the same site following anastomosis. 
No intraoperative actions were taken based on the results. Out of 77 patients 
there were 14 leaks. They found that reduced St02 at the perianastomotic site 
was associated with AL, specifically a rise in St02 was seen in the group of 
patient who did not have a leak (Karliczek et al., 2010). Hirano et al also looked 
at perianastomotic St02 using near infrared oxygen spectroscopy. They found 
that the 18/20 patients with no post-operative complications had a > 66% St02 
rise whereas the 2 patients with complications had a reduction in St02 (Hirano et 
al., 2006).  
 
Kudszus et al used indocyanine green with laser fluorescence angiography (LF 
ICG) to assess the perianastomotic site. In their study with 402 patients, 201 had 
assessment with LF ICG and the other 201 did not. In the LF ICG group, 28 
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patients had their operative management altered on the basis of the 
measurement. This essentially halved the number of anastomotic leaks with 
7/201 in the LF ICG group suffering a leak compared to 15/201 in the control 
group (Kudszus et al., 2010). Several other studies have proved that 
measurement of tissue perfusion with indocyanine green is feasible and has the 
potential to be useful in anastomotic surgery (Jafari et al., 2013, Sherwinter, 
2012, Sherwinter et al., 2013). The usefulness of this promising technology will 
be assessed in a multinational RCT (“The InAct Study”, the protocol for which 
was published in August 2018. Over 3 years 880 patients undergoing either high 
or low anterior resection for adenocarcinoma will be recruited. The primary 
outcome measure will be clinical AL at 90 days (Armstrong et al., 2018). 
 
 
1.7.2 Devices 
Over the years, attempts have been made to create mechanical devices to 
prevent, or reduce the consequences of AL. In a recent review, these devices 
were classified as transanal decompressive devices, intracolonic devices and 
biodegradable devices (Morks et al., 2011).  
Transanal decompressive devices keep the anal sphincter open and thus reduce 
intraluminal pressure and consequently reduce the pressure on the anastomosis. 
The results have been mixed. In a 2001 study of 50 patients undergoing low 
anterior resection, Sterk et al found that the rate of AL was not significantly 
different in those who received a transanal stent compared to those who 
received a loop colostomy (Sterk et al., 2001). In contrast, a large trial of 
transanal stents was stopped early due to increased complication rates in the 
stent group (Bülow et al., 2006). 
Several intraluminal devices have been trialled in animals with promising results 
(Morks et al., 2011). Intraluminal devices do not prevent the formation of an AL 
but they prevent faeces contacting the anastomotic site and therefore prevent 
leakage of faeces into the peritoneal cavity. In the 1980s a device called the 
“Coloshield”, which is a latex, rubber or silicon tube sutured to the submucosa 
proximal to the anastomosis which is naturally expelled several days after 
surgery, was developed for use in humans (Ravo, 1997). There were some 
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promising results but also some complications related to the device and it 
therefore did not achieve widespread acceptance. Another group used a latex 
condom which was sutured in place and naturally expelled around 10 days after 
surgery. In a group of 10 patients having a low anterior resection the condom 
was shown to be safe, practical and none of the patients went on to have an AL 
(Yoon et al., 1994). However, details about the patients in the study were 
lacking. As a result, intraluminal devices have not been adopted into common 
practice. 
Recently attention has focused on biodegradable devices. A Dutch group has 
developed a device called a “C-seal”. It is a thin-walled tube like a soft sheet or 
a condom with tapes at either end. The tapes are glued to the anvil of the 
circular stapler. This allows it to be fixed just proximal to the anastomosis. It 
degrades after about 10 days. In a pilot study of 15 patients undergoing stapled 
low anterior resections the device was safe and there were no ALs (Kolkert et 
al., 2011). However, in an RCT of the C-seal involving 402 patients undergoing 
colorectal anastomosis ≤15cm from the anal verge, those with the C-seal were 
found to have a higher rate of AL. Technical failures and complications of 
inserting the device were observed. Some of this may have been attributable to 
a lack of experience of surgeons inserting the device but overall the results 
mean that the C-seal is unlikely to become commonly used (Bakker et al., 2017).    
Overall, much of the work looking at intraluminal devices to prevent/reduce the 
consequences of anastomotic leak involves pilot studies in animals or small 
numbers of human subjects. However, it appears some of the work has had 
promising results and merits further investigation by clinicians and engineers 
working together. 
 
 
1.7.3 Electrical resistance 
Recently DeArmond et al (DeArmond et al., 2010) have used animal models of an 
upper gastrointestinal leak to detect anastomotic leak using changes in 
electrical resistance. In a pilot study using 8 rats with a surgically created 
gastrotomy they were able to show that when passing hypertonic saline solution 
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through the stomach there were electrical resistance changes in the rats with 
the gastrotomy. They have followed this up by comparing the technique to the 
performance of barium fluoroscopy in the detection of an anastomotic leak. 
Detection of electrical resistance had 100% sensitivity and specificity and was 
superior to barium fluoroscopy (DeArmond et al., 2013). However, this was a 
small study with only 10 rats. Similar studies have not been carried out in animal 
models of colorectal anastomotic leak or in humans. It would be interesting to 
see further research in this area as the technique has the advantages of being 
available at the bedside, giving rapid results and not being affected by the 
underlying pathological disease state. 
 
 
1.7.4 Measurement of peritoneal fluid biomarkers  
1.7.4.1  Definition of a peritoneal fluid biomarker 
A ‘biomarker’ is defined as, “…an objectively measured characteristic, which is 
an indicator of a physiological or pathogenic process, or a pharmacological 
response to a therapeutic intervention” (Colburn et al., 2001). There has been 
interest in trying to identify a biomarker of AL in the immediate environment of 
the anastomosis by sampling peritoneal fluid. These local biomarkers reflect 
conditions in the milieu of the anastomosis and have the potential to detect AL 
earlier and with greater specificity than systemic observations and blood 
parameters. In 2008 Komen et al suggested criteria for biomarkers of AL in 
peritoneal fluid (Komen et al., 2008) (table 1.10).  
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TABLE 1.10 SUGGESTED CRITERIA FOR A BIOMARKER OF AL. 
 
 Significant change in biomarker concentration in anastomotic 
leakage, 
 Stability of the biomarker in the peritoneal environment and drain 
fluid, 
 Biomarker level not influenced by the primary disease, 
 Biomarker with sufficient sensitivity and specificity  for anastomotic 
leakage, 
 Biomarker allows for easy, fast and cheap real-time  testing.  
 
 
1.7.4.2  Biomarkers of ischaemia 
Seven studies have looked at biomarkers of ischaemia measured either by 
microdialysis or in peritoneal drain fluid (table 1.11). The principle of this 
approach is that ischaemia at the anastomosis or in nearby bowel (just proximal 
or distal to the anastomosis) increases the risk of a leak (Thornton and Barbul, 
1997, Locke et al., 1984). In particular, studies have used lactate and pH as 
markers of ischaemia. 
 
1.7.4.1.1 Lactate 
1.7.4.1.1.1 Discovery of lactate 
Lactate was first discovered and described in sour milk in 1780 (Oberkofler et 
al., 2012). It takes its name from lact-, the latin for milk. In 1808 a Swedish 
chemist, Jons Jakon Berelius, found lactic acid in fluid extracted from meat 
(Constantinides et al., 2007, Platell et al., 2007). The first description of lactic 
acid as a pathological finding was in 1843 by Johann Joseph Scherer. He 
identified lactic acid in the blood of young women who had died of puerperal 
fever (Ricos C, 1999). Several years later in 1891 Araki and Zillessen 
demonstrated the relationship between tissue hypoxia and lactic acid. They 
showed that if they interrupted the oxygen supply to muscles in mammals and 
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birds lactic acid was formed and the levels of lactic acid increased (T, (1891) , 
T, 1891, T, 1892b, T, 1892a, H, 1891).  
 
1.7.4.1.1.2 Lactate metabolism 
Lactate is a metabolite formed during the cellular production of energy 
(adenosine triphosphate, ATP). Glycolysis is the first step in energy production 
and occurs in the cytoplasm of a cell. Glucose is broken down into two 
molecules of pyruvate and two molecules of ATP (figure 1.6). In the presence of 
oxygen, energy production proceeds via the aerobic pathway whereby pyruvate 
enters the Krebs’ cycle, a series of reactions takes place which removes carbon 
dioxide and generates hydrogen ions (figure 1.7). These high energy electrons 
then pass into the electron transfer chain on the inner membrane of the 
mitochondria. This is the final pathway in the production of energy and provides 
34 molecules of ATP. In the absence of oxygen, pyruvate does not pass into the 
mitochondria and instead undergoes fermentation. The enzyme lactate 
dehydrogenase (LDH) catalyses the conversion of pyruvate to lactate (figure 
1.8). The purpose of this is to oxidise the electron carriers so that they can 
participate in glycolysis again - NADH is oxidized to NAD+ which is then re-used 
in glycolysis. 
 
The rate of glycolysis can increase much more rapidly than oxidative 
phosphorylation, so briefly in times of cellular stress, glycolysis can produce 
more ATP than oxidative phosphorylation. Excess pyruvate rapidly accumulates 
and it is converted into lactate. ATP is also generated via this route in the 
absence of oxygen (anaerobic respiration), this again leads to an excess 
production of lactate. Therefore, elevated lactate can serve as a marker of a 
hypoxic environment. This relationship between tissue hypoxia and lactate has 
been confirmed by several studies (Cain, 1965, Zhang and Vincent, 1993). The 
balance of aerobic/anaerobic metabolism can be measured by the 
lactate/pyruvate ratio (LP ratio) with an increased ratio also indicating an 
ischaemic environment. Lactate and other markers of ischaemia can be 
measured in peripheral blood but they lack specificity in detecting AL (Corke 
and Glenister, 2001). 
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FIGURE 1.6 INTER-CONVERSION OF PYRUVATE TO LACTATE BY THE ENZYME LDH 
 
 
FIGURE 1.7 THE KREB’S CYCLE (STATE, 2002) 
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FIGURE 1.8. FERMENTATION OF PYRUVATE 
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TABLE 1.11 SUMMARY OF STUDIES LOOKING AT BIOMARKERS OF ISCHAEMIA 
 
Author, year Biomarkers 
studied 
Study 
design 
Definition of AL No. of 
patients 
No. 
of 
leaks 
Operations Method of 
biomarker 
measurement 
Frequency and 
duration of 
biomarker 
measurement 
Main results 
Millan, 
2006(Millan et 
al., 2006) 
pH Prospective All patients had 
CT or contrast 
imaging on POD 
6. Divided into 
subclinical and 
clinical but 
analysed 
together. 
90 10 Anterior 
resections for 
colorectal 
cancer 
Tonometry 
catheter 
placed just 
superior to the 
anastomosis.  
Samples taken at 
24 & 48hrs after 
surgery 
pH at 24 hrs, but not 
48 hrs, significantly 
lower in those with AL 
Matthiessen, 
2007(Matthiessen 
et al., 2007b) 
LP ratio, 
glucose 
Prospective Peritonitis 
caused by 
leakage, pelvic 
abscess or 
discharge of 
faeces from 
drain or a fistula. 
Confirmed by 
imaging or DRE. 
23 7 Anterior 
resections for 
colorectal 
cancer 
Measurement 
via 
microdialysis  
Samples every 2 
hours until POD 2 
and then every 6 
hours until POD 6. 
LP ratio significantly 
increased on POD5 & 
6 in those with AL.  
Glucose not 
significant. 
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Pedersen, 2009 
(Pedersen et al., 
2009) 
Glucose, 
lactate, 
pyruvate, 
glycerol, LP 
ratio 
Prospective Peritonitis or 
abscess with 
“proven 
dehiscence” – no 
mention of how 
it was proven. 
Fistulas NOT 
counted as AL. 
50 4 Low anterior 
resections for 
cancer 
Measurement 
via 
microdialysis 
Samples every 4 
hours until 
discharge or POD 
10 
3 patients had a late 
leak and lactate 
levels and LP ratio 
was significantly 
increased prior to 
onset of symptoms. In 
one case of early leak 
increased lactate 
coincided with onset 
of symptoms 
Horer, 
2011(Horer et 
al., 2011) 
Glycerol, 
lactate, 
pyruvate, 
glucose, LP 
ratio 
Prospective No definition 
given. AL 
included in 
“major 
complication” 
category. 
60 16*  Various 
gastrointestinal 
and intra-
abdominal 
vascular 
surgeries 
Measurement 
via 
microdialysis 
Every 2 hrs until 48 
hrs post surgery 
LP ratio was 
significantly elevated 
and glycerol levels 
significantly lower in 
those with AL 
 
Lactate alone - no 
significant difference 
Yang, 2013(Yang 
et al., 2013) 
pH Prospective Pelvic abscess, 
faecal/purulent 
discharge from 
drain, fistulas, 
peritonitis 
confirmed 
753 57 Anterior 
resections for 
cancer 
Peritoneal 
drain sample  
Daily until POD 12 pH < 6.978 on POD 3  
significantly 
associated with AL, 
sensitivity 98.7% and 
specificity 94.7% 
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radiologically 
and all needed 
additional 
surgical 
treatment. 
Bini, 2014(Bini et 
al., 2014) 
Lactate Prospective No definition 
given. AL 
included in group 
requiring 
“reintervention”. 
88 31 * Various 
gastrointestinal 
operations 
Measurement 
from 
peritoneal 
drain on POD 4 
in those 
meeting the 
criteria: late 
passage of 
flatus, pain, 
pyrexia & 
raised white 
cell count 
Once on POD 4 Peritoneal lactate 
level >9.1mmol and 
peritoneal: serum 
lactate level ratio > 
4.5 significantly 
associated with 
requiring 
reintervention 
Daams, 
2014(Daams et 
al., 2014) 
Lactate, 
pyruvate, 
glucose, 
glycerol 
Prospective Clinical suspicion 
of intra-
abdominal 
complication was 
investigated by 
CT to diagnose 
AL. All AL were 
24 3 Left sided 
colonic 
resections for 
cancer or 
diverticular 
disease 
Measurements 
via 
microdialysis  
Every 4 hours until 
POD 5 
Mean intra-peritoneal 
lactate levels, but not 
LP ratio, was 
significantly higher in 
those with AL 
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confirmed at 
reoperation or 
endoscopy. 
*End point was “patient requiring reintervention”, of the 31 in this group 11 had an AL 
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1.7.4.1.1.3 Studies using lactate as a marker of ischaemia 
Several of the studies used microdialysis (Matthiessen et al., 2007b, Pedersen et 
al., 2009, Horer et al., 2011, Daams et al., 2014) to measure lactate. This 
technique has been previously used to study tissue ischaemia (Kanthan et al., 
1995) and involves inserting very small probes with dialysis membranes into the 
operative field at the end of a procedure. Fluid then flows through the circuit 
constantly allowing measurement of various analytes including lactate and 
pyruvate. Trials in animal models of intestinal ischaemia showed that increased 
lactate and LP ratios were reliable markers of local ischaemia (Klaus et al., 
2002, Sommer and Larsen, 2004).  
 
Matthiessen et al (Matthiessen et al., 2007b) measured LP ratio and glucose for 6 
days following anterior resections in 23 patients. Four “early leaks” on post-
operative days (PODs) 2-14 and 3 “late leaks” on PODs 18-22  were analysed  
together as a “leak group”. LP ratios on PODs 5 & 6 were significantly higher in 
those with AL, glucose was not significantly different. However, as the numbers 
were low it was not possible to determine cut-off levels for LP ratio to indicate 
the likelihood of a leak.  Pedersen et al (Pedersen et al., 2009) looked at 45 low 
anterior resections. In one AL on POD 5 lactate levels were significantly 
increased 18 hours before the onset of symptoms and LP ratio became 
significantly elevated at the onset of symptoms.  Three other patients developed 
a leak at day 10 or later. LP ratio and lactate levels were significantly increased 
compared to controls throughout the first 5 days following surgery (Pedersen et 
al., 2009). Daams et al (Daams et al., 2014) measured lactate, pyruvate, 
glycerol and glucose every 4 hours for 96 hours in 24 patients undergoing left 
sided colorectal anastomoses. In 3 patients with ALs median intraperitoneal 
lactate levels, but not LP ratio were significantly higher. There appeared to be 
spikes in lactate prior to POD 3 in the leak group but cut-off values were not 
described. It is important to note that 2 of the leaks occurred early at PODs 4 
and 5, the third was said to have occurred at POD 97 but the three were grouped 
together. Horer et al (Horer et al., 2011) had similar findings, they noted that 
increased LP ratio and decreased glycerol levels were associated with “major 
intra-abdominal complications”. However, this was in a varied cohort of 
abdominal surgeries including colorectal anastomosis, abdominal aortic 
aneurysm (AAA) repair, gastric procedures and cholecystectomy.  
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Bini et al (Bini et al., 2014) looked at lactate via peritoneal drain fluid on POD 4 
in patients who met all 4 of the following criteria: pyrexia (>38.3), raised white 
cell count (>12), delayed passage of flatus (>72 hours) and abdominal pain. A 
peritoneal/serum lactate level > 4.5 or peritoneal lactate level > 9.1 were 
significantly associated with postoperative complications requiring intervention 
(ALs were included in this group). However, this selection bias with no control 
group limits the interpretation of these findings.  
 
1.7.4.1.2 pH 
1.7.4.1.2.1 The definition of pH 
pH is a numerical scale from 0 - 14 that specifies the acidity or alkalinity of a 
solution. pH 7 is neutral, solutions with a pH < 7 are acidic and those with pH > 7 
are alkaline. pH is  measure of the concentration of hydrogen ions {H+} and can 
be calculated as follows: 
pH = - log {H3O+} 
 
1.7.4.1.2.2 pH as a marker of ischaemia 
In a hypoxic environment mitochondria cannot produce sufficient ATP. The rate 
of glycolysis is therefore increased to provide extra ATP. Whilst increased 
glycolysis helps to compensate for reduced ATP from oxidative phosphorylation 
it cannot bind the additional hydrogen cations that result from ATP hydrolysis. 
This leads to an increased hydrogen cation concentration (thus a reduction in 
pH) (Hochachka and Mommsen, 1983). Therefore a low pH is a marker of a 
hypoxic environment. 
 
Adequate perfusion and oxygenation are essential for healing of an anastomosis 
(Thornton and Barbul, 1997). In the 1960s it was shown that intramucosal pH 
correlated with blood supply to the mucosa (Bergofsky, 1964) – a low pH being 
indicative of poor perfusion. Measurement of pH via tonometry, a non-invasive 
method of measuring intramucosal pH, was found to be a good prognostic 
indicator of the viability of the gastroesophageal anastomosis following thoracic 
oesophagectomy (Tarui et al., 1999). This has lead to pH being investigated as a 
potential biomarker for colorectal AL. 
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1.7.4.1.2.3 Studies using pH as a marker of ischaemia 
Two studies have investigated pH as a biomarker. In the first, a catheter was 
sited intraluminally just above the anastomosis and pH measured via tonometry 
(a non-invasive method to measure intramucosal pH in hollow organs). All 
patients were imaged on POD 6 and “clinical” and “subclinical” leaks were 
analysed together in a “leak group”. The “leak group” had a significantly lower 
pH. A pH < 7.28 yielded a specificity of 98.3% but sensitivity was only 28.1% 
(Millan et al., 2006).  Yang et al (Yang et al., 2013) measured the pH of fluid 
collected from peritoneal drains up to POD 12 following rectal surgery in 753 
patients. There were 57 leaks (7.6%) on PODs 6-12 requiring surgical 
intervention, subclinical leaks were not included. pH was significantly lower in 
patients who leaked. pH < 6.978 on POD 3 showed excellent sensitivity (98.7%) 
and specificity (94.7%).  However, no confidence intervals or ranges were 
provided so it is difficult to know how much overlap there is between groups. 
The authors highlight the decline in pH was notable prior to the detection of a 
leak in all of the patients. Whilst the results of the large study by Yang et al 
would suggest that POD 3 drain pH is an extremely useful test for AL, it has not 
gained widespread acceptance as a test. This is perhaps because it remains a 
single centre study and surgeons are reticent about changing practice based on 
one study alone. It is therefore important to attempt to replicate this study to 
validate or refute the findings. 
 
Overall, of the biomarkers of ischaemia, lactate and pH emerge as the best 
candidates for further research. Most studies measured lactate by microdialysis 
(Matthiessen et al., 2007b, Pedersen et al., 2009, Daams et al., 2014, Horer et 
al., 2011) which is expensive, labour-intensive and technically challenging (e.g. 
9 (20% of cases) technical failures in (Daams et al., 2014)). In contrast, 
measurement of lactate from peritoneal drain fluid may provide a quick, easy 
and inexpensive alternative. The stability of lactate and pH in peritoneal 
drainage fluid needs to be addressed. The stability of these biomarkers in 
peritoneal fluid has not been explored but it has been shown that lactate levels 
rise in blood if there is a delay in analysis (Calatayud and Tenias, 2003). It would 
therefore be pertinent to address this issue in peritoneal fluid. 
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1.7.4.3  Biomarkers of bacterial infection 
This approach is based upon the principle that if the colorectal anastomosis 
breaks down bacteria which are normally contained within the bowel lumen can 
spill into the peritoneal cavity. Four studies have explored whether detection of 
intra-peritoneal bacteria and its quantitative assessment could aid early 
detection of AL (table 1.12).  
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TABLE 1.12 SUMMARY OF STUDIES LOOKING AT BACTERIAL BIOMARKERS 
 
Author, 
year 
Bacterial 
biomarker studied 
Study 
design 
Definition of 
AL 
No. of 
patients 
No. 
of 
leaks 
Operations Method of 
biomarker 
measurement 
Duration and 
frequency of 
measurement 
Main results 
Junger, 
1996 
(Junger et 
al., 1995) 
Lipopolysaccharide 
(LPS) 
Prospective “Clinical signs 
of a leak” 
22 3 “Colorectal 
anastomoses” 
Sample from 
peritoneal 
drain fluid. 
Daily until POD 
8 
LPS 
significantly 
increased in 
those with AL 
Komen, 
2009(Komen 
et al., 
2009) 
E coli, e faecalis Prospective Not defined 9 0 Various 
colorectal 
resections 
from 
ileocaecal 
resections – 
low anterior 
resection; 
benign & 
malignant 
Sample from 
peritoneal 
drain fluid.  
 
Fluid sent for 
bacterial 
culture and for 
RT-PCR to 
detect 
bacteria. 
Morning daily 
sample until 
POD 5 
RT-PCR 
results fully 
concordant 
with culture 
results but 
there were 4 
false 
positives. 
Fouda, 
2011(Fouda 
et al., 
2011) 
E coli, Klebsiella, 
pseudomonas, 
bacteroides 
Prospective Gas, pus, or 
faecal 
discharge 
from the 
56 8 Low anterior 
resections for 
malignancy 
Sample from 
peritoneal 
drain fluid.  
 
Samples on 
POD 1, 3 & 5 
E coli, 
Klebsiella, 
pseudomonas 
& bacteroides 
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drain, faecal 
discharge 
from the 
operative 
wound, pelvic 
abscess, 
peritonitis, 
and 
rectovaginal 
fistula. 
Confirmed by 
radiological 
contrast 
study, CT 
scan or digital 
rectal 
palpation. 
 
cultured 
significantly 
more often 
from patients 
with AL 
Komen, 
2014(Komen 
et al., 
2014b) 
E coli, e faecalis Prospective A clinical 
state 
requiring 
reintervention 
confirmed by 
243 19 Left sided 
colorectal 
resections; 
benign and 
malignant 
Sample from 
peritoneal 
drain fluid.  
 
Fluid sent for 
Morning daily 
sample until 
POD 5 
E coli 
concentration 
significantly 
increased on 
POD 4 & 5 and 
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radiological 
studies, 
operative 
findings or 
faecal 
discharge 
from the 
drain. 
RT-PCR to 
detect 
bacteria. 
E faecalis on 
POD 2,3 &4 in 
those with AL. 
Best 
diagnostic 
odds ratio was 
e faecalis on 
POD 3. 
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Fouda et al (Fouda et al., 2011) looked at intra-peritoneal bacterial colonization 
in peritoneal drain fluid samples from 56 low anterior resections on POD 1, 3 and 
5. Eight ALs were “detected clinically” and confirmed on imaging.  E Coli, 
Bacteroides and Pseudomonas were cultured significantly more often on POD 1, 
3 and 5; and Klebsiella on PODs 3 and 5 in patients with AL. However, specificity 
was low as there were several false positives with all 4 bacteria detected in 
patients who did not develop  AL.  
 
The time delay in growing cultures limits its applicability and usefulness as a 
rapidly analysable biomarker of AL. Komen et al addressed this in a pilot study 
of 17 patients using real-time polymerase chain reaction (RT-PCR). Peritoneal 
drain fluid was sampled daily up to POD 5 using E Coli and Enterococcus Faecalis 
as indicator organisms. RT-PCR results were fully concordant with 
microbiological cultures. However, the technique lacked specificity as there 
were 4 false positive results (Komen et al., 2009). The authors progressed to a 
multicentre study of 243 patients undergoing elective left sided colonic 
anastomosis. There were 19 leaks (7.8%) on mean POD 6 (2-26 days).  E Coli 
concentration was significantly increased on PODs 4 & 5 and E Faecalis on PODs 
2, 3, & 4 in those with AL. E Faecalis on POD 3 achieved the best results with a 
sensitivity and negative predictive value of 92.9% and 98.7% respectively, the 
diagnostic odds ratio was 31.6 but specificity and positive predictive value were 
only 70.9% and 30.2% respectively (Komen et al., 2014b). Despite the large 
number of false positives the study demonstrated that the absence of E Faecalis 
on day 3 could potentially exclude AL.  
 
In 1996 Junger et al (Junger et al., 1995) looked at peritoneal drain 
lipopolysaccharide (LPS) levels (a component of the outer wall of gram-negative 
bacteria) in 22 patients. LPS levels were significantly elevated in 3 patients with 
AL. However, 2 of these patients had surgery for perforated sigmoid 
diverticulitis so levels may have been elevated due to pre-existing bacterial 
contamination. LPS has not been explored again. 
 
Overall, bacterial biomarkers for AL may have some utility in acting as a “rule-
out” test for AL. Whilst RT-PCR for bacteria offers fast, real-time testing it is not 
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commonly performed in most hospital laboratories which may limit its 
usefulness. 
 
 
1.7.4.4  Biomarkers of inflammation (cytokines) 
Seven studies have explored the measurement of peritoneal cytokines to detect 
AL (table 1.13). Cytokines are glycoproteins involved in regulating inflammation 
and are thought to be the main mediators of the systemic inflammatory response 
to sepsis (Dinarello, 1984, Hesse et al., 1988, Wong and Clark, 1988, Castell et 
al., 1989). Peritoneal cytokine levels are elevated compared to serum cytokine 
levels after major abdominal surgery and in peritonitis (Herwig et al., 2002, 
Jansson et al., 2004, Wiik et al., 2001).  
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TABLE 1.13 SUMMARY OF STUDIES LOOKING AT CYTOKINES 
 
Author, year Biomarkers 
studied 
Study 
design 
Definition of 
AL 
No. of 
patients 
No. 
of 
leaks 
Operations Method of 
measurement 
Frequency 
and duration 
of 
measurement 
of biomarkers 
Main results 
Herwig, 
2002(Herwig et 
al., 2002) 
IL-1, IL-6, 
TNFa 
Prospective Clinical 
diagnosis 
confirmed by 
endoscopy, 
contrast 
radiology and 
finally 
confirmed at 
laparotomy 
24 12 Right 
hemicolectomy 
to anterior 
resections for 
malignancy, 
inflammatory 
bowel disease, 
diverticulosis 
and trauma  
Peritoneal drain 
fluid sample taken 
daily within 2 
hours of emptying 
drainage bag 
Daily until 
POD 4-9 
IL-6 & TNFa from POD 1 
and IL-1 from POD 3 
significantly increased in 
those with AL  
Bertram, 
2003(Bertram et 
al., 2009) 
IL-6, TNFa Prospective No definition 
provided but 
states AL was 
confirmed at 
relaparotomy 
25 3 Right 
hemicolectomies 
to anterior 
resections for 
adenomas and 
cancers 
Peritoneal drain 
fluid sample taken 
daily at 8am  
Daily until 
POD 7 
IL-6 and TNFa not helpful 
in predicting AL 
Matthiessen, IL-6, IL-10, Prospective Peritonitis 23 7 Anterior Peritoneal drain Peritoneal IL-6, IL-10 significantly 
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2007(Matthiessen 
et al., 2007b) 
TNFa caused by 
leakage, 
pelvic abscess 
or discharge of 
faeces from 
drain or a 
fistula. 
Confirmed by 
imaging or 
DRE. 
resections for 
colorectal 
cancer 
fluid sample drain sample 
every 6 hours 
until 42 hours 
after surgery 
increased from POD 1&2 
in those with AL 
TNFa only significant on 
POD 1 
Ugras, 
2008(Ugras et 
al., 2008) 
IL-6, IL-10, 
TNFa 
Prospective “Clinical signs 
(gas, pus, 
faeces from 
pelvic drain; 
pelvic abscess, 
peritonitis, 
pus from 
rectum or 
rectovaginal 
fistula) along 
with biological 
tests and 
abdominal CT 
findings”. 
34 4 Right 
hemicolectomies 
to low anterior 
resections for 
colorectal 
cancer 
Peritoneal drain 
fluid samples 
Daily from 
peritoneal 
drains until 
POD 5 
IL-6, IL-10, TNFa all 
significantly increased in 
those with AL on all days.  
Those without AL had 
decreasing cytokine 
levels. 
 79 
Fouda, 
2011(Fouda et 
al., 2011) 
IL-6, IL-10, 
TNFa 
Prospective Gas, pus or 
faecal 
discharge from 
the drain, 
faecal 
discharge from 
the wound, 
pelvic abscess, 
peritonitis and 
rectovaginal 
confirmed by 
CT, contrast 
scan or rectal 
palpation. 
56 8 Low anterior 
resections for 
rectal cancer 
Peritoneal drain 
fluid sample 
Peritoneal 
drain samples 
on PODs 1,3 & 
5 
IL-6 & IL-10 significantly 
increased on POD 1,3&5 
and TNFa significantly 
increased on POD 3 & 5 in 
those with AL 
Yamamoto, 
2011(Yamamoto 
et al., 2011) 
IL-1, IL-6, 
TNFa 
Prospective Post-operative 
peritonitis 
with leak 
thereafter 
confirmed by 
contrast 
study, 
ultrasound or 
CT scan. 
100 8 Anterior 
resections & AP 
resections for 
colorectal 
cancer 
Peritoneal drain 
fluid sample taken 
within 2 hours of 
emptying the drain 
Peritoneal 
drain samples 
on PODs 1,2 & 
3 
IL-1, IL-6 and TNFa 
significantly increased on 
POD 3 in those with AL. 
Cytokine levels 
significantly increased 
over the days in those 
with AL and fell in those 
without AL. 
Alonso, IL-6 Prospective Clinical 60 30 Right Baseline IL-6 level Peritoneal IL-6 significantly 
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2015(Alonso et 
al., 2015) 
suspicion of a 
leak was 
confirmed by 
radiological 
study or 
findings at 
reoperation. 
Intra-
abdominal 
abscesses 
were not 
classified as 
AL but abscess 
and ALs were 
analysed 
together as an 
“infective 
complications” 
group. 
hemicolectomies 
to anterior 
resections for 
colorectal 
cancer 
measured by 
lavaging abdominal 
cavity immediately 
after laparotomy 
or creation of 
pneumoperitoneum 
 
Post-operative 
samples taken 
from peritoneal 
drain fluid  
drain sample 
at 48 hrs and 
4 days post 
surgery 
increased at both time 
points in those with AL 
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There is wide heterogeneity in the type of operations performed, underlying 
pathology and definitions of AL. In addition, most involved small cohorts and 
measurements of peritoneal cytokines have been taken at varying times and 
frequencies from every 4 hours for 2 days (Matthiessen et al., 2007b) to once 
daily for 7 days (Bertram et al., 2009).  
 
Tumour necrosis factor alpha (TNFa) 
Herwig et al (Herwig et al., 2002), Ugras et al (Ugras et al., 2008) and 
Matthiessen et al (Matthiessen et al., 2007b) found that TNFa was significantly 
higher on POD 1 in patients who developed an AL. However, no cut-off value 
could be established to give an estimate of risk and confidence intervals were 
overlapping in each group. Fouda et al (Fouda et al., 2011) and Yamamoto et al 
(Yamamoto et al., 2011), which contained the largest sample of patients 
(n=100), found TNFa did not reach statistical significance until POD 3. Both also 
noted that TNFa decreased significantly from POD 1 to 3 in patients who did not 
develop a leak(Fouda et al., 2011, Yamamoto et al., 2011). In contrast, Bertram 
et al (Bertram et al., 2009), who used similar methodology, looked at TNFa 
levels for 7 days in 25 patients and found that TNFa was not helpful in predicting 
AL.  
 
Interleukin -6 (IL-6) 
Ugras et al (Ugras et al., 2008), Herwig et al (Herwig et al., 2002), Matthiesen et 
al (Matthiessen et al., 2007b) and Fouda et al (Fouda et al., 2011) all found IL-6 
to be significantly higher in patients who developed an AL from POD 1, however 
Yamamoto et al (Yamamoto et al., 2011) demonstrated no significant difference 
until POD 3 and Bertram et al (Bertram et al., 2009) found no difference in IL-6 
levels at anytime in the first 7 days post-op.  
 
A more recent case-control study by Alonso et al (Alonso et al., 2015) looked at 
IL-6 levels on PODs 2 and 4 in 60 patients after various colorectal resections. 30 
leaks and intra-abdominal abscesses were grouped into an “infection” category 
and compared to 30 controls with an uncomplicated recovery. IL-6 was 
significantly higher on both days in the “infection group”. They did not state 
how or when the leaks were detected.  
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Other cytokines 
Of other cytokines studied, the pro-inflammatory interleukin 1b (IL-1b) was 
found to be significantly elevated on POD 3 (Herwig et al., 2002, Yamamoto et 
al., 2011) and the anti-inflammatory interleukin 10 (IL-10) on POD 1 in patients 
who developed an AL (Fouda et al., 2011, Matthiessen et al., 2007b, Ugras et 
al., 2008).  
 
Overall, despite some conflicting results, a meta-analysis (which did not include 
Alonso et al (Alonso et al., 2015)) found that IL-6 and TNFa were significantly 
raised from POD 1 and 2 respectively in those who developed a leak (Cini et al., 
2013). Studies with larger sample sizes and better standardization of definitions 
and sampling protocols are required to clarify their role.  
 
 
1.7.4.5  Biomarkers of wound repair (matrix metalloproteinases; MMPs) 
MMPs are zinc dependent enzymes responsible for tissue turnover by 
extracellular matrix degradation. Tissue inhibitors of metalloproteinase (TIMPs) 
are the natural inhibitors of MMPs. The balance of MMPs and TIMPs is involved in 
physiological and pathological processes including inflammation (Verma and 
Hansch, 2007). Three papers, with wide variation in study population, sampling 
frequency and end points have explored peritoneal MMPs and TIMPs (table 1.14). 
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TABLE 1.14 SUMMARY OF STUDIES LOOKING AT BIOMARKERS OF WOUND REPAIR 
 
Author, year Biomarkers 
studied 
Study 
design 
Definition of 
AL 
No. of 
patients 
No. 
of 
leaks 
Operations Methods of 
biomarker 
measurement 
Frequency and 
duration of 
biomarker 
measurement 
Main results 
Baker, 
2003(Baker 
and Leaper, 
2003) 
MMP-1, 
2,3,8,9 TIMP-
1,2 
Prospective Not specified – 
AL grouped 
with “major 
complications” 
58 NS* Right 
hemicolectomies 
to AP resections 
for colorectal 
cancer 
Sample from 
peritoneal 
drain  
Daily until POD 5-8 MMP-2 (POD 3), MMP-2 
(POD 6), MMP-9 (POD 6 
& 7) positively 
correlated with 
complications 
 
TIMP-2 (POD 2&3), 
TIMP-1 (POD 7) 
negatively correlated 
with complications 
Pasternak, 
2009(Pasternak 
et al., 2010) 
MMP-
1,2,3,7,8,9,13 
TIMP-1,2 
Prospective Clinical 
diagnosis 
including 
fistulas 
confirmed by 
CT, contrast 
study or DRE 
29 10 Low anterior 
resections for 
colorectal 
cancer 
Sample from  
peritoneal 
drain  
Once at 4 hours post-
operation 
MMP-8 & 9 
significantly increased 
in those with AL 
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Kostic, 
2015(Kostic et 
al., 2015) 
MMP-9 Prospective Clinical 
diagnosis – 
finding of 
pus/faeces in 
drain, pelvic 
abscess, 
peritonitis or 
fistula 
150 15 Left sided 
colorectal 
resections for 
cancer 
Sample from  
peritoneal 
drain. 
 
MMP-9 
measured via 
ELISA. 
On PODs 1, 3, 5 & 7 MMP-9 not 
significantly different 
in those with AL 
*NS – not specified 
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Pasternak et al (Pasternak et al., 2010) measured MMP-1, 2, 3, 7, 8, 9 and 13 
once at 4 hours after low anterior resections in 30 patients. Five early leaks 
between PODs 2 – 13 and 5 late leaks between PODs 13 -41 were analysed 
together. Only MMP-8 and 9 at 4 hours post surgery were significantly elevated 
in the AL group.  
 
Baker et al (Baker and Leaper, 2003) measured MMP-1-3, 8, 9 and TIMP-1 and 2 
for 7 days after various colorectal anastomoses in 58 patients. The end point was 
“major complications” which included AL. Levels of MMP-2 (day 3) MMP-2 (day 6) 
and MMP-9 (days 6, 7) were positively correlated with complications whereas 
TIMP-2 (days 2, 3) and TIMP-1 (day 7) were negatively correlated. Only MMP-9 
was significantly elevated in both studies. However, Kostic et al (Kostic et al., 
2015), who looked specifically at MMP-9 on PODs 1, 3, 5 and 7 in 150 patients 
undergoing elective left sided colorectal resections (with 15 clinically detected 
ALs), found that levels were not significantly different to those without a leak.  
The inconsistent results for MMPs limit their usefulness in future research. 
 
 
 1.7.5.6 Summary of peritoneal biomarkers 
Peritoneal cytokines, lactate and pH have the potential to identify AL early. The 
consistency of the results for lactate and pH, alongside the fact they are simple, 
quick and inexpensive to test, makes them the strongest targets. In addition to 
clarifying their stability in peritoneal fluid, in the future studies should aim to 
use a homogenous study population with a standardized AL definition. The wide 
variability in the definition and measurement of AL is not unique to this group of 
studies. A 2001 review of 97 studies identified 56 different definitions of AL 
(Bruce et al., 2001). Since then the International Study Group on Rectal Cancer 
have set out a definition of AL and graded its severity (A-C) depending on the 
impact on clinical management (Rahbari et al., 2010). Adoption of this definition 
and grading system in future work would be useful. Ultimately, it is to be hoped 
that incorporation of a biomarker sensor into a peritoneal drain or biodegradable 
implantable device could provide early recognition of AL leading to early 
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initiation of intervention and significant reductions in patient morbidity and 
mortality.   
 
 
1.8 Statement of project aims 
 
The aims of this project are as follows: 
1. To characterise the stability of the biomarkers lactate and pH in 
peritoneal fluid from a selected control group (Chapters 4 & 5) 
2. A prospective analysis of the characterisation of post-operative daily 
peritoneal drain fluid biomarkers (lactate and pH) in detecting 
anastomotic leak in patients undergoing colorectal resection (Chapter 6) 
3. A comparison of peritoneal fluid biomarkers in the detection of colorectal 
anastomotic leak to blood biomarkers (Chapter 7) 
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2 Chapter 2 – Materials and methods 
 
 
2.1 Materials 
This section lists and describes the materials used for the testing of lactate 
and pH from clinical and non-clinical samples in chapters 3 – 6. When 
reading chapters 3 – 6 refer back to this section.  
 
2.1.1 Virkon 
The multi-purpose disinfectant Virkon was purchased from Antec International, 
(Sudbury, Suffolk, UK). 
 
2.1.2 Ethanol 
Ethanol solution was purchased from Sigma-Aldrich (UK). 
 
2.1.3 Deionised water 
Deionised water was purified using an Elga Purelab system (Elga Process Water , 
UK). 
 
2.1.4 Sodium l-lactate 
Sodium l-lactate was purchased from Sigma-Aldrich (UK). 
 
2.1.5 Sterile water 
‘Water for injection BP’ was purchased from Braun, Germany. This is sterile 
water and was used for the dilution of peritoneal drain fluid samples.  
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2.1.6 Blue nitrile gloves 
Blue nitrile gloves were purchased from Robinson Healthcare (Worksop, UK). 
 
2.1.7 Face shield 
A “Sphere” face shield was purchased from Bollé Safety (Villeurbanne, France). 
It was worn when handling clinical samples in the laboratory.  
 
2.1.8 UN3373 packaging kit 
To comply with guidelines for the transport of biological substances (category 
UN 3373), a UN 3373 packaging kit was purchased from Dakla Pack (Chiswick, 
UK). The kit consisted of a cardboard outer box, 500ml green leak proof 
container, plastic shock absorbers and absorbing tube holders (see figure 2.1). 
 
 
 
FIGURE 2.1 UN 3373 PACKAGING KIT 
 
 
2.1.9 Lactate Pro 2 
The ‘Lactate Pro 2’ handheld lactate test meter and ‘Lactate Pro 2 Test Strips” 
manufactured by Arkay (Japan) were purchased from HaB International Ltd 
(Southam, UK). 
 90 
 
2.1.10 Omega pH meter 
The ‘pH pocket tester, PHH-7011’ manufactured by Omega was purchased from  
‘Omega Engineering Ltd” (Manchester, UK). In addition, pH 4, 7 and 10 buffer 
solutions for calibration of the meter were purchased from the same 
manufacturer. 
 
2.1.11 Clinical chemistry analyser 
The ‘Labsystems Multiskan Ascent’ (Thermo Electron Corporation, USA) was used 
to measure absorbance in order to determine the lactate level of standard 
solutions and of peritoneal drain fluid samples in chapters 3 and 6 respectively. 
 
2.1.12 Colorimetric lactate assay 
L-lactate colorimetric assay kits were purchased from Randox Laboratories, 
County Antrim, UK. 
 
2.1.13 Mettler Toledo pH meter  
The “Mettler Toledo S220 Seven Compact “ pH meter (Mettler Toledo, USA) was 
used to measure the pH standard solutions and of peritoneal fluid samples in 
chapters 3, 5 and 6. 
 
2.1.14 pH standard solutions 
pH 4 and 7 tablets from Fischer Scientific (Loughborough, UK) and pH 10 buffer 
solution (Arcos Organics, UK) were used to calibrate the “Mettler Toledo S220 
Seven Compact” used in chapters in chapter 3 and 6. 
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2.2 General methods 
This section describes the background and methodology for the testing of 
lactate and pH from clinical and non-clinical samples in chapters 3 – 6. 
When reading chapters 3 -6 refer back to this section. Any additional 
methods will be defined and explained in each relevant chapter. 
 
2.2.1 Measuring lactate 
2.2.1.1  Methods with the Lactate Pro 2 
This section provides information about the hand-held lactate meter, the 
Lactate Pro 2, and why it was chosen for use in this project. 
 
2.2.1.1.1  Background information and product specification 
The Lactate Pro 2 is a hand-held portable analyser designed to quantitatively 
measure the lactate level in human fresh capillary whole blood (see figure 2.2). 
Product specifications are shown in table 2.1. A sample of blood is added to the 
test strip and the reagent strip fills by capillary action. The sensor used is 
amperometric. The lactate in the sample reacts with potassium ferricyanide and 
lactate oxidase to form potassium ferrocyanide and pyruvate. A voltage is 
applied and ferrocyanide is oxidised, electrons are released producing a current. 
This current is measured amperometrically and is directly proportional to the 
lactate level of the sample.  
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FIGURE 2.2 THE HANDHELD LACTATE PRO 2 
 
 
TABLE 2.1 LACTATE PRO 2 PRODUCT SPECIFICATION (INCLUDE PHOTOGRAPHS OF 
METER AND TEST STRIPS) 
Manufacturer Arkray KDK, Japan 
Method of 
measurement 
Amperometric reagent 
Minimum sample size 0.3 μl 
Analysis time 15 seconds 
Operating environment 5 – 40 °C 
Measurement range 0.5 – 25.0 mmol/L 
Calibration Automatic 
 
 
2.2.1.1.2  Uses of the Lactate Pro 2 
The Lactate Pro 2, is primarily used by athletes to evaluate training performance 
and prescribe training intensities and has been validated for this purpose 
(Bonaventura et al., 2015). The Lactate Pro (Arkray, Japan), the predecessor of 
the Lactate Pro 2, has also been validated for use in hospital emergency 
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department triage areas to identify those with an elevated lactate who would 
benefit from early treatment of sepsis (Goyal et al., 2010, Gaieski et al., 2013). 
The manufacturer only provides validation data for the measurement of lactate 
from blood, however, studies in veterinary medicine have shown that portable, 
hand-held lactate analysers such as the Lactate Pro can be used to measure 
lactate levels in other fluids such as peritoneal fluid. The Lactate Pro has been 
validated against a standard bench-top blood gas analyser and also a gold 
standard laboratory colorimetric enzymatic assay for the measurement of 
peritoneal fluid from horses (Nieto et al., 2015). 
 
2.2.1.1.2 Lactate Pro 2 testing procedure 
Testing the lactate level of a solution with the Lactate Pro 2 is carried out as 
follows: 
1. Insert a test strip into the Lactate Pro 2  
2. Touch the tip of the testing strip against the solution 
3. Let the test strip draw up solution until the check window is filled with 
solution 
4. After 15 seconds the test result appears on the screen. 
 
2.2.1.2  Colorimetric lactate assay 
A colorimetric assay is a gold standard method of analysing lactate. The 
assay and equipment required to perform this analysis is kept at the 
Wolfson Centre, University of Strathclyde. It was used to test the lactate 
concentration of non-clinical samples in chapter 3 and a subset of clinical 
samples in chapter 6. 
The  L-lactate assay (Randox Laboratories) was used to determine the lactate 
concentration of peritoneal fluid via a colorimetric method on a ‘Labsystems 
Multiskan Plate Reader’. The concentration of L-lactate in the sample is 
determined according to the following reaction: 
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L − Lactate + O2   
Lactate oxidase
→             pyruvate + H2 O2 
H2O2  + 4 − aminoantipyrine + TOOS  
Peroxidase
→        purple product + 4H2O 
(TOOS = N-ethyl-N-(2-hydroxy-3-sulphopropyl) m-toluidine) 
 
Serial dilutions of a 20mmol sodium lactate solution were created to make 
concentrations of 10 mmol, 5 mmol, 2.5 mmol and 1.25 mmol. 2.5μl of 
calibration solution, along with 2.5μl of  peritoneal fluid samples and a blank 
solution (2.5μl deionized water), were added to a 96 well plate reader as shown 
in Figure 2.3. Next 250μl of the enzyme reagent was added to each well 
contained a sample, calibration solution or blank. The plate reader was then 
placed in the Multiskan Plate Reader. Settings for the plate reader were: 
incubation temperature 37°C, low speed shake for 5 minutes and the absorbance 
550nm (as per Randox assay instructions). The results were saved into a Excel 
file and a calibration curve was calculated. From this an equation is generated 
which allows the lactate level of the samples to be determined (see figure 2.4). 
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FIGURE 2.3 SET UP OF 96 WELL PLATE READER FOR L-LACTATE ASSAY. 
(KEY: B=BLANK SAMPLE, S=SAMPLE REPEAT (E.G. S1=SAMPLE 1 REPEAT), PURPLE 
WELLS= CALIBRATION SOLUTIONS) 
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FIGURE 2.4 EXAMPLE CALIBRATION CURVE WITH EQUATION AND CORRELATION 
DISPLAYED ON CHART 
 
 
2.2.2 Measuring pH 
2.2.2.1  Omega PH-7011 Meter 
This section provides information about the hand-held pH meter, the Omega 
PH-7011 used in chapters 3, 5 and 6. 
 
The Omega PH-7011 meter (Omega Engineering, UK) is a handheld 
potentiometric electronic pH meter (see figure 2.5). Potentiometric pH meters 
work by measuring the voltage between 2 electrodes (the glass electrode and 
the reference electrode) and then convert the result into a pH value. Commonly 
the 2 electrodes are contained together in a combination electrode. The glass 
electrode (pH electrode) has a voltage that varies with the pH of the solution 
being measured. This electrode is a hydrogen ion sensitive glass bulb (often 
referred to as the glass electrode) with a millivolt output that varies with the 
relative change in hydrogen ion concentration inside and outside the glass bulb. 
The reference electrode output does not vary with differing hydrogen ion 
concentrations and gives a constant output. The potential between the 2 
electrodes is therefore a measure of the number of hydrogen ions in the solution 
y = 0.1016x - 0.0125
R² = 0.9985
0
0.5
1
1.5
2
2.5
0 5 10 15 20 25
Absorbance
Standard solution lactate concentration (mmol/l)
Example calibration curve
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which can then be converted into a pH value.  
The Omega meter was chosen because it was portable, light-weight, easy to use 
and featured temperature compensation (temperature is known to affect the 
measurement of pH). 
 
 
 
FIGURE 2.5 THE OMEGA PH-7011 METER 
 
 
2.2.2.1.1 Omega PH-7011 Meter testing procedure 
Before testing of a solution the meter must be calibrated. Calibration, testing 
and storage of the meter is carried out as follows: 
1. Remove the protective cap and unscrew the soaking cap from the meter 
and rinse the electrode with clean water and wipe it dry. 
2. Switch on the meter. 
3. Dip the electrode into the buffer solution pH 7. Stir gently and wait until 
the display stabilises.  
4. Press and hold the power/calibration button to enter calibration mode, 
the CAL icon appears and flashes 7.00 
5. Hold electrode in the pH 7 solution until the display stops flashing and 
indicates “SA”, then “End”. 
6. Rinse the electrode again in clean water and wipe dry. 
7. Dip the electrode into buffer solution pH 4. Stir gently and wait until the 
display stabilises. 
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8. Press and hold the power/calibration button to enter calibration mode, 
the CAL icon appears and flashes 4.00 
9. Hold the electrode in the pH 4 buffer solution until the display stops 
flashing and indicates “%” (percentage of slope), then “SA”, then “End”. 
10. If the percentage of the slope (PTS) is between 70-130% calibration has 
been successful. A percentage < 70% or >130% indicates that the electrode 
needs to be replaced. 
11. Rinse the electrode in clean water and wipe dry. 
12. Dip the electrode into the sample solution to be measured. Stir gently and 
wait until a stable reading is obtained. 
13. Once the pH of the solution has been recorded the electrode should be 
rinsed in clean water, wiped dry and then placed in in the protective cap 
containing storage solution. 
The pH reading takes time “to settle” and does not beep or flash to indicate 
that a reading is complete. It was therefore decided to hold the meter in the 
sample for 2 minutes and use the reading displayed at 2 minutes as the pH of the 
solution. This time was chosen because on trialling the meter it was noted that 
the reading at 2 minutes was steady and keeping the meter submerged for 
longer only resulted in small changes of 0.01 every 30 seconds – 1 minute. 
 
2.2.2.2  Mettler Toledo pH meter 
The Mettler Toledo pH meter is a gold standard piece of laboratory 
equipment kept at the Wolfson Centre, University of Strathclyde, for 
measuring pH. It was used to test the pH of non-clinical samples in chapter 
3 and a subset of clinical samples in chapter 6. 
2.2.2.1.2 Mettler Toledo pH meter calibration and testing procedure 
In accordance with the manufacturers instructions the meter must be calibrated 
with pH 4, 7 and 10 buffer solutions prior to use. The electrode has to be 
cleansed with deionised water between being placed in each buffer solution. 
Once calibration has been successfully completed the electrode is rinsed in 
deionised water then placed in the solution to be tested. The electrode is held 
in place until the meter indicates that the reading is complete and gives the pH 
value. The electrode is then rinsed in deionised water and placed in a pH 4 
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buffer solution for storage. See figure 2.6 for an image of the meter. 
 
FIGURE 2.6 THE METTLER TOLEDO PH METER 
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3 Chapter 3 – The validation of handheld lactate and pH 
meters with standard laboratory solutions  
  
3.1 Introduction 
 
Previous studies that have looked at lactate and pH in human peritoneal fluid 
have used either microdialysis (Matthiessen et al., 2007b, Pedersen et al., 2009, 
Horer et al., 2011, Daams et al., 2014) or a blood gas analyser (ABL700 Blood 
Gas Analyser, Radiometer, Copenhagen, Denmark) (Bini et al., 2014) to measure 
lactate, whilst for pH tonometry catheters (Millan et al., 2006) and a bench top 
pH analyser (pH meter pp-15, Sartorius Ltd, Germany) (Yang et al., 2013) have 
been used. Initially the researcher had hoped to use the hospital blood gas 
analyser (GEM Premier 4000, Instrumentation Laboratory, Bedford, MA, USA) to 
measure lactate and pH for the work in chapters 3 -6. It offered the advantages 
of being readily available, simple to use and had been successfully used in a 
previous veterinary study for analysing peritoneal drain fluid samples. Via 
personal communication with the manufacturer it was confirmed that, although 
reference ranges for peritoneal fluid samples had not been created, running a 
peritoneal fluid sample through the machine was possible and would not damage 
it. Unfortunately the hospital laboratory was concerned that a peritoneal fluid 
sample may contaminate the machine and therefore did not grant permission for 
its use. Consequently the use of commercial and established handheld meters 
was investigated.  
 
The use of handheld meters was investigated. Lactate is used in the sporting 
world as a guide to training and performance (I, 1986), this has lead to the 
development of a range of handheld lactate meters that can be used at the 
track side to give instant results from finger-prick blood samples. These meters 
are quick and simple to use. Use of these meters has also been described in the 
veterinary world (Nieto et al., 2015). Peritoneal fluid lactate is used in the 
diagnosis and management of suspected horse colic. A recent study has shown 
that handheld monitors such as the Lactate Pro, Lactate Plus and Lactate Scout 
 102 
are reliable measures of horse peritoneal fluid lactate in the field when 
compared to standard bench top analysers and a gold standard laboratory assay 
(Nieto et al., 2015). In the study by Nieto et al(Nieto et al., 2015), the Lactate 
Pro performed best in the analysis of horse peritoneal fluid lactate. The Lactate 
Pro has been superseded by the Lactate Pro 2 (Arkray, Japan); this was selected 
as our handheld lactate meter. The Lactate Pro 2 (LP2) is designed primarily for 
whole blood samples in the range 0.5 – 25.0 mmol/L and so provision was made 
for calibration of this device for peritoneal fluid.  
 
pH is measured in a range of situations – including medical scenarios, soil 
analysis and home beer brewing. As such there are a wide range of handheld pH 
meters available on the open market. The Omega PH-7011 (Omega Engineering, 
UK) was selected as it was easily portable and automatically compensated for 
temperature.  
 
To date, neither the LP2 nor the Omega pH meter have been used to measure 
lactate or pH in human peritoneal fluid. 
 
 
  
3.2 Aims 
The aim of this chapter was to assess the intra-analyser variability of the Lactate 
Pro 2 and Omega PH-7011 meters and to compare their performance to that of a 
laboratory gold standard method of measurement of lactate and pH.  
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3.3 Methods 
 
3.3.1 Validation of the Lactate Pro 2  
 
3.3.1.1 Intra-analyser variability of the Lactate Pro 2 – testing standard 
solutions 
To test the intra-analyser variability of the Lactate Pro 2 standard solutions of 
“high”, “medium” and “low” lactate concentrations were created. A 20mmol 
solution of sodium lactate was prepared and then serially diluted with distilled 
water (by the method outlined in section 2.2.2) to produce lactate solutions of 
concentration 10mmol, 5mmol and 2.5mmol. Each of these solutions was then 
measured 10 times with the Lactate Pro 2 using a single batch of test strips 
(A173B01L) to determine variability. The standard deviation, mean and 
coefficient of variation were then calculated. A coefficient of variation is a 
statistical test that has ben used to assess the variability of quantitative assays 
and intra-analyser performance (Reed et al., 2002). There are no absolute 
agreed cut-offs for an acceptable level of variation but a low percentage 
variation indicates low variability (Spiegel, 1961) and indicates that a test is 
reliable. In addition, the impact of different batches of Lactate Pro 2 test strips 
was analysed by testing with 2 different batches (serial numbers A173B01L and 
J163B01L). A paired T-test performed to look for differences between different 
batches of strips. Data was analysed using ‘Statistical Package for the Social 
Sciences’ (SPSS) version 22. P < 0.05 was considered statistically significant.  
 
3.3.1.2 Comparison of the Lactate Pro 2 to laboratory gold standard – testing 
standard solutions 
A 20mmol solution of sodium lactate was prepared and then serially diluted with 
distilled water (by the method outlined in section 2.2.2) to produce lactate 
solutions of concentration 20mmol, 10mmol, 5mmol, 2.5mmol and 1.25mmol. 
Each solution was measured in triplicate with the Lactate Pro 2 and in triplicate 
by a colorimetric method on the ‘Labsystems Multiskan Plate Reader’ using an L-
lactate assay (method as described in section 2.2.2). A scatter graph was drawn 
to compare the results with the 2 analysers and a Pearson correlation coefficient 
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was calculated to look for agreement between the 2 meters. The graphs were 
drawn and Pearson correlation coefficient calculated using Excel, 2011.  
 
3.3.2 Validation of the Omega PH-7011 Meter 
 
3.3.2.1 Intra-analyser variability of the Omega PH-7011 Meter 
A standard pH 7 buffer solution was prepared by adding one pH 7 tablet (Fischer 
Scientific general purpose buffer tablets) to 100ml distilled water. Prior to use 
the Omega PH-7011 meter was calibrated via the method outlined in section 
2.2.3.2. A total of 10 serial measurements were made of this pH 7 solution using 
the Omega PH-7011 Meter. The standard deviation, mean and coefficient of 
variation were then calculated. Data was analysed using SPSS version 22. P < 
0.05 was considered statistically significant.  
 
3.3.2.2 Comparison of the Omega PH-7011 Meter to the laboratory gold-
standard Mettler Toledo pH meter – standard solutions 
The pH 4, 7 and 10 buffer solutions were prepared as per section 2.2.4.1. They 
were measured in triplicate on the Omega PH-7011 Meter (as per the method in 
section 2.2.3.2) and on the Mettler Toledo pH Meter (as per the method 
described in section 2.2.4.1). A scatter graph was drawn to compare the results 
with the 2 analysers and a Pearson correlation coefficient was calculated to look 
for agreement between the 2 meters. The graphs were drawn and Pearson 
correlation coefficient calculated using Excel, 2011.    
 
 
3.4 Results 
3.4.1 Validation of the Lactate Pro 2 
3.4.1.1 Intra-analyser variability and accuracy of the Lactate Pro 2 
Table 3.1 shows the results for the repeated measurement of low, medium and 
high concentrations of sodium lactate with the Lactate Pro 2 (LP2) meter. It was 
noted that the LP2 meter was not accurate in measurement of the standard 
solutions as it consistently over-estimated the lactate level of the standard 
solutions by just over double the concentration of the standard solution. 
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However, variations in readings made by the LP2 was minimal. The coefficient of 
variation for low, medium and high concentrations were 5.97%, 3.29% and 2.03% 
respectively. These low values indicate that the Lactate Pro 2 produces 
consistent measurements of lactate at a range of concentrations. As shown in 
figure 3.1 there was good correlation (R=0.99) between measurements on the 
Lactate Pro 2 versus the colorimetric assay, the linear equation was: 
Y = 0.4227x – 0.0282, 
This can be used to calculate the true lactate concentration based on the 
measurements made on the Lactate Pro 2. 
 
 
TABLE 3.1 INTRA-ANALYSER VARIABILITY AT 10MMOL, 5MMOL AND 2.5MMOL 
CONCENTRATION OF SODIUM LACTATE 
 Repeat number 
Lactat
e 
conc 
(mmol
/l) 
1 2 3 4 5 6 7 8 9 10 SD Me
an 
Coeffici
ent of 
variatio
n (%) 
10 24.
6 
23.
1 
23.
4 
23.
2 
23.
1 
23.
6 
23.
5 
23.
7 
22.
9 
23.
3 
0.4
8 
23.
4 
2.03 
5 12.
6 
12.
5 
13.
8 
12.
6 
12.
7 
12.
3 
12.
7 
12.
5 
12.
6 
12.
4 
0.4
2 
12.
7 
3.29 
2.5 5.8 5.7 6.3 5.2 5.4 5.4 5.2 5.4 5.5 5.4 0.3
3 
5.5 5.97 
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FIGURE 3.1 CORRELATION BETWEEN LACTATE CONCENTRATION MEASURED BY LP2 
METER AND COLORIMETRIC ASSAY 
 
Table 3.2 displays the serial measurements made of low and medium 
concentrations of sodium lactate with 2 different batches of test strips – 
A173B01L and J163B01L. For a medium concentration  (5 mmol) the A73B01L 
group had a mean of 12.7 (SD 0.42), the J163B01L  group had a mean of 12.2 (SD 
0.44); there was no significant difference between the 2 groups (p = 0.12). At 
lower concentration  (2.5mmol)  the A73B01L group had a mean of 5.5 (SD 0.33) 
and the J163B01L group had a mean of 5.4 (SD 0.18), the difference between 
the groups was not statistically significant (P = 0.15).  
 
 
y = 0.4227x - 0.0282
R² = 0.994
0
2
4
6
8
10
12
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Lactate 
cocentration 
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TABLE 3.2 COMPARISON OF DIFFERENT BATCHES OF TEST STRIP AT 5MMOL & 
2.5MMOL CONCENTRATION OF SODIUM LACTATE 
  Repeat number 
Serial 
numb
er 
Lacta
te 
conc 
(mmo
l/l) 
1 2 3 4 5 6 7 8 9 10 SD Me
an 
P 
val
ue 
A173B
01L 
5 12
.6 
12
.5 
13
.8 
12
.6 
12
.7 
12
.3 
12
.7 
12
.5 
12
.6 
12
.4 
0.4
2 
12.
7 
 
J163B
01L 
5 6.
5 
11
.5 
12
.1 
12
.6 
11
.9 
12
.3 
12
.4 
12
.3 
11
.9 
13
.0 
0.4
4* 
12.
2* 
0.1
2 
A173B
01L 
2.5 5.
8 
5.
7 
6.
3 
5.
2 
5.
4 
5.
4 
5.
2 
5.
4 
5.
5 
5.
4 
0.3
3 
5.5  
J163B
01L 
2.5 5.
7 
5.
5 
5.
6 
5.
4 
5.
2 
5.
1 
5.
3 
5.
5 
5.
3 
5.
4 
0.1
8 
5.4 0.1
5 
 
 
 
3.4.2 Validation of the Omega PH-7011 Meter 
 
3.4.2.1 Intra-analyser variability of the Omega PH-7011 Meter  
 
Table 3.3 displays the results of the serial measurements made on the Omega 
PH-7011 Meter. It displayed low intra-analyser variability with excellent 
repeatability of measurements. The coefficient of variation was 0.47% which is 
very low.  
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TABLE 3.3 RESULTS OF OMEGA PH-7011 METER SERIAL MEASUREMENTS OF PH 7 
SOLUTION 
 Repeat number 
pH 
met
er 
1 2 3 4 5 6 7 8 9 10 SD Mea
n 
Coeffici
ent of 
variatio
n (%) 
Ome
ga 
7.2
7 
7.3
3 
7.3
5 
7.3
5 
7.3
4 
7.3
6 
7.3
7 
7.3
8 
7.3
8 
7.3
9 
0.0
3 
7.3
5 
0.47 
 
 
3.4.2.2 Comparison of the Omega PH-7011 Meter to the laboratory gold-
standard Mettler Toledo pH meter – standard solutions 
 
Table 3.4 shows the measurements made on the Omega and Mettler pH meters 
of standard buffer solutions of pH 4, 7 and 10. The readings made on the Omega 
pH meter were slightly lower than on the Mettler Toledo Meter. However, as 
shown in figure 3.2 there is good correlation (R = 0.99) between the results 
made on the two meters, the linear equation was: 
Y = 0.9757x + 0.2687. 
This can be used to calculate the true pH based on the measurement made on 
the Omega PH-7011 Meter. 
 
 
TABLE 3.4 MEASUREMENTS OF PH 4, 7 AND 10 BUFFER SOLUTIONS ON THE OMEGA 
AND METTLER PH METERS 
 Omega PH-7011 Meter readings Mettler Toledo Meter readings 
 1 2 3 Mean 1 2 3 Mean 
pH 4 3.87 3.85 3.84 3.85 3.99 4.03 4.02 4.01 
pH 7 6.91 6.96 6.97 6.95 7.07 7.09 7.08 7.08 
pH 
10 
9.98 10.01 10.03 10.01 10.04 10.00 10.03 10.02 
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FIGURE 3.2 CORRELATION BETWEEN PH MEASUREMENTS OF STANDARD BUFFER 
SOLUTIONS MADE ON THE OMEGA AND METTLER TOLEDO PH METERS 
 
 
3.5 Discussion 
 
The LP2 and Omega pH meters had low intra-analyser variability and provided 
reliable measurements of lactate and pH respectively. However, both meters 
lacked accuracy when compared to laboratory gold standard meters.  
 
The LP2 consistently over-estimated the lactate level of a standard solution by a 
factor of just over 2. The results were consistent and it was shown that they had 
good correlation with the results of the colorimetric assay (R = 0.99). The linear 
equation generated can thus be used to calculate the true lactate level of a 
sample based on the measurement made by the LP2. The LP2 is an ampometric 
meter and uses lactate oxidase to react with the sample. The laboratory gold 
standard is a colorimetric assay that also uses lactate oxidase to react with the 
sample. Therefore the discrepancy in the results between the LP2 and the 
colorimetric assay is not due to the use of different reagents. The LP2 was 
designed to measure lactate concentration of whole blood samples. Previous 
studies have validated its performance against bench top lab blood gas analysers 
in measuring samples of whole blood (Tanner et al., 2010, Pyne et al., 2000). 
They have found it be reliable and accurate across a range of lactate 
y = 0.9757x + 0.2687
R² = 0.9999
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concentrations. It was not tested against laboratory solutions of sodium lactate. 
It may therefore be that the specific design of the LP2 to measure unfiltered 
whole blood samples accounts for the differences seen when testing the 
laboratory standard solutions. Despite its lack of accuracy, the LP2 does provide 
reliable results with low levels of intra-analyser variability making it a valid 
choice for assessing change in lactate levels in a clinical setting. This study was 
performed in order to assess the potential for the LP2 to be used to measure 
lactate from human peritoneal fluid samples in the work carried out in chapters 
4 and 6. There is no documentation in the literature of the LP2 having been used 
in this manner before. It has however been successfully used to measure the 
lactate level in other in-vivo settings (e.g. peritoneal fluid from horses). In the 
proposed work in chapters 3 and 6 no clinical decisions would be made based on 
the lactate measurements. Trends in lactate concentration and changes over 
time rather than absolute cut-off levels were anticipated to be more important. 
Consequently, the finding that the LP2 could provide reliable results was 
sufficient to consider it a satisfactory substitute for measurement on a standard 
laboratory analyser.  
 
The Omega pH meter slightly under-estimated the pH of standard buffer 
solutions compared to the Mettler Toledo Meter. However, like the LP2, it had 
low intra-analyser variability and good correlation with the Metter Toledo meter 
(R = 0.99). Both pH meters featured temperature compensation and measured 
pH by the same method (see sections 2.2.3.1 & 2.2.4.1). The Omega pH meter 
and probe were stored in storage solution as per the manufacturers instructions 
and calibration was completed successfully before use. During calibration a 
slope percentage is calculated and a value outwith 70 – 130% indicates that the 
electrode has expired. Prior to testing the slope percentage fell within these 
limits indicating satisfactory condition of the electrode. It is therefore difficult 
to explain the difference between the results of the Omega and Mettler Toledo 
pH meters. However, as mentioned above this work was undertaken to assess 
the potential of the Omega pH meter to be used for the measurement of human 
peritoneal fluid, clinical decisions would not be based on the results and trends 
in pH and changes over time were considered more important than absolute cut-
off levels. This is similar to the approach taken to the interpretation of post-
operative blood tests, for example, a declining CRP and WCC, rather than a drop 
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to below a set cut-off value, in a patient who has received treatment for an 
infective complication would be interpreted as a good response to treatment. 
 
 
In conclusion, based on the findings of this chapter the handheld meters, LP2 
and Omega PH-7011, were judged to be valid analysers for the measurement of 
lactate and pH from peritoneal fluid. The linear equations generated by their 
comparisons to laboratory gold-standard meters in section 3.4 should be used to 
adjust the results obtained. 
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Chapter 4 – The stability of lactate 
in peritoneal fluid 
 
 
 
 
 
 
 
 
 
  
 113 
4 Chapter 4 – The stability of lactate in peritoneal fluid 
 
4.1 Introduction 
 
Several of the studies that have attempted to find a local, intra-abdominal 
biomarker of anastomotic leak have looked at biomarkers of intestinal ischaemia 
(Matthiessen et al., 2007b, Pedersen et al., 2009, Horer et al., 2011, Bini et al., 
2014, Daams et al., 2014). The confirmed relationship between lactate and 
tissue hypoxia has lead to lactate being a key target for much of this research. 
The majority have used microdialysis (Matthiessen et al., 2007b),(Pedersen et 
al., 2009),(Horer et al., 2011),(Daams et al., 2014) which provides a real-time 
measurement of lactate. However, this technique is expensive and technically 
challenging. Bini et al explored lactate by measuring the lactate level of drain 
fluid (Bini et al., 2014). They describe obtaining a sample of abdominal fluid 
from the drainage bag and then immediately analysing it using an ABL700 blood 
gas analyser (Radiometer, Copenhagen, Denmark). This represents a simpler, 
cheaper and non-invasive method by which to measure lactate as a biomarker of 
intestinal ischaemia/AL.  
 
When measuring substances from fluid in a peritoneal drain it is necessary to 
consider the stability of the substance in the fluid. In clinical practice the fluid 
collected in a drainage bag is emptied at set intervals, commonly once per day 
just before the clinical ward round allowing drain volume over a 24 hour period 
to be calculated and interpreted clinically. This means that fluid often sits in a 
drainage bag for several hours. This may modify biomarkers in drain fluid as 
occurs with a blood sample.  
 
When a whole blood sample is drawn glycolysis continues, in part due to the fact 
that erythrocytes do not have mitochondria (Astles R, 1994). This means that 
over time the lactate level of the sample will increase. Noordally et al found 
that when blood samples were stored at room temperature lactate levels 
increased from 2.36mol/l +/- 1.68mmol/l to 2.52mmol/l +/- 1.74mmol/l over 10 
minutes. Whilst this was a statistically significant increase, the clinical 
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significance of this is debatable (Noordally and Vincent, 1999). Calatayud et al 
(Calatayud and Tenias, 2003) found that by 15 minutes at room temperature 
lactate levels increased by > 0.2mmol/l which they considered to be clinically 
significant. The rate of increase in lactate was significantly associated with the 
white cell count (WCC) of the sample (the higher the WCC then quicker the rate 
of rise). They found that when the samples were stored on ice there was no 
significant change in lactate over 15 minutes. Astles et al (Astles R, 1994)  
demonstrated that the rise in lactate could be mitigated by the addition of the 
antiglycolytic agents sodium fluoride and potassium oxalate; their addition also 
prevented the increase seen with samples which had a leucocytosis. The results 
of these studies has lead to the general guidance that when measuring the 
lactate level in blood the analysis should be performed within 15 minutes or if a 
prolonged delay is expected then the sample should be placed in a tube with 
fluoride oxalate. 
 
To date, no studies have explored the effect of time on the lactate level of 
peritoneal drain fluid. This is an important question if we are to attempt to use 
lactate from drain fluid samples to aid detection of AL. Fluid in the drain is 
likely to have a different cellular makeup compared to whole blood. There will 
be fewer red blood cells and the fluid may be diluted by the remnants of saline 
wash used at the end of the operation to irrigate the abdomen. Fewer red blood 
cells may mean less glycolysis and therefore a less pronounced change in lactate 
levels over time. In recently published work, a group aiming to develop a lactate 
sensor for anastomotic leak found wide variability in lactate concentrations in 
peritoneal fluid. They specifically cited the stability of lactate in peritoneal fluid 
as a potential causative factor and recommended it be explored (Hirst, 2014). 
 
 
4.2 Chapter 4 aim 
The aim of the study was to investigate the effect of time on lactate levels in 
peritoneal fluid from the abdominal cavity.  
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4.3 Use of ascitic fluid as surrogate of drain fluid 
 
Gaining a fresh sample of peritoneal fluid in a post-operative patient presents 
difficulties. For example, sampling the first 10mls that enter a drainage bag will 
not yield a truly fresh sample as it will have taken a variable amount of time to 
travel down the drainage tubing into the bag which can typically be 20cm or 
more in length. The speed of this will be affected by the position of the patient, 
position of the drain, diameter of the drainage tubing, the viscosity of the fluid 
and the speed at which it flows through the tube. The alternative would be to 
obtain a sample of free fluid under radiological guidance. However, this involves 
an invasive procedure under local anaesthetic in which a needle is inserted into 
the abdominal cavity under ultrasound (US) or CT guidance. Targeting a small 
pool of fluid comes with the risk of damaging surrounding structures such as 
bladder, bowel and blood vessels within the abdomen. A procedure under CT 
guidance would also expose the patient to ionising radiation. The patient would 
also experience some discomfort during the procedure. In addition, it is not 
possible to use healthy subjects as a control because there is normally only 
about 100mls of fluid in the peritoneal cavity which would be extremely 
challenging to sample even under a radiologically guided procedure.  
 
Patients with ascites (a term for the pathological accumulation of free fluid 
within the peritoneal cavity due to a wide range of causes (see table 4.1) 
(Chapman RW, 2006) can frequently have up to 10 – 20 litres of excess fluid 
within their abdominal cavity. This can cause symptoms such as discomfort and 
respiratory difficulties. Consequently, many of these patients require elective 
placement of a peritoneal drain as a therapeutic procedure to drain the excess 
fluid. Insertion of a drain is typically performed at the bedside with local 
anaesthetic and does not require exposure to ionizing radiation. This group of 
patients would therefore represent a surrogate sample group. Whilst the fluid 
may have a slightly different composition to that in a post-operative abdomen, 
obtaining a sample of fluid at the time of insertion of a peritoneal drain 
represented a practical means of obtaining a fresh sample of fluid from the 
peritoneal cavity for immediate analysis without the need for an 
additional/unnecessary procedure to the patient. Between 10 – 30% of patients 
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admitted to hospital with ascites due to cirrhosis have infected ascites 
(spontaneous bacterial peritonitis, SBP) (Piddock et al., 2000). This is detected 
by a high WCC in a sample of their peritoneal fluid. Peritoneal fluid in the 
abdomen following colorectal surgery frequently contains bacteria (Komen et 
al., 2009), this is likely due to overspill from the colon when it is divided and 
then anastomosed. Therefore, a significant proportion of the group of patients 
having elective drainage of ascites will potentially have peritoneal fluid similar 
to patients in the post-operative setting, making them a useful surrogate group.  
  
 
TABLE 4.1 CAUSES OF ASCITES 
Common causes Other causes 
Malignant disease (hepatic or 
peritoneal) 
Infection (e.g. spontaneous bacterial 
peritonitis, TB)  
Cardiac failure Hypoproteinaemia (e.g. nephrotic 
syndrome) 
Hepatic cirrhosis Hepatic venous occlusion (e.g. Budd-
Chiari syndrome) 
 Pancreatitis 
 Lymphatic obstruction 
 Rare causes (e.g. Meigs’ syndrome, 
Vasculitis, renal dialysis, 
hypothyroidism) 
 
 
4.4 Methods 
Ethical approval was granted by the Wales REC 7 NHS Ethics Committee 
(reference 16/WA/0142, see appendix 1) and approval from the NHS Greater 
Glasgow & Clyde (NHS GGC) Research and Development Department (reference 
GN16SG091, see appendix 2) in May 2016 to perform serial lactate and pH 
measurements on peritoneal fluid obtained from patients who were admitted to 
the Gastroenterology Ward at The Royal Alexandra Hospital (RAH), Paisley, for 
drainage of excess peritoneal fluid (ascites) over an 8 month period (July 2016 – 
March 2017). The full study protocol is available in appendix 3. 
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Patients were eligible if they were over 18 years old and had capacity to 
consent. Patients known to have blood borne viruses (HIV, hepatitis B, hepatitis 
C) were excluded. The clinical team looking after the patient (liver nurse 
specialist and doctors from the gastroenterology department) informed the 
researcher about potential patients who met the criteria. The researcher then 
screened their medical record to confirm eligibility. A patient information sheet 
(PIS) (appendix 4) was provided, if they were willing to participate written 
consent (appendix 5) was obtained. The researcher then attended the ward 
when the clinical team inserted the peritoneal drain. Routinely a small sample is 
sent to the lab for cell count and culture and then several litres are drain over a 
24 hour period and discarded. At the time the drain was inserted 20mls of fluid 
was collected in a 20ml syringe and given to the researcher. This was placed into 
a universal white top container and stored at room temperature. The Lactate 
Pro 2 was then used to measure lactate levels within 5 minutes, at 1 hour, 2 
hours and 24 hours after the sample was taken (as per the method in section 
2.2.1.4). The linear equation generated in section 3.4: 
Y = 0.4227x – 0.0282, 
was applied to calculate the true lactate concentration. Once the experiment 
was complete the sample of peritoneal fluid was discarded via the hospital 
clinical waste stream. Patient demographics, underlying diagnosis and blood and 
peritoneal fluid tests taken by the clinical team on the day of drain insertion 
were recorded and stored under an anonymous study number. 
 
Statistical analysis 
Statistical analysis was carried out on SPSS (version 22). Median and interquartile 
ranges were calculated for lactate levels and a Sign test used to test for 
differences in lactate over time from paired samples. P < 0.05 was considered 
significant. 
Clinical significance 
There is no standard consensus in the literature about what represents a 
clinically significant change in peritoneal lactate. In the paper by Calatayud et 
al (Calatayud and Tenias, 2003), which looked at the effect of time on the 
lactate concentration of whole blood, they considered a change of > 0.2mmol/l 
to be clinically significant. In the absence of other evidence in the published 
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literature, a pragmatic decision was taken to use the same cutoff for clinical 
significance in the present study.  
 
 
4.5 Results 
Over an 8 month period a total of 20 patients were identified, screened and 
recruited to the study. The majority of patients included in the study were male  
(90%), the median age was 59 (46 – 69 years) and the most common underlying 
diagnosis was alcoholic liver disease (ALD) (see table 4.2). Three of the 20 
patients (numbers 8, 9 and 17) had a fluid WCC count > 250 indicative of 
spontaneous bacterial peritonitis (SBP). However, only 2 (patients 8 and 17) had 
a positive bacterial culture, both growing the bacteria E. coli in cultures of their 
peritoneal fluid.  
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TABLE 4.2 PATIENT CHARACTERISTICS 
Characteristic Number (%) 
Sex 
Male 18 (90) 
Female 2 (10) 
Age 59 (46 – 69)* 
Underlying diagnosis 
Alcoholic liver disease (ALD) 17 (85) 
Malignancy 2 (10) 
ALD & malignancy 1 (5) 
Peritoneal fluid WCC 
WCC < 250 17 (85) 
WCC > 250** 3 (15) 
Fluid bacterial culture result  
Negative 18 (90%) 
Positive 2 (10%) 
* Age represented as median and interquartile range 
**WCC > 250 indicative of spontaneous bacterial peritonitis (SBP) 
 
 
Table 4.3 shows the results for the lactate analysis from the 20 patients. Figure 
4.1 illustrates the trend in lactate levels over time in patients who had all 4 data 
points collected. The change in lactate over time was small. The median change 
at 1 hour was 0 mmol/l. At 2 and 24 hours the median change was 0.1 mmol/l 
(see table 4.4). The change at 1 and 2 hours was considered statistically 
significant (P < 0.05) but it was not a clinically significant change (i.e. not > 0.2 
mmol/l). The change in lactate at 24 hours was not statistically or clinically 
significant. No patient had a significant decline in lactate over time. Although 
the change in lactate concentration over time was small there are two outliers – 
patients 8 and 17 who had larger increases in lactate at 24 hours (see table 4.3 
and figure 4.1). These were the two patients with positive bacterial cultures 
from their peritoneal drain fluid. 
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TABLE 4.3 LACTATE OVER TIME RESULTS 
 
      Lactate (mmol/l) 
Patien
t no. 
Se
x 
Ag
e 
Diagnosis Fluid WCC 
(cells/mm3
) 
Bacteria
l culture 
5 
min
s 
1h
r 
2hr
s 
24hr
s 
1 M 57 Malignanc
y 
0 Negative 3.2 * 2.9 3.1 
2 M 70 Malignanc
y 
86 Negative 2.3 * 2.3 2.6 
3 M 46 ALD 114 Negative 3.0 2.9 2.9 * 
4 M 46 ALD 88 Negative 3.1 3.0 3.1 3.0 
5 M 65 ALD 100 Negative 2.7 2.7 2.6 2.6 
6 M 46 ALD 5 Negative 4.1 3.8 3.9 3.5 
7 M 46 ALD 92 Negative * 3.9 4.2 4.1 
8 M 64 ALD 2768 Positive 2.8 2.7 2.9 4.3 
9 M 59 ALD 332 Negative 1.5 1.4 * 1.5 
10 F 76 ALD 110 Negative 1.3 1.3 1.3 1.2 
11 F 76 ALD 0 Negative 1.2 1.0 0.9 0.9 
12 M 65 ALD 88 Negative 1.6 1.6 1.5 1.5 
13 M 59 ALD 128 Negative 1.7 1.7 1.6 1.7 
14 M 46 ALD 50 Negative 5.8 5.6 5.7 5.8 
15 M 59 ALD 180 Negative 1.7 1.7 1.7 * 
16 M 71 ALD 106 Negative 1.5 1.5 1.4 1.5 
17 M 70 ALD & 
malignanc
y 
5020 Positive 3.5 3.5 3.5 5.1 
18 M 44 ALD 74 Negative 1.8 1.8 1.7 1.8 
19 M 57 ALD 126 Negative 1.2 1.2 1.2 1.2 
20 M 60 ALD 56 Negative 1.5 1.5 1.4 1.4 
* missing data due to protocol deviations; shaded data = those with positive 
bacterial cultures 
 
 
 
 121 
 
 
 
FIGURE 4.1 CHANGE IN LACTATE OVER TIME IN EACH PATIENT WITH COMPLETE DATA 
SET. EACH LINE REPRESENTS AN INDIVIDUAL PATIENT; THE PURPLE AND BLUE LINES 
WITH AN UPWARD TREND REPRESENT PATIENTS 8 AND 17 RESPECTIVELY. 
 
 
TABLE 4.4 THE MEDIAN CHANGE IN LACTATE LEVELS WITH TIME 
 Lactate level (mmol/l)  
Timing of 
sample 
(hours) 
Median (IQ 
range) 
Median 
change (IQ 
range) 
P value (Sign 
test) 
0 1.8 (1.5 - 
3.1) 
  
1 1.8 (1.5 – 
3.1) 
0.0 (0 – 0.1) 0.008 
2 2.3 (1.4 – 
3.1) 
0.1 (0 – 0.01) 0.021 
24 2.2 (1.4 – 
3.7) 
0.1 (0 – 0.3) 0.077 
 
 
0
1
2
3
4
5
6
7
0 hrs 1hr 2hrs 24hrs
Lactate 
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4.6 Discussion 
At room temperature lactate levels show a small change over time in peritoneal 
fluid. The median change is not clinically significant within the first 24 hours and 
statistically the changes are considered significant at 1 and 2 hours but not at 24 
hours. This is at odds with the clinical picture. It is likely that these statistical 
results are the consequence of the small sample size and therefore more 
emphasis should be placed on the clinical significance (this has been discussed 
with a statistician, personal correspondence).  
The finding that lactate levels in peritoneal fluid rise slightly over time is in 
keeping with the previous work in whole blood (Noordally and Vincent, 1999, 
Calatayud and Tenias, 2003, Astles R, 1994). However, the rise occurs more 
slowly in peritoneal fluid as clinically significant changes occurred at 15 minutes 
in whole blood. This is likely due to the different cellular make up of the fluid, 
with peritoneal fluid containing fewer red blood cells (RBCs) and white blood 
cells (WBCs). The reference range for RBCs in whole blood from the local 
hospital lab is 4.5 – 6.5 x 1012/L for males and 3.8 – 5.8 x 1012/L for females 
whereas peritoneal fluid usually contains few RBCs, with < 100/μl being 
considered normal. As previously mentioned RBCs lack mitochondria so generate 
energy via glycolysis thus generating lactate, less glycolysis may help explain the 
slower rise in lactate levels in peritoneal fluid over time. WBCs will also act as 
reservoirs for glycolysis. The normal WBC in blood in adult humans is 4.0 – 11.0 x 
109/L. Again the WBC of peritoneal fluid is lower with < 250 cells/mm3 (which 
equates to 0.25 x 109/L) being considered normal. Calatayud et al(Calatayud and 
Tenias, 2003) observed that a higher WBC count in blood was associated with a 
quicker rise in lactate. Our findings are in keeping with this as the 2 patients 
who had the greatest change in lactate over 24 hours – patient 8, 2.8 mmol/l to 
4.3 mmol/l, and patient 17, 3.5 mmol/l to 5.1 mmol/l  are the only patients 
with a peritoneal fluid WCC > 1000/mm3 and the only 2 to have positive fluid 
cultures growing E. Coli. Although the sample size is small, the findings in these 
two patients in particular highlight that peritoneal fluid behaves differently in 
the presence of infection, even though at the time neither patient had clinical 
signs of sepsis such as abdominal pain or pyrexia. This lends support to the 
theory that local measurable changes which reflect the overall disease state 
occur early in peritoneal and therefore analysis of the peritoneal environment 
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following creation of an anastomosis may provide an earlier warning of an AL 
than clinical assessment alone. 
 
A limitation of this study is the use of peritoneal fluid from patients with ascites 
as a surrogate for peritoneal fluid from the post-operative abdomen. It is 
possible that the peritoneal fluid present post-operatively may have a different 
cellular composition, e.g. higher levels of RBCs, WBCs and the presence of 
bacteria. During the operation there will inevitably be some bleeding and it is 
unlikely that the saline wash used at the end of the operation will remove all 
the blood. If the post-operative fluid were therefore to contain a higher 
concentration of RBCs than ascitic fluid then it could be postulated that lactate 
levels will be less stable and rise more quickly. A study by Komen et al(Komen et 
al., 2014a) looking at the presence of bacteria in post-operative drain samples 
as a marker of AL found that E. Coli and E. Faecalis were frequently cultured 
from patients who did and did not develop AL. This indicates that bacteria will 
commonly be found in peritoneal fluid in the post-operative environment. This 
would likely have an impact on the stability of lactate – as demonstrated by the 
finding in our study that the 2 patients with E. Coli cultured from their fluid had 
a large increase in lactate levels at 24 hours whereas those who were bacterial 
culture negative had a median change of < 0.1 mmol/l. As a future piece of work 
it would be useful to compare the RBC count, WBC count and bacterial culture 
results of samples of peritoneal drain fluid to those in our study population.   
 
A further limitation is the sample size. Over the duration of the study there 
were certainly more than 20 eligible patients. However, the ethics committee 
stipulated that patients had to be identified by the clinical team and the 
researcher then informed, the researcher was not permitted to screen 
admissions to the gastroenterology ward. Owing to admissions out of hours, 
weekends and frequent changes of medical staff on the gastroenterology ward 
eligible patients were frequently not highlighted to the researcher. It is not 
possible to ascertain how many eligible patients were excluded.  
Despite these limitations, the study still has unique and useful findings. It is the 
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first to explore the stability of lactate in peritoneal fluid finding that over time, 
unless the fluid has a high WBC concentration, the lactate concentration remains 
fairly constant and the minor changes that do occur are not clinically significant. 
In those with a high WBC and positive bacterial cultures (patients’ 8 and 17) by 
24 hours lactate concentration had markedly increased and this increase was 
considered clinically significant. Given the likelihood that bacteria will be found 
in the peritoneal fluid of patients following colorectal surgery this has important 
implications for the interpretation and exploration of lactate as a local 
biomarker of anastomotic leak. The one study that had looked at lactate 
measured from a peritoneal drain made no mention of the timing of sample 
collection(Bini et al., 2014). On the basis of the findings in this study it is clear 
that the timing of sample collection could have impacted on the results. Future 
studies looking at lactate from peritoneal drain fluid samples as a marker of AL 
should aim to collect as fresh a sample as possible. A suggested strategy would 
be to empty the drain and then obtain a sample from the drain within 2 hours 
and measure lactate immediately. Within 2 hours one would expect enough fluid 
to gain a sufficient sample and our findings illustrate that, even in the presence 
of a high WBC count and positive bacterial cultures, clinically relevant changes 
in lactate concentration are unlikely to have occurred within this timeframe.  
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5 Chapter 5 – The stability of pH in peritoneal fluid 
 
 
5.1 Introduction 
As outlined previously (section 1.8.4.2.2.1) pH is a marker of hypoxia. Its 
exploration in relation to assessment of the viability of gastroesophageal 
anastomoses has lead to it being explored as a biomarker for colorectal 
anastomotic leak (Millan et al., 2006, Yang et al., 2013). 
 
As concluded in chapter 4, analysis of fluid from a peritoneal drain following 
surgery is a simple and non-invasive means of assessing the milieu of a colorectal 
anastomosis. Yang et al (Yang et al., 2013) also took advantage of this method 
and measured the pH from pelvic drain fluid in the days following anterior 
resection for rectal cancer. They found that a pH lower than 6.978 on post-
operative day 3 had a sensitivity of 98.7% and specificity of 94.7% for predicting 
AL. This is a potentially exciting finding. However, the exact timing of the drain 
fluid sampling is not stated and this may have important implications for the 
clinical applicability of the results. Simmen et al (Simmen and Blaser, 1993) 
measured the pH from peritoneal fluid obtained at the time of laparotomy or 
post-operatively via a passive drainage system. They found that a 2 hour delay in 
analysis of the sample resulted in an average change in pH of 0.5%. No comment 
was made as to the statistical or clinical significance of this in their study but it 
does provide evidence that pH may change over time in a peritoneal fluid 
sample. No other studies have addressed this issue in peritoneal fluid but it has 
been studied in pleural fluid analysis where pH has been found to change over 
time. pH is commonly measured in pleural fluid samples with an acidic pH 
considered a marker of infection(Maskell and Butland, 2003). Rahman et al 
(Rahman et al., 2008) defined a change in pH of 0.05 as being clinically 
significant. In 92 samples of pleural fluid they found a clinically significant 
change in pH in 13% at 1 hour, 26% at 4 hours and in 68% of samples at 24 hours. 
The difference was statistically significant at 4 and 24 hours. These results 
highlight the importance of investigating the stability of pH in peritoneal fluid. If 
significant changes occur over time then there are important implications for 
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protocols for fluid sampling, handling and interpretation of results. Furthermore, 
in working towards creation of a pH biosensor for AL an understanding of its 
stability in peritoneal fluid is required to inform the design of this technology.  
 
 
5.2 Aims  
The aim of the study was to determine the effect of time on pH levels of 
peritoneal fluid from the abdominal cavity. 
 
 
5.3 Methods 
This study was carried out in conjunction with the study in chapter 4 looking at 
the effect of time on lactate levels. The use of ascitic fluid as a surrogate for 
peritoneal fluid from post-operative patients is described in section 4.3. 
 
pH levels were concurrently measured from the same peritoneal fluid samples. 
The ethical and R&D approvals and method of patient identification, sample 
collection and disposal for this study are identical to those described in section 
4.4.    
 
pH specific methods: 
The pH measurements were made on the Omega PHH-7011 meter. The meter 
was calibrated daily with pH 7 and 4 buffer solutions and measurements made as 
per the protocol in section 2.2.3. The linear equation generated in section 3.4: 
Y = 0.9757x + 0.2687, 
was applied to calculate the true pH level. 
 
Statistical analysis 
Statistical analysis was carried out on SPSS (version 22). Median and interquartile 
ranges were calculated for pH values and a Sign test used to test for differences 
in  pH levels over time from paired samples. P < 0.05 was considered significant. 
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Clinical significance 
There is not a universally agreed definition of a “clinically significant change in 
pH”. In looking at pleural fluid Rahman et al(Rahman et al., 2008) considered a 
change of 0.05 to be significant. However, in a trial published in ‘The Lancet’ 
Gutierrez et al used gastric pH monitoring as a guide to management of patients 
in the Intensive Care Unit (ICU) and used 0.10 as a cut-off for a clinically 
significant change (Gutierrez et al., 1992). At pH 7.00 a change of 0.05 and 0.10 
represent changes of 0.73% and 1.43% respectively. Both represent very small 
changes, a less than 1% change is perhaps too small to be reliably detected so in 
this study it was decided to use 0.10 as a marker of clinical significance.  
 
 
5.4 Results 
A total of 20 eligible patients were recruited to the study. The demographics of 
the patients and their pH results are displayed in table 5.1. The majority were 
male (90%) and had a diagnosis of alcoholic liver disease (ALD) (90%). Three of 
the 20 patients (numbers 8, 9 and 17) had a fluid WCC count > 250 which is 
indicative of spontaneous bacterial peritonitis (SBP). However, only 2 of them 
(patients 8 and 17) had a positive bacterial culture growing E. coli in their 
peritoneal fluid. 
 
Table 5.1 includes the results for the pH analysis from the 20 patients. Patient 8 
did not have a 24 hour pH recorded as the meter developed an error and could 
not be calibrated, this also precluded measurement of pH in patients 9 – 12 until 
the issue was resolved. Protocol errors resulted in pH measurements being 
missed at 1 hour in patients 1 and 2 and at 24 hours in patients 3 and 15. One 
patient was excluded – patient 6 who had an initial pH of 9.17, this is likely a 
measurement error. Figure 5.1 shows the change in pH over time in patients who 
had a full data set collected. The overall median pH at the time of drain 
insertion was 7.66 (IQR 7.56 – 7.73) and at 1 hour, 2 hours and 24 hours was 7.75 
(IQR 7.69 – 7.83), 7.81 (IQR 7.69 – 7.88) and 7.98 (IQR 7.85 – 8.11) respectively.  
pH rose steadily over time in patients with negative bacterial cultures. However, 
in the 2 patients with a high WCC and positive bacterial cultures this was not the 
case. Patients 8 and 17 showed a decrease in their pH over time. In patient 8 pH 
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at 1 (7.52) and 2 hours (7.57) was lower than the starting pH of 7.92 (24 hour pH 
was not recorded). In patient 17 the initial pH was 7.58; there was a small rise 
to 7.65 at hours 1 and 2 and then it fell slightly to 7.63 at 24 hours. The median 
overall change in pH at 1 hour is 0.11, at 2 hours is 0.17 and at 24 hours is 0.37 
(table 5.2). These changes are all considered to be statistically and clinically 
significant. 
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TABLE 5.1 PH RESULTS 
Patien
t no. 
Se
x 
Ag
e 
Diagnosis Fluid WCC 
(cells/mm3
) 
Bacteria
l culture 
pH 
0 
pH 
60 
min 
pH 
120 
min 
pH 
24hr
s 
1 M 57 Malignanc
y 
0 Negative 7.5
2 
* 7.6
6 
7.98 
2 M 70 Malignanc
y 
86 Negative 7.4
7 
* 7.6
9 
7.91 
3 M 46 ALD 114 Negative 7.4
5 
7.7
1 
7.8
4 
* 
4 M 46 ALD 88 Negative 7.7
0 
7.7
6 
7.9
5 
8.13 
5 M 65 ALD 100 Negative 7.6
7 
7.6
8 
7.8
1 
7.85 
6 M 46 ALD 5 Negative 9.2
2 
7.8
2 
8.0
7 
8.21 
7 M 46 ALD 92 Negative * 7.5
6 
7.8
1 
7.71 
8 M 64 ALD 2768 Positive 7.9
2 
7.5
2 
7.5
7 
* 
9 M 59 ALD 332 Negative * * * * 
10 F 76 ALD 110 Negative * * * * 
11 F 76 ALD 0 Negative * * * * 
12 M 65 ALD 88 Negative * * * * 
13 M 59 ALD 128 Negative 7.6
1 
7.7
6 
7.8
6 
7.98 
14 M 46 ALD 50 Negative 7.7
0 
7.8
8 
7.9
5 
8.15 
15 M 59 ALD 180 Negative 7.7
2 
7.8
3 
7.8
7 
* 
16 M 71 ALD 106 Negative 7.8
8 
8.0
0 
8.0
5 
8.28 
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17 M 70 ALD & 
malignanc
y 
5020 Positive 7.5
8 
7.6
5 
7.6
5 
7.63 
18 M 44 ALD 74 Negative 7.7
5 
7.8
3 
7.8
8 
8.05 
19 M 57 ALD 126 Negative 7.6
1 
7.6
8 
7.7
1 
7.87 
20 M 60 ALD 56 Negative 7.6
5 
7.7
5 
7.8
0 
7.98 
*missing data 
 
 
 
FIGURE 5.1 CHANGE IN PH OVER TIME FOR PATIENTS WITH COMPLETE DATA SETS; 
EACH COLOURED LINE REPRESENTS AN INDIVIDUAL PATIENT. 
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TABLE 5.2 THE MEDIAN CHANGE IN PH LEVELS WITH TIME 
 pH  
Timing of 
sample 
(hours) 
Median (IQ 
range) 
Median 
change (IQ 
range) 
P value (Sign 
test) 
0 7.66 (7.56 – 
7.73) 
  
1 7.75 (7.69 – 
7.83) 
0.11 (0.08 – 
0.18) 
0.006 
2 7.81 (7.69 – 
7.88) 
0.17 (0.14 – 
0.24) 
0.002 
24 7.98 (7.85 – 
8.11) 
0.37 (0.26 – 
0.44) 
0.001 
 
 
5.5 Discussion  
The median changes of 0.11 at 1 hour, 0.17 at 2 hours and 0.37 at 24 hours 
represent a 1.4%, 2.2% and 4.8% change from the baseline respectively. These 
changes were all statistically significant. However, as previously discussed there 
is no universally agreed cut-off for a clinically significant change in pH in the 
literature. It has not been investigated in peritoneal fluid but based on work in 
pleural and gastric fluid we considered a change of 0.1 to be clinically 
significant. Although by this definition the median change at 1 hour of 0.11 is 
technically clinically significant it represents a small (1.4%) change from the 
baseline and overall it was thought that this may not prove to be truly clinically 
significant.  
In our study pH generally increased over the 24 hour period. However, as in 
chapter 4, patients 8 and 17, who grew E. Coli in their peritoneal fluid, behaved 
differently. They did not show a continual increase in pH over time. This is most 
likely due to the high levels of bacteria in their fluid causing a high level of 
metabolic activity which lowers the pH. This will counteract the factors 
discussed later in this section which generally led to a rise in pH over time in our 
samples. In pleural fluid, a low pH is considered a marker of infection. The 
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finding that pH, along with lactate in chapter 4, behaved differently in these 
two patients adds further support to the theory that investigation of peritoneal 
fluid surrounding an anastomosis may yield early clues as to the health of the 
anastomosis. 
On immediate testing of the fluid sample the median pH was 7.66 (IQ range 7.56 
– 7.73). No standard accepted reference range for peritoneal fluid pH exist. This 
is largely due to the difficulty in sampling “normal” peritoneal fluid in healthy 
individuals. A study by Noh et al (Noh, 2003) attempted to answer this question. 
They measured the pH of fluid in the subhepatic space on opening the abdomen 
of patients undergoing surgery for non-serosal invasive gastric adenocarcinoma 
without know ascites or metastatic disease, the assumption being that this 
would represent “normal peritoneal fluid”. They sampled 134 patients and found 
the mean pH to be 7.73 with a range of 7.46 - 8.10. In another study, Simmen et 
al (Simmen et al., 1994) measured pH in samples from peritoneal fluid drains of 
patients making an uncomplicated recovery from abdominal surgery and 
recorded a median pH of 7.49 with range 7.04 – 7.94. Our findings are 
concordant with these two previous studies.  
 
The stability of pH in peritoneal fluid has only been mentioned briefly once 
before in the literature. Simmens et al commented that a delay in analysis of pH 
from peritoneal fluid taken intra-operatively or post-operatively from a 
peritoneal drain resulted in a change of 0.5%. They do not display the data, 
provide ranges or state whether this was an increase or decrease in pH. 
However, as outlined in section 4.3 stability of pH in pleural fluid has been 
studied with the finding that pH generally increased over time. The mean 
difference at 1, 4 and 24 hours was 0.01, 0.03 and 0.05 respectively. This is a 
smaller difference than in our study (0.11, 0.17 and 0.37 at 1, 2 and 24 hours 
respectively). One possible explanation for this difference is the exposure of our 
samples to air. Samples were collected in a 20ml syringe which had had the air 
expelled but the samples were then stored in white topped universal container. 
Whilst the container was air tight the container was not completely full and 
therefore would have contained air. In addition, when the samples were 
retested the containers were reopened thus providing additional exposure to air. 
Simmens et al looked at the impact of exposure of the pleural fluid samples to 
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air and found that air exposure lead to a mean increase in pH of 0.08 (95% C.I. 
0.06 – 0.09). They also measured partial pressure of O2 (p02) and partial pressure 
of CO2 (pCO2) and found that the change in pH with the presence of air was 
correlated to a change in CO2. They suggested that the mechanism for a rise in 
pH with exposure to air might be that the gradient between the partial pressure 
of CO2 in pleural fluid and air (much higher partial pressure in pleural fluid) 
would result in a rapid diffusion of CO2 through the fluid-air interface, thus 
raising the pH of the fluid. This may explain why our samples had a larger 
increase in pH over time. In future work it would be useful to measure the PO2 
and PCO2 levels of the samples in an effort to elucidate the mechanism by which 
pH rises over time. 
A limitation of this study is the small sample size owing to missing data. 
Unfortunately prior to measuring the 24 hour pH from patient 8 the meter 
developed an error – it could not be calibrated. This also precluded 
measurement of pH in patients 9 – 12. It transpired that the fault developed 
because the probe was not being kept in enough storage fluid. Once this was 
identified and resolved pH measurements were resumed for the remainder of 
patients recruited. The 1 hour pH measurements were missed in patients 1 and 2 
and the 24 hour measurements missed in patients 3 and 15 due to protocol 
errors. The researcher was reliant upon members of the gastroenterology team. 
One person was also trained to measure samples.  However, on occasion due to 
ward pressures it was not possible to complete measurements at the correct 
time thus resulting in several missing results.  
This study is the first to document the stability of pH in peritoneal fluid over a 
24 hour period. On the basis of these results, future work looking at the pH of 
peritoneal fluid samples should aim to measure the peritoneal fluid within 1 
hour of sampling and to minimise exposure of the sample to air. 
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6 Chapter 6 – The serial measurement of lactate and pH 
from peritoneal drain fluid as a marker of colorectal 
anastomotic leak 
 
 
6.1 Introduction 
As outlined in chapter 1, anastomotic leak (AL) following colorectal surgery 
leads to significant morbidity, mortality and poorer oncological outcomes. A 
range of pre-, intra- and post-operative risk factors have been identified but as 
yet there is no reliable test to accurately detect or predict AL. Recent work 
exploring the utility of biomarkers from the perianastomotic environment was 
appraised in chapter 1 and in a literature review published by the researcher 
(Wright et al., 2017). Lactate and pH emerged as the most promising biomarkers 
of anastomotic leak. Studies exploring lactate and pH have consisted of small, 
heterogeneous cohorts, used variable definitions of AL, different end points and 
widely differing measurement techniques and protocols.  
 
Several studies used microdialysis to measure lactate (Matthiessen et al., 2007b, 
Pedersen et al., 2009, Horer et al., 2011, Daams et al., 2014). This can be 
technically difficult and connection of a patient to a microdialysis circuit may 
make mobilisation in the early post-operative period challenging. ‘Enhanced 
recovery after surgery’ (ERAS) protocols, a key component of which is early 
mobilisation, are considered the standard of care following colorectal surgery 
(Varadhan et al., 2010). This challenges the applicability of microdialysis as a 
means by which to monitor the anastomotic environment and detect AL. The use 
of peritoneal drains following colorectal surgery used to be routine but this is 
now debated. A Cochrane review found no reduction in the rate of AL when a 
drain was placed (Karliczek et al., 2006). There was some suggestion that drains 
may have a role in infra-peritoneal rectal anastomoses, but further trials are 
needed to clarify this. Despite this, many surgeons still place pelvic or 
abdominal drains on an individual basis allowing researchers the potential to 
serially measure lactate and pH in peritoneal fluid.  
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The future may lie in the use of biosensor technology. Screen-printed sensors 
can be created at a low cost and are capable of measuring samples with volumes 
as small as several microlitres (Ahmed et al., 2016). Creation of such a sensor 
for lactate/pH is a realistic aim. This could be incorporated into a tiny 
removable piece of tubing. Furthermore, wireless technology creates the 
possibility of producing a biodegradable implant that could be fixed around the 
anastomosis and remotely signal information about the perianastomotic 
environment. Such a device may be several years away but the first stage in its 
conception and development is to determine what biomarker the sensor should 
aim to measure. As discussed lactate and pH appear to show the greatest 
potential. The work of Yang et al in relation to pH is potentially exciting but 
requires confirmation. For lactate, given the limitations of the studies exploring 
it, further work is also necessary to confirm its utility in relation to the 
detection of AL in a larger cohort of patients using a standardised definition of 
AL. Clarification of the utility of lactate and pH will help to direct development 
of a biosensor device for the detection of AL. Measurement of lactate and pH via 
peritoneal drain fluid, whilst not likely to be a long term recommendation, 
offers a simple and convenient way to measure these biomarkers for the 
purposes of confirming their clinical utility prior to biosensor development.  
 
The work in chapters 3 and 4 demonstrate that lactate and pH are stable over 
short period of time in peritoneal fluid. The finding of a clinically significant rise 
in lactate over a 24 hours period in patients who were found to have SBP 
provides further evidence that measurement of local biomarkers may provide 
useful insights into the milieu of the peritoneal cavity. 
 
 
6.2 Aims 
The primary aim of the study was to determine if the serial measurement of 
lactate or pH from intra-abdominal drains in the post-operative period could 
predict colorectal anastomotic leak. The secondary outcome was the ability of 
lactate or pH to predict other complications following colorectal surgery, this 
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has not previously been explored and the potential to identify other intra-
abdominal complications early is an exciting prospect.  
 
 
6.3 Methods 
 
Ethical approval was granted by the NHS Leicester Central Research Ethics 
Committee (reference 16/EM/0394, see appendix 6) in September 2016 to 
measure lactate and pH levels in peritoneal drain fluid in patients following 
colorectal surgery. The study was also approved by the NHS Greater Glasgow & 
Clyde Research and Development Department (reference GN16GA471, see 
appendix 7), September 2016. The full study protocol is available in appendix 8. 
 
All patients attending the Royal Alexandra Hospital (RAH) over a 12.5 month 
period from October 15th 2016 to October 31st 2017 for elective colorectal 
surgery, for both benign and malignant disease, with the pre-operative intention 
of creation of an anastomosis or leaving a stapled off segment of bowel within 
the abdominal cavity (e.g. a stapled off rectal stump in a Hartmann’s procedure) 
were eligible. Potential patients were identified by the researcher via the 
weekly colorectal team multidisciplinary team meeting (MDT) and via consultant 
electronic operation lists. Ultimately the decision regarding the creation of an 
anastomosis or decision to leave a stapled off segment of bowel within the 
abdomen was made by the individual consultant responsible for the patient’s 
surgery. If intra-operative findings or events meant that the decision whether or 
not to perform an anastomosis changed, patients were eligible and included in 
the study based on the pre-operative planned operation on an intention to treat 
basis. Patients were excluded if they were under 18 years of age or were known 
to have a blood-borne virus (e.g. HIV, hepatitis B, hepatitis C). Patients were 
given an information sheet (appendix 9) prior to surgery and signed a consent 
form (appendix 10) before their operation. Placement of a peritoneal drain, and 
the subsequent timing of its removal, was at the discretion of the operating 
surgeon.  If a peritoneal drain was inserted fluid was taken daily as per the drain 
sampling protocol from post-operative day 1 until removal of the drain.  
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Drain sampling protocol 
Drains were routinely emptied on the ward at 6am each day. A fresh sample was 
then taken within 2 hours for measurement of lactate and pH. This time frame 
was chosen based on the findings in this thesis. Obtaining a peritoneal fluid 
sample and storing it at room temperature in a universal white topped container 
was thought to be analogous to a sample of fluid sitting in a drainage bag 
outwith the abdominal cavity. In chapter 5 it was recommended that pH was 
sampled and analysed within an hour. The pH meter required a minimum of 3mls 
for analysis. Following drain emptying it was observed that within 1 hour the 
volume of fluid that had drained into the bag was frequently insufficient for pH 
analysis, however by 2 hours the volume was sufficient. As demonstrated in 
section 4.5 lactate levels would be expected to be stable within 2 hours. 
Therefore, to ensure a sufficient volume of fluid was available for analysis a 
pragmatic decision was taken to obtain samples for pH and lactate analysis 
within 2 hours of the drain being emptied each day. 
Lactate was measured with the Lactate Pro 2 and pH with the Omega PHH-7011 
meter (see sections 2.2.1.4 and 2.2.3.2 for protocols for testing using the 
handheld meters). The linear equations generated in section 3.4.1.1 for 
correcting lactate and pH measurements were applied to determine absolute 
peritoneal values. 
 
Validation of the handheld lactate and pH meters for the measurement of 
human peritoneal drain fluid 
In chapter 3 the ‘Lactate Pro 2’ (LP2) and the ‘Omega PHH-7011’ meters were 
validated against laboratory meters in measuring lactate and pH from standard 
solutions. Previous work demonstrated that the LP2 had been successfully used 
to measure lactate from the peritoneal fluid of horses (Nieto et al., 2015). The 
Omega pH meter had not previously been used in a clinical context. Given that 
this was the first time that both meters were to be used to measure human 
peritoneal fluid it was decided that a subset of peritoneal fluid samples should 
be tested in duplicate on the handheld meters and on laboratory gold standard 
meters to ensure external validation. 
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A total of 9 samples of human peritoneal drain fluid were transferred to 
Strathclyde University for analysis. Following measurement of lactate and pH on 
handheld meters 10mls of peritoneal drain fluid was placed in a universal white-
topped container. This was then placed in a protective secondary pack and then 
an outer rigid pack in line with the guidelines for the transport of category B 
biological substances (Agents, 2005). The specimen was then immediately 
transported from The Royal Alexandra Hospital to the biomedical engineering 
laboratory in The Wolfson Centre at the University of Strathclyde. Upon arrival 
at the lab the sample was removed from its protective container. It was then 
divided into 2 equal measures. One was used to measure lactate on a 
colorimetric assay on a ‘Labsystems Multiskan Plate Reader’ using an L-lactate 
assay (via the method outlined in section 2.2.2). The other half of the sample 
was then used to measure pH on the Mettler Toledo Meter in triplicate via the 
methods outlined in sections 2.2.4.1. Once testing was complete the samples 
were disposed of in line with University Guidance for the handling and disposal 
of clinical samples via the University clinical waste stream (see appendices 11 – 
13 for the Standard Operating Procedures (SOPs) and Control of Substances 
Hazardous to Health (COSHH) assessments and protocols that applied to the 
testing and handling of the clinical samples).  
 
Data collection 
Patient demographics, underlying diagnosis and results of routine post-operative 
blood tests (e.g. WCC, CRP, albumin) performed by the clinical team were 
recorded. Patients were followed for 30 days post-operatively; complications 
and 30 day mortality were recorded.  
Definition of anastomotic leak 
Anastomotic leak was defined and graded as per the ‘International Study Group 
on Rectal Cancer’ as, “a defect of the intestinal wall at the anastomotic site 
(including suture and staple lines of neorectal reservoirs) leading to a 
communication between the intra- and extraluminal compartments. Grade A 
anastomotic leakage results in no change in patients’ management, whereas 
grade B leakage requires active therapeutic intervention but is manageable 
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without re-laparotomy. Grade C anastomotic leakage requires re-laparotomy” 
(Rahbari et al., 2010). If clinically an AL was suspected, a CT scan was 
performed. These were reported by a Consultant Radiologist. The following are 
recognised features of an AL on CT:  the presence of perianastomotic air, 
perianastomotic collection and a defect in staple-line integrity. Where a left 
sided anastomoses has been created the use of rectal contrast increases the 
diagnostic confidence (Kaur et al., 2014). 
 
Definition of a post-operative complication 
The definition of Dindo et al of a post-operative complication as, “…any 
deviation from the normal postoperative course”, was used (Dindo et al., 2004). 
Dindo describes a classification of complications -  ‘The Clavien-Dindo 
Classification’ which grades complications from 1 – 5 based on increasing 
severity. Complications of all grades were recorded. 
 
Statistical analysis 
(i) Prediction of AL and post-operative complications 
Data are presented as median and interquartile range. A Mann-Whitney test was 
used to identify significant differences in the lactate and pH of those who did 
and did not develop AL or other complications. A chi squared test was used to 
look for significant differences in rate of complications based on whether 
patients had a drain inserted or not. P values of < 0.05 were considered 
statistically significant. Analysis was performed on SPSS version 24 for Mac. 
(ii) Validation of the handheld lactate and pH meters for measuring human 
peritoneal drain fluid  
A scatter graph was drawn to compare the results with the handheld meters vs. 
the standard laboratory meters and a Pearson correlation coefficient was 
calculated to look for agreement. The graphs were drawn and Pearson 
correlation coefficient calculated using Excel, 2011.  
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A power calculation was not performed. The study was a preliminary, 
exploratory study to determine if the work of a previous large study of 
peritoneal fluid pH could be replicated, and to determine if lactate measured 
directly from the perianastomotic peritoneal fluid via a drain had any correlation 
to AL. The aim was to guide and direct future work towards the develop a 
biosensor for anastomotic leak rather than to determine exact cut-off values of 
lactate and pH to use for clinical decision making. The time-frame available for 
the study was limited and it was anticipated that fewer than 100 patients could 
be recruited. However, it was felt even with a smaller cohort meaningful trends 
could be identified to guide future biosensor development.  
6.4 Results 
 
A total of 66 patients were recruited (see figure 6.1). One patient was excluded 
because following recruitment they were deemed to be unfit to proceed with 
surgery. A further 7 were excluded as they ultimately underwent an 
abdominoperineal resection (APR) and therefore did not have an anastomosis or 
a rectal stump in situ. In some cases the decision was taken intra-operatively 
and in others the plan was changed after consent for the study had been 
obtained.  As shown in table 6.1, the majority of patients were female (51.7%), 
aged < 65 (51.7%), with a BMI > 25 (58.6%), ASA grade II (63.8%), had an 
underlying diagnosis of cancer (55.2%), had an open operation (72.4%) and had a 
left sided resection (65.5%). The majority of those with cancer did not have 
neoadjuvant chemotherapy (93.5%), 15.5% had a covering stoma and 6.9% had an 
end stoma. Most patients (55.2%) had a drain inserted and were discharged in 
under 7 days (60.3%). The 30 day mortality and complication rates were 1.7% 
and 36.2% respectively (see table 6.1). There were no anastomotic leaks. 
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FIGURE 6.1 CONSORT DIAGRAM OF RECRUITMENT 
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TABLE 6.1 PATIENT DEMOGRAPHICS – ALL PATIENTS (N=58) 
Variable        Number (%) 
Age 
 < 65        30 (51.7) 
 ≥65        28 (48.3) 
Gender 
 Male        28 (48.3) 
 Female       30 (51.7) 
BMI 
 < 25        24 (41.4) 
 25-29        17 (29.3) 
 ≥30        17 (29.3) 
ASA grade 
 I        7 (12.1) 
 II        37 (63.8) 
 III        13 (22.4) 
 IV        1 (1.7) 
Diagnosis 
 Cancer       32 (55.2) 
 IBD        11 (19) 
 Diverticular disease      9 (15.5) 
 FAP        2 (3.4) 
 Dysplastic polyp      4 (6.9) 
Open v lap 
 Open        42 (72.4) 
 Lap        16 (27.6) 
Operation 
 Right hemicolectomy     15 (25.9) 
 Anterior resection      23 (39.7) 
 Hartmanns       2 (3.4) 
 Reversal of Hartmanns     2 (3.4) 
 Sigmoid colectomy      1 (1.7) 
 Reversal ileostomy      3 (5.2) 
 Ileoanal pouch      1 (1.7) 
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 Subtotal colectomy & end ileostomy   1 (1.7) 
 Subtotal colectomy & ileorectal anastomosis  1 (1.7) 
 Completion proctectomy & end ileostomy  1 (1.7) 
 Completion proctectomy & ileoanal pouch  1 (1.7)  
 Left hemicolectomy     3 (5.2) 
 Ileocolic resection      1 (1.7) 
 Resection ileocolic anastomosis    1 (1.7) 
 Total colectomy and ileorectal anastomosis  1 (1.7) 
 En bloc ileocolic and rectosigmoid resection  1 (1.7) 
Stoma formation 
 No        45 (77.6) 
 Yes – covering stoma     9 (15.5) 
 Yes – end stoma      4 (6.9) 
Neoadjuvant treatment 
 No         30 (51.7) 
 Yes        2 (3.4) 
 N/A        26 (44.8) 
30 day mortality 
 No        57 (98.3) 
 Yes        1 (1.7) 
30 day complication 
 No        37 (63.8) 
 Yes        21 (36.2) 
Drain inserted 
 No        26 (44.8) 
 Yes        32 (55.2) 
Day of discharge 
 < POD 7       35 (60.3) 
 ≥ POD 7       23 (39.7) 
 
 
The demographics of the patients who did and did not have a drain inserted is 
shown in table 6.2. Although the difference was not statistically significant, 
patients were more likely to have a drain inserted if they had left-sided surgery 
compared to those having right-sided surgery (63.2% vs. 40%, P = 0.092).  
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TABLE 6.2. DEMOGRAPHICS OF PATIENTS WITH/WITHOUT A DRAIN  
     No drain (n=26) Drain (n=32) 
Variable    Number (%)    P value 
Age 
 < 65    11 (36.7)   19 (63.3)  
 ≥65    15 (53.6)  13 (46.4) 0.291 
Gender 
 Male    12 (42.9)  16 (57.1)  
 Female   14 (46.7)  16 (53.3) 0.798 
BMI 
 < 25    13 (54.2)  11 (45.8)   
 25-29    9 (52.9)  8 (47.1)  
 ≥30    4 (23.5)  13 (76.5) 0.110 
ASA grade 
 I    2 (28.6)  5 (71.4)  
 II    18 (48.6)   19 (51.4)  
 III    6 (46.2)  7 (53.8)   
 IV    0 (0)   1 (100) 0.618 
Diagnosis 
 Cancer   17 (53.1)  15 (46.9)  
 IBD    3 (27.3)  8 (72.7)  
 Diverticular disease  3 (33.3)  6 (66.7)  
 FAP    0 (0)   2 (100)  
 Dysplastic polyp  3 (75.0)  1 (25.0) 0.211  
Open v lap 
 Open    18 (42.9)  24 (57.1)  
 Lap    8 (50)   8 (50)  0.625 
Operation 
 Right hemicolectomy 12 (80)   3 (20)   
 Anterior resection  9 (39.1)  14 (60.9)  
 Hartmanns   0 (0)   2 (100)   
 Reversal of Hartmanns 1 (50)   1 (50)   
 Sigmoid colectomy  1 (100)  0 (0)   
 Reversal ileostomy  0 (0)   3 (100)   
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 Ileoanal pouch  0 (0)   1 (100)   
 Subtotal colectomy   (0)   1 (100) 
 & end ileostomy  
 Subtotal colectomy  0 (0)   1 (100) 
 & ileorectal anastomosis  
 Completion proctectomy 0 (0)    1 (100) 
 & end ileostomy 
 Completion proctectomy 0 (0)   1 (100) 
 & ileoanal pouch   
 Left hemicolectomy 2 (66.7)  1 (33.3)  
 Ileocolic resection  0 (0)   1 (100)   
 Resection ileocolic   0 (0)   1 (100)   
 anastomosis     
 Total colectomy and  (0)   1 (100)   
 ileorectal anastomosis   
 En bloc ileocolic and  1 (100)  0 (0)   
 rectosigmoid resection    
Covering stoma 
 No    24 (50)  24 (50)   
 Yes    2 (20)   8 (80)  0.083 
Neoadjuvant treatment 
 No     17 (56.7)  13 (43.3)  
 Yes    0 (0)   2 (100)   
 N/A    9 (34.6)  17 (65.4) 0.110 
30 day mortality 
 No    26 (45.6)  31 (54.4)  
 Yes    0 (0)   1 (100)   
30 day complication 
 no    17 (45.9)  20 (54.1)  
 yes    9 (42.9)  12 (57.1) 0.820 
 
 
Morbidity and mortality 
At 30 days, the majority of patients were still alive (98.3%) and had recovered 
without any complications (63.8%). One post-operative death occurred from 
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acute renal failure on post-operative day 1. Table 6.3 displays the complications 
experienced and whether or not the patients had a drain inserted. There was no 
significant difference in the incidence of complications between those with and 
without a drain (P = 0.82).  There was no significant difference in the rate of 
non-infective vs infective complications in those with and without a drain (non-
infective: P = 0.199 and infective: P = 0.098). There were a total of 21 
complications, 5 infective and 16 non-infective complications. There were no 
anastomotic leaks. 
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TABLE 6.3. COMPLICATIONS SUFFERED IN ALL PATIENTS (WITH/WITHOUT DRAIN) 
Complication 
Drain 
inserted 
  Totals 
P value 
  No Yes    
None 17 20 37  
Any complication  9 12 21 0.82 
Infective complication 4 1 5 0.098 
LRTI 1 0 1  
UTI 0 1 1  
Wound infection 2 0 2  
Gram negative sepsis 1 0 1  
Anastomotic leak 0 0 0  
         
Non-infective complication 5 11 16 0.199 
Renal failure 0 1 1  
Ileus 2 5 7  
AF 2 0 2  
N&V 0 1 1  
Heart block & perforated stress 
ulcer 
1 0 1 
 
Pancreatitis 0 1 1  
Wound dehiscence 0 1 1  
SVT 0 1 1  
Death 0 1 1  
 
 
 
Diagnostic potential of drain lactate & pH 
As previously stated the decision to insert a drain and the timing of its removal 
was at the discretion of the operating surgeon. Of the 32 patients who had a 
drain inserted, the majority (78.1%) had it removed on POD3 (see table 6.4) 
meaning that it was possible to measure lactate and pH in 32 patients on POD1, 
in 29 on POD2 and in 25 on POD3. Table 6.5 shows the actual number of lactate 
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and pH measurements that were made on POD 1-3 for all patients. Of a total of 
172 possible measurements, 154 (89.5%) were made and 18 (10.5%) were missed. 
The reasons for missing data points were as follows: 12 protocol deviations, 5 
due to meter errors and 1 due to insufficient drain sample for analysis. Of the 12 
protocol deviations, 6 were due to the drain not being emptied in the morning 
and the other 6 were due to the researcher being unexpectedly unable to attend 
to collect the samples (due to illness). 
 
 
TABLE 6.4. WHEN POST-OPERATIVE DRAINS WERE REMOVED 
Day of drain removal (total n = 32) Number 
POD 1 3 
POD 2 4 
POD 3 25 
 
 
TABLE 6.5. NUMBER OF LACTATE AND PH MEASUREMENTS THAT WERE MADE 
POD Number of 
patients 
with a drain 
Number of 
lactate 
measurements 
Number of pH 
measurements 
Number of 
measurements 
missing 
1 32 29 30 5 
2 29 24 25 9 
3 25 23 23 4 
Total  76 78 18 
 
 
When lactate measurements were made for the first 5 patients the Lactate Pro 2 
consistently read them as “high” i.e. greater than 25 mmol/l which was the 
upper limit of the device. This was unexpected given that when lactate was 
measured in chapter 4 the readings on the LP2 using peritoneal fluid, prior to 
applying the correction, were between 2.1 – 13.9 mmol/l. An adjustment was 
therefore made to the protocol to dilute the samples with distilled water in a 
50:50 ratio, 3mls of peritoneal fluid was mixed with 3mls of distilled water. 
Although this would affect the values obtained for lactate concentration it 
would still allow a change in concentration to be detected. As previously 
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mentioned in section 3.5, it is thought that the change, rather than absolute 
concentration of lactate may be more important in detecting AL and other 
complications. This modification allowed lactate to be measured on the Lactate 
Pro 2. The correction generated in section 3.4.1.1 was then applied. This 
reduced the number of lactate measurements available for analysis to 28 on 
POD1, 25 on POD2 and 22 on POD3. Measurement of pH was not affected.  
 
 
Primary outcome – drain lactate and pH as a predictor of anastomotic leak 
There were no anastomotic leaks detected within 30 days in any of the 58 
patients. It was therefore not possible to assess the primary aim of the study. 
 
Secondary outcome – drain lactate and pH as a predictor of complications 
Table 6.6 shows the peritoneal drain fluid lactate levels on PODs 1-3 from all 
patients. There was wide variability in lactate levels ranging from 0.7 – 
10.5mmol/l. In those without complications, the median lactate levels rose from 
POD 1 (5.4 mmol/l) to POD 3 (7.3 mmol/l) (see table 6.7) but, as shown in table 
6.6 and the boxplots in figure 6.2, there was wide variability in the 
measurements from each patient with some falling and others rising on PODs 2 
and 3 compared to POD 1. In those with complications the median lactate level 
rose from 4.7 mmol/l on POD 1 to 7.6 mmol/l on POD 2 then fell to 5.4 mmol/l 
on POD 3 but again there is wide variability in the results for individual patients. 
There was no significant difference in the POD 1-3 lactate between those with 
and without complications (table 6.7).  
 
 
 152 
TABLE 6.6. LACTATE LEVELS IN ALL PATIENTS 
  Lactate (mmol/l) 
Patient 
Number Day drain out POD 1 POD 2 POD 3 
1 3 8.9 High* High 
2 2 High 8 
 3 3 High High High 
5 3 8 High High 
7 3 High 
 
8.7 
8 3 2.1 
 
3.3 
12 3 7 8.5 7.2 
16 3 5.4 2.1 7.6 
17 3 8.2 7.6 0.7 
18 3 3 7.4 6.9 
21 3 2.3 2.8 4.8 
23 3 8.1 10.1 10.2 
24 3 3.6 4.7 6.9 
27 1 10.1 n/a n/a 
28 3 8.4 9.9 7.3 
29 3 5.2 8 9.9 
33 3 10.5 9.7 9 
36 3 4.3 6.9 6.1 
38 3 3.9 3.9 6.8 
44 2 3.1 2.9 n/a 
45 2 7.5 5.1 n/a 
46 1 6.1 n/a n/a 
51 3 5.5 5.6 1.0 
55 3 4 8 5.9 
56 3 3.9 6.3 5.6 
58 3 7.7 10.5 9.1 
59 3 5.3 7.8 2.2 
62 1 2.8 n/a n/a 
64 3 
  
10.5 
66 2 4.6 6.6 n/a 
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No shading = those without complications; grey shading = those with 
complications; 
N/a = not applicable, drain already removed, *High = above upper limit of 
detection of Lactate Pro 2 
 
 
TABLE 6.7. MEDIAN AND IQ RANGES OF LACTATE SAMPLED FROM DRAINS IN THOSE 
WITH AND WITHOUT POST-OPERATIVE COMPLICATIONS 
 Lactate (mmol/l) 
 No complication Complication P value 
 Median (IQR) Median (IQR)  
POD 1 5.4 (3.9 – 8.1) 4.7 (2.6 – 8.3) 0.397 
POD 2 6.8 (4.5 – 8.8) 7.6 (4.9 – 8.6) 0.718 
POD 3 7.3 (6.3 – 9.6) 5.4 (2.4 – 8.2) 0.115 
 
 
FIGURE 6.2. BOX PLOT OF MEDIAN LACTATE (MMOL/L) WITH IQR IN THOSE WITH 
AND WITHOUT COMPLICATIONS 
 
 
Table 6.8 shows the peritoneal drain fluid pH levels on PODs 1-3 from all 
patients. Although there was variation, in those without complications pH 
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generally rose each day with the median values on POD 1-3 being 7.71, 7.88 and 
8.12 respectively (see table 6.9 and figure 6.3). For those with complications the 
median pH on POD 1 was lower at 7.61, it rose to 7.70 on POD 2 and, in contrast 
to those without complications, the pH decreased from POD 2 to POD 3 (7.60). 
Despite the trend, the differences between pH in those with/without 
complications was not significantly different on any post-operative day.  The 
median rise in pH from POD 1 to POD 3 was smaller in those with vs. without 
complications (0.18 and 0.32 respectively) but it was not statistically significant 
(P = 0.51).  
 
 155 
TABLE 6.8. PH LEVELS IN ALL PATIENTS 
  pH 
Patient 
number Day drain out POD 1 POD 2 POD 3 
1 3 6.92 7.99 7.33 
2 2 7.01 8.2 n/a 
3 3 8.65 6.22 7.08 
5 3 6.93 6.74 7.17 
7 3 8.37 
 
7.15 
8 3 7.97 
 
7.49 
12 3 7.66 7.65 7.78 
16 3 7.82 8.19 8.39 
17 3 7.27 8.1 8.26 
18 3 7.65 
 
7.71 
21 3 7.7 7.95 8.46 
23 3 7.71 6.93 
 24 3 7.54 7.46 7.86 
27 1 7.21 n/a n/a 
28 3 7.01 7.77 8.19 
29 3 7.66 7.5 7.24 
33 3 7.41 7.72 7.84 
36 3 8.06 8.15 8.21 
38 3 8.19 8.09 8.12 
44 2 8.7 8.15 
 45 2 7.82 8 n/a 
46 1 7.88 n/a n/a 
51 3 7.47 7.47 8.39 
55 3 7.61 7.67 7.78 
56 3 7.68 8.21 8.39 
58 3 7.49 7.7 7.48 
59 3 
 
7.92 8.1 
62 1 8.76 n/a n/a 
64 3 7.52 7.7 7.51 
66 2 7.73 7.34 n/a 
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No shading = those without complications; grey shading = those with 
complications; 
N/a = not applicable, drain already removed  
 
 
TABLE 6.9. MEDIAN AND IQ RANGES OF PH SAMPLED FROM DRAINS IN THOSE WITH AND 
WITHOUT POST-OPERATIVE COMPLICATIONS 
 pH 
 No complication Complication P value 
 Median (IQR) Median (IQR)  
POD 1 7.71 (7.52 – 8.06) 7.61 (7.21 – 7.97) 0.312 
POD 2 7.88 (7.49 – 8.16) 7.70 (7.47 – 7.95) 0.263 
POD 3 8.12 (7.65 – 8.32) 7.60 (7.29 – 8.17) 0.186 
Difference 
POD 3 – POD 1 
0.32 (-0.04 – 0.63) 0.18 (-0.24 – 0.59) 0.512 
 
 
 
FIGURE 6.3. BOX PLOT OF PH IN THOSE WITH AND WITHOUT COMPLICATIONS 
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6.4.1 Comparison of the Lactate Pro 2 and colorimetric assay testing clinical 
samples of peritoneal drain fluid 
 
A total of 9 clinical samples were transported from the Royal Alexandra Hospital 
to the University of Strathclyde for testing with the colorimetric lactate assay. 
Table 6.10 displays a comparison of the results of the lactate measurements 
made for each of the samples with the Lactate Pro 2 and the colorimetric 
lactate assay. There is little agreement between the results obtained with the 
different measurement techniques. The scatter graph in figure 6.4 confirms the 
lack of correlation between the results (R = 0.21). 
 
 
TABLE 6.10. LACTATE MEASUREMENTS MADE ON THE LP2 AND LAB COLORIMETRIC 
ASSAY 
Clinical sample 
number 
Lactate Pro 2 (mmol/l) Colorimetric assay 
(mmol/l) 
S044.1 3.1 11.0 
S045.1 7.5 27.2 
S046.1 6.1 5.1 
S044.2 2.9 19.7 
S045.2 5.1 16.5 
S050.1 5.4 19.8 
S056.1 3.9 13.9 
S059.1 5.3 25.8 
S062.1 2.8 6.6 
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FIGURE 6.4. CORRELATION BETWEEN LACTATE READINGS OF LP2 VS. THE LAB 
COLORIMETRIC ASSAY 
 
 
6.4.2 Comparison of the Omega PH-7011 Meter and Mettler Toledo pH meter 
testing clinical samples of peritoneal drain fluid 
 
A total of 9 clinical samples were transported from the Royal Alexandra Hospital 
to the University of Strathclyde for testing with the Mettler Toledo pH meter. 
Table 6.11 displays a comparison of the results of the pH measurements made 
for each of the samples with the Omega PH-7011 Meter and the Mettler Toledo 
Meter. As shown in figure 6.5 there is a good correlation between the results of 
the Omega Meter and the Mettler Toledo Meter (R = 0.97) however, for each 
sample the reading from the Omega meter is higher indicating that the readings 
are not accurate. 
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TABLE 6.11. PH MEASUREMENTS MADE ON OMEGA AND METTLER TOLEDO PH METERS 
Clinical sample 
number 
Omega pH meter Mettler Toledo pH 
meter 
S044.1 8.70 8.4 
S045.1 7.82 7.53 
S046.1 7.88 7.55 
S044.2 8.15 7.78 
S045.2 8.00 7.58 
S050.1 8.11 7.91 
S056.1 7.68 7.40 
S059.1 * 7.42 
S062.1 8.76 8.48 
*size of clinical sample insufficient for measurement with Omega pH meter 
 
 
 
FIGURE 6.5. CORRELATION BETWEEN PH READINGS OF OMEGA VS. METTLER TOLEDO 
PH METERS 
 
 
6.5 Discussion 
 
The absence of any ALs in the study meant that it was not possible to confirm or 
refute the primary aim of the study: the ability of peritoneal fluid lactate and 
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pH to serve as early markers of AL. A recent systematic review quoted the rate 
of AL as ranging from 1-19% depending on the anatomical site: enteroenteric 1-
2%, ileocolic 1-4%, colocolic 2-3%, ileorectal 3-7%, colorectal/coloanal 5-19% and 
ileoanal pouch 4-7% (McDermott et al., 2015). In the current study there were a 
total of 58 patients with 65.5% having left-sided surgery. Based on a perhaps 
conservative estimated leak rate for the study of 5%, a minimum of 3 ALs would 
have been expected. Whilst 58 patients does not represent a large cohort it is 
still unusual that there were no ALs.  
 
The secondary outcome was any complication following surgery. Although there 
was a trend towards a steady increase in pH in those making an uncomplicated 
recovery, there was no significant difference in lactate and pH from the 
peritoneal drain fluid on POD 1-3 in those with and without post-operative 
complications.  
 
The lactate measurements showed wide variation, both between patients and 
within individual patients. The median POD 1 lactate level in all patients without 
complications was 5.4 mmol/l with a large interquartile range (IQR) of 3.9 – 8.1 
mmol/l. An example of the variation in results within one individual is patient 
016 who made an uncomplicated recovery: POD 1 5.4 mmol/l, POD 2 2.1 
mmol/l, POD 3 7.6 mmol/l. Rather than peritoneal drain fluid lactate not being 
associated with complications, the findings may reflect that either lactate is 
unstable in peritoneal drain fluid in the immediate post-operative period or that 
the LP2 meter was cross reacting with something in the fluid and was therefore 
unable to accurately measure lactate in this setting. It is possible that both of 
these issues were present simultaneously. 
 
In comparison to the fluid tested from patients in chapters 4 and 5, the post-
operative peritoneal drain fluid was more obviously blood-stained but this would 
not have been anticipated to be problematic because the LP2 was designed and 
validated to test lactate from whole blood samples. It would be useful to 
examine the cellular makeup of the drain fluid and measure the concentration of 
RBCs and WBCs. As demonstrated by Komen et al (Komen et al., 2009), bacteria 
are also likely to be present. It maybe that on going metabolism by the bacteria 
influence the stability of lactate levels on a day to day basis. As shown in 
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chapter 4, when a sample had a high WCC and bacteria were cultured the 
lactate level increased considerably over 24 hours. It maybe that variation in the 
number of bacteria present in the drain each day might contribute to the 
variation in results. The presence of a high level of bacteria may also explain 
why the lactate levels in the drain fluid were much higher than in the samples 
obtained from the control group in chapter 4. In future work it would be 
worthwhile performing bacterial culture on the samples and also to quantify the 
bacterial load in order to determine its impact and relationship to the lactate 
concentration of the drain fluid. This would help to determine whether the 
variable results for lactate were a consequence of instability of lactate in post-
operative peritoneal fluid.  
 
As mentioned, the other possible explanation for the variable lactate results 
would be that the LP2 was cross-reacting with something in the fluid and 
therefore not able to provide accurate measurements. Such an issue was not 
anticipated given the successful validation of the LP2 in chapter 3 and the fact it 
had been used and validated against a blood gas analyser and laboratory 
colorimetric assay in the veterinary world for measuring the lactate level of 
peritoneal fluid from horses with suspected colic (Nieto et al., 2015). 
Furthermore, in chapter 4 it appeared to provide reliable measurements of 
lactate from peritoneal fluid in patients with ascites. However, it may be the 
case that the peritoneal fluid from post-operative patients may have a 
substantially different cellular and/or biochemical make up to that of patients 
with ascites. In addition, in the study by Nieto et al(Nieto et al., 2015) the 
peritoneal fluid samples from horses were centrifuged and only the supernatant 
tested with the handheld lactate meters. This may have removed cellular 
constituents that would otherwise have cross-reacted with the LP2. Further 
evidence that the unreliable results were due to an issue with the meter is the 
finding that there was no correlation between the 9 lactate levels measured on 
both the LP2 meter and in the laboratory at Strathclyde University on the 
colorimetric assay (see section 6.4.1). A limitation of this comparison is the fact 
that there was a delay in analysis on the colorimetric assay. The laboratory was 
a 30 minute journey from the hospital and once there it took 30 minutes to 
unpack the samples and set up the assay. This meant samples tested on the 
colorimetric assay were more than 2 hours old. However, the variation seen 
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(e.g. sample 044.2 from 2.9mmol/l to 19.7mmol/l and sample 056.1 from 
3.9mmol/l to 13.9mmol/l) was much greater than that seen in the in any of the 
patients over 24 hours in section 4.5, including those with high WBC counts and 
positive bacterial cultures. Testing of all the samples before and after 
centrifugation with LP2 and then on a colorimetric lab assay within 2 hours 
would be a useful next step to determine whether the results were due to the 
sample being unstable or an effect of the cellular constituents of the sample on 
the LP2 meter. 
 
Although the pH levels on POD 1-3 were not significantly different in those with 
and without complications they were more consistent and showed less variability 
than the lactate results. As mentioned in section 4.7 no normal range exists for 
peritoneal pH but 2 previous studies attempting to answer this question had 
quoted means of 7.73 and 7.49 and ranges of 7.46 - 8.10 and 7.04 – 7.94 
respectively (Noh, 2003, Simmen et al., 1994). In addition, in chapter 5 the 
samples of peritoneal fluid yielded a median of 7.66 and IQ range of 7.56 – 7.73. 
The POD 1-3 medians and IQ ranges (see table 6.9) found in patients in this study 
are in line with these results. pH has only previously been explored in relation to 
detection of AL and not complications in general. It is therefore difficult to draw 
conclusions from this work due to the relatively small sample size. However, the 
tentative results suggesting that trend in pH may have some utility in prediction 
of post-operative complications lead the author to propose further work with a 
larger patient cohort to explore these findings. With regard to the choice of pH 
meter in future studies, the author would not recommend using the Omega PH-
7011 meter. In chapter 3 it was shown that it could produce reliable but not 
accurate results compared to a laboratory gold standard meter. When 9 samples 
of peritoneal drain fluid were tested on the handheld Omega meter and then the 
Mettler Toledo meter in the lab (see section 6.4.1.2), there was correlation 
between the meters but the Omega meter again lacked accuracy. However, 
some of this variation may have been due to the delay in analysis on the Mettler 
Toledo which was a consequence of the transit time and sample preparation 
time detailed earlier in this section. The Omega meter was considered sufficient 
to illustrate trends in pH and differences between those with and without 
complications but the absolute values would have to be interpreted with 
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caution. The author recommends that future work exploring pH uses a laboratory 
standard meter to measure all samples rather than the handheld Omega meter. 
 
A major limitation of the study is the small sample size. Over the first 9 months 
of the study there were a total of 104 eligible patients. 76 were approached, of 
these 62 agreed to participate. Suitable patients were identified by the 
researcher via the colorectal MDT and theatre lists. Most patients attended a 
pre-operative assessment clinic 1 – 2 weeks prior to surgery and it was arranged 
that clinic staff would hand out the PIS. After a period of time it became 
apparent that the PIS was frequently not being given to patients thus reducing 
the number of patients who could be recruited. Therefore the researcher and a 
colleague attempted, when possible, to attend the pre-assessment clinic to give 
out the PIS. This improved the rate of patients getting the PIS and boosted 
recruitment.  
 
Of the 58 patients recruited and included in the study, only 32 patients (55.1%) 
had a drain inserted. Whilst the literature does not support the routine use of a 
drain in colonic resections, their role in rectal resections is less clear and the 
use of a drain in rectal resections may still be advisable (McDermott et al., 
2015). Although insertion of a drain was at the discretion of the operating 
surgeon, the fact that 63.3% had left sided surgery means that one may have 
expected a slightly higher percentage of patients to have a drain inserted. In 
planning further work looking at the analysis of post-operative peritoneal drain 
fluid the low percentage having a drain inserted would need to be taken into 
account and consideration given to a longer recruitment period or recruiting 
from more than one site to increase the number of eligible patients over a set 
period of time. An alternative strategy would be to design a study that requires 
insertion of a drain into all patients. Use of a very fine bore piece of tubing such 
as a wound catheter draining into an external bag may represent a reasonable 
option. This would likely have very little impact on the patient and may be more 
acceptable to operating surgeons who are reluctant to place a wide bore drain.  
This would help to increase the sample size. 
 
Overall, it was not possible to assess the utility of lactate and pH from post-
operative peritoneal drain fluid in predicting AL. In assessing the secondary 
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outcome of the development of post-operative complications, the findings from 
pH, although not significant, are encouraging and require further exploration. In 
the current study, lactate from peritoneal drain fluid, was not found to be a 
useful biomarker of post-operative complications.  In chapter 4 lactate was 
found to be stable in peritoneal fluid, and in patients with positive bacterial 
cultures from their peritoneal fluid it rose over 24 hours to a much greater 
degree than in those with culture negative peritoneal fluid. Given these findings 
it is felt likely that the results in this chapter are a consequence of a high level 
of bacteria in the drain samples and possibly a cross-reaction between the LP2 
and constituents of the drain fluid. This study has therefore identified a number 
of issues that should be elucidated before the utility of lactate in detecting AL 
and other post-operative complications can be re-explored. 
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7 Chapter 7 – Comparison of peritoneal drain fluid 
biomarkers to blood biomarkers in the detection of 
colorectal anastomotic leak  
 
 
7.1 Introduction 
 
In the early stages the signs and symptoms of AL can be subtle. Prompt 
detection currently relies upon clinician awareness of the pre- and intra-
operative risk factors to which the patient has been exposed and close attention 
to deviations in clinical observations and in the expected progress of the 
patient. As described in section 1.7.2 blood biomarkers such as and c-reactive 
protein (CRP) and procalcitonin (PCT) can provide a useful adjunct. CRP has 
been much more extensively investigated than PCT. A recent systematic review 
suggested that high levels of CRP (>150mg/l) or procalcitonin on post-operative 
day (POD) 3 - 5 should act as an alert for clinicians to monitor the patient closely 
and consider investigations for signs of AL (McDermott et al., 2015). White cell 
count (WCC) is also commonly measured in the post-operative period and is a 
marker of infection/inflammation. It has previously also been identified as a 
useful marker of AL alongside CRP (Platt et al., 2012) but the results are not 
consistent (Warschkow et al., 2011). Elevated blood biomarkers, in the presence 
of concerning clinical features, frequently lead to further investigation, most 
often a CT scan, to look for evidence of an AL. As described in section 1.7.3 CT 
scans are not 100% sensitive or specific for AL. This is particularly true in the 
early post-operative period when one would still expect to see fluid and possibly 
also some gas in the vicinity of the anastomosis. This is why pursuit of a readily 
measurable local biomarker of AL is an attractive target as it may help to 
differentiate between “normal” postoperative appearances versus AL on CT, 
thus facilitating the appropriate management of the patient in a timely manner.  
 
If technology is to be developed to allow the measurement of local 
perianastomotic biomarkers of AL such as lactate and pH then these biomarkers 
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should have a superior performance to that of pre-existing blood biomarkers 
such as WCC, CRP and procalcitonin which are cheap and simple to analyse and 
are the current standard of care.  
 
 
7.2 Aims 
The primary aim of the study was to determine if the serial measurement of 
blood biomarkers – WCC, CRP and PCT in the post-operative period could predict 
colorectal anastomotic leak. The secondary outcome was the ability of blood 
WCC, CRP and PCT to predict other complications following colorectal surgery. 
 
 
7.3 Methods 
This study was run in conjunction with the study in chapter 6. The ethical 
approval, recruitment, inclusion and exclusion criteria are outlined in section 
6.3. Patients were recruited over a 12.5 month period from October 15th 2016 – 
October 31st 2017.  
Data collection 
Patient demographics and underlying diagnosis were recorded prospectively in a 
data base. As routine standard of care within the department daily post-
operative blood tests including WCC and CRP were taken on each post-operative 
day until discharge. These results were recorded. In addition, between Oct 15th 
2016 – July 31st 2017, each patient had a procalcitonin (PCT) level measured on 
post-operative days 1, 3 and 5. Patients were followed for 30 days post-
operatively. Complications and 30 day mortality were recorded.  
Definition of anastomotic leak and post-operative complications 
This study used the same definitions of AL and post-operative complications as 
described in section 6.3. 
Statistical analysis 
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Data are presented as the median and interquartile range. A Mann-Whitney test 
was used to look for significant differences in median CRP, WCC and PCT levels 
in those with/without complications. P values of < 0.05 were considered 
statistically significant. To compare the performance of CRP, WCC and PCT in 
predicting complications  ROC curves and the corresponding area under curve 
(AUC) were used. All analyses were performed on SPSS version 24 for Mac. 
 
 
7.4 Results 
Between October 2016 – October 2017  a total of 66 patients were recruited. 
One patient then did not go on to have surgery (due to poor fitness) so was 
excluded from further analysis. As described in section 6.4 a further 7 patients 
were excluded because they ultimately underwent an APR. The demographics of 
these patients are described in section 6.4. At 30 days, the majority of patients 
were still alive (98.3%) and had recovered without any complications (68.3%). 
One post-operative death occurred from acute renal failure on post-operative 
day 1. A total of 58 patients were available for analysis. Figure 7.1 shows the 
post-operative days on which patients were discharged. The median day of 
discharge was POD 6 (IQR 4 - 8).  
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FIGURE 7.1 DAY OF DISCHARGE FOLLOWING SURGERY. (POD 1 DISCHARGE = PATIENT 
DEATH ON POD 1) 
 
 
There were a total of 21 complications, 5 infective and 16 non-infective 
complications (see table 7.1). There were no anastomotic leaks. 
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TABLE 7.1. RECOVERY FOLLOWING COLORECTAL SURGERY 
Complication Totals 
    
None 36 
Any complication  21 
Infective complication 5 
LRTI 1 
UTI 1 
Wound infection 2 
Gram negative sepsis 1 
Anastomotic leak 0 
    
Non-infective complication 16 
Renal failure 1 
Ileus 7 
AF 2 
N&V 1 
Heart block & perforated stress ulcer 1 
Pancreatitis 1 
Wound dehiscence 1 
SVT 1 
 
 
Primary outcome – blood biomarkers for the prediction of AL  
As there were no anastomotic leaks it was not possible to address the primary 
outcome. 
 
Secondary outcome – blood biomarkers for the prediction of other complications  
 
C-reactive protein (CRP) 
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The relationship between CRP and complications on PODs 1 - 5 is shown in table 
7.2 and boxplots for POD 1 - 5 in figure 7.2. Compared with patients who did not 
develop a post-operative complication, median CRP on POD 3 - 5 was 
significantly higher in those who developed a complication (P = 0.0032, P = 0.003 
and P = 0.002 respectively). On PODs 1 and 2 there was no significant difference 
in CRP between those with and without complications.  
  
 
TABLE 7.2. MEDIAN POST-OPERATIVE CRP (MG/L) IN THOSE WITH/WITHOUT 
COMPLICATIONS 
 POD 1 POD 2 POD 3 POD 4 POD 5 
No 
complication 
111* (78-
151)  
143 
(108-
186) 
101 (78-
188) 
68 (48-126) 49 (29-102) 
Any 
complication 
103 (75-
122) 
168 
(129-
202) 
151 (111-
230) 
131 (85-
210) 
136 (73-
184) 
P value 0.195 0.150 0.032 0.003 0.002 
*values presented as median and IQ range 
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FIGURE 7.2. POD 1 – 5 CRP IN PATIENTS WITHOUT V WITH COMPLICATIONS 
 
 
To establish a threshold for the relationship between post-operative CRP and 
complications Receiver Operator Curves were plotted for CRP on PODs 3 -5 
(figure 7.3). POD 5 CRP performed best. The area under the curve (AUC) values 
for PODs 3 – 5 were 0.567 (P = 0.527), 0.683 (P = 0.082) and 0.804 (P = 0.004) 
respectively. For CRP on POD 5 the optimum threshold was 153mg/l with a 
sensitivity of 37.5% and specificity of 93.3%. 
 
 173 
 
FIGURE 7.3. ROC CURVE FOR CRP ON POD 3-5 AS A PREDICTOR OF ANY 
COMPLICATION FOLLOWING SURGERY 
 
 
When complications were divided into non-infective (see table 7.3) and infective 
complications (see table 7.4), CRP was still useful in discriminating between the 
groups. In the 16 patients with non-infective complications, CRP was 
significantly higher on POD 3 – 5 (P = 0.03, P = 0.01 and P = 0.008 respectively). 
Only 5 patients suffered an infective complication. CRP was only significantly 
higher on PODs 4 and 5 (P= 0.044 and 0.012 respectively) in those with infective 
complications versus no complications (see table 7.4).  
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TABLE 7.3 MEDIAN POST-OPERATIVE CRP (MG/L) IN THOSE WITHOUT COMPLICATIONS 
V THOSE WITH NON-INFECTIVE COMPLICATIONS 
 POD 1 POD 2 POD 3 POD 4 POD 5 
No 
complication 
111* (78-
151)  
143 
(108-
186) 
101 (78-
188) 
68 (48-126) 49 (29-102) 
Non-infective 
complication 
99 (69-
114) 
171 
(130-
211) 
151 (115-
230) 
128 (82-
203) 
126 (58-
184) 
P value 0.158 0.157 0.030 0.010 0.008 
*values presented as median and IQ range 
 
 
TABLE 7.4. MEDIAN POST-OPERATIVE CRP (MG/L) IN THOSE WITHOUT 
COMPLICATIONS V THOSE WITH INFECTIVE COMPLICATIONS 
 POD 1 POD 2 POD 3 POD 4 POD 5 
No 
complication 
111* (78-
151)  
143 
(108-
186) 
101 (78-
188) 
68 (48-126) 49 (29-102) 
Infective 
complication 
116 (76-
145) 
149 
(122-
223) 
141 (88-
248) 
159 (76-
220) 
136 (126-
190) 
P value 0.781 0.551 0.476 0.044 0.012 
*values presented as median and IQ range 
 
 
White cell count (WCC) 
As demonstrated in figure 7.4 there was little difference in the WCC on PODs 1 - 
5 in patients making an uncomplicated recovery vs. those who suffered a 
complication. This was confirmed by the finding that there was no statistically 
significant difference between the median WCC in any of the groups on POD 1 - 
5 (see table 7.5). Subdivision into infective and non-infective complications did 
not lead to an improvement in the performance of WCC (data not shown). 
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FIGURE 7.4. POD 1 – 5 WCC IN PATIENTS WITHOUT V WITH COMPLICATIONS 
 
 
TABLE 7.5. RELATIONSHIP BETWEEN MEDIAN POST-OPERATIVE WCC AND 
COMPLICATIONS  
 POD 1 POD 2 POD 3 POD 4 POD 5 
No 
complication 
13.7* 
(10.4-
15.4) 
10.7 
(8.5-
12.3) 
9.3 (7.6-
11.7) 
8.0 (6.4-
9.7) 
8.7 (6.7-
10.6) 
Any  
complication 
14.8 
(10.5-
17.8) 
12.2 
(8.3-
15.4) 
9.4 (7.7-
13.2) 
8.9 (7.7-
13.1) 
10.4 (7.4-
13.6) 
P value 0.367 0.155 0.747 0.065 0.253 
*values presented as median and IQ range 
 
 
Procalcitonin (PCT) 
 
As demonstrated in figure 7.5 the PCT levels in those making an uncomplicated 
recovery vs. those who suffered a complication was similar.  
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FIGURE 7.5 POD 1, 3 & 5 PCT IN PATIENTS WITHOUT V WITH COMPLICATIONS 
 
 
As PCT is known to be a marker of bacterial infection, PCT levels in those 
without complications vs those with infective complications were compared. 
Only 5 patient suffered an infective complication. One of those patients (unique 
number 065) had surgery after August 2017 when PCT was no longer being 
recorded, this meant only 4 patients could be analysed. The POD 1, 3 & 5 PCT 
results for these patients are shown in table 7.6. Due to logistical difficulties in 
measuring PCT (discussed further in section 7.5) several PCT measurements were 
missed. Although several of the patients had high levels of PCT (5.21ng/mL on 
POD 5 in patient 008; 3.05ng/mL on POD 1 in patient 042 and 3.40ng/mL on POD 
4 in patient 047), the results were not significant and the median PCT did not 
differ between those with infective complications and those without 
complications (table 7.7). It was not significantly different in the “no 
complication” versus “any complication” groups (see table 7.7) nor in the “no 
complication” versus “non-infective complications” groups (data not shown). 
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TABLE 7.6. POST-OPERATIVE PCT (NG/ML) IN PATIENTS WITH INFECTIVE 
COMPLICATIONS 
Unique 
patient 
number 
POD 1 POD 3 POD 4 POD 5 Complication Day of 
discharge 
004 1.47 - 0.11 - Wound 
infection 
6 
008 0.23 0.20  5.21 UTI** 12 
042 3.05 0.20   Wound 
infection 
4 
047 - - 3.40 - LRTI 12 
065*** - -  - Gram 
negative 
sepsis 
18 
*LRTI: lower respiratory tract infection; **UTI: urinary tract infection; ***outwith 
PCT collection period 
 
 
TABLE 7.7 RELATIONSHIP BETWEEN MEDIAN POST-OPERATIVE PCT (NG/ML) AND 
COMPLICATIONS  
 No 
complication 
Any 
complication 
 Infective 
complication 
 
 Median (IQR) Median (IQR) P  Median (IQR) P  
POD 
1 
0.58* (0.28-
2.10) 
1.45 (0.11-
2.91) 
0.912 1.47 (0.23-1.47) 0.673 
POD 
3 
0.69 (0.26-
2.15) 
0.28 (0.11-
1.83) 
0.155 0.2** 0.104 
POD 
5 
0.46 (0.15-
2.03) 
0.10 (0.05-
5.21) 
0.287 5.21*** 0.267 
*values presented as median and IQ range; **No IQR as n=2; ***No IQR as n=1 
 
 
Comparison of peritoneal drain fluid lactate and pH to blood biomarkers 
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As there were no ALs it was not possible to compare the performance of 
peritoneal fluid lactate and pH to blood biomarkers as predictors of AL. 
 
In relation to the secondary outcome of “other post-operative complications”, 
peritoneal fluid pH showed a trend towards a steady increase in those making an 
uncomplicated recovery (see section 6.4) but the difference was not statistically 
significant. The blood biomarker CRP, but not WCC or PCT, had a superior 
performance as it was found to be statistically significantly higher from POD 3 
onwards in those who developed a post-operative complication (table 7.8). 
 
 
TABLE 7.8 COMPARISON OF PERITONEAL FLUID BIOMARKERS TO BLOOD BIOMARKERS ON 
EACH POST-OPERATIVE DAY 
 P values for no complications versus complications 
Biomarker POD 1 POD 2 POD 3 POD 4 POD 5 
pH 0.312 0.263 0.186 - - 
Lactate 0.397 0.718 0.115 - - 
CRP 0.195 0.150 0.032 0.003 0.002 
WCC 0.367 0.155 0.747 0.065 0.253 
PCT 0.912 - 0.155 - 0.287 
P < 0.05 = statistically significant 
 
 
7.5 Discussion 
 
As there were no ALs in the study it was not possible to assess the primary 
outcome – comparing the performance of blood biomarkers to peritoneal drain 
fluid lactate and pH in the detection of anastomotic leak. As previously 
mentioned in section 6.5 this is unfortunate as even with the relatively small 
sample size of 58 patients a minimum of 3 ALs would have been expected. 
 
In relation to the secondary outcome of the detection of any complication 
following colorectal surgery, the blood biomarker CRP, but not WCC or PCT, 
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performed better than peritoneal drain fluid lactate and pH. POD 3 - 5 CRP was 
significantly higher in those who developed a complication. In particular POD 5 
CRP > 153mg/l had a specificity of 93.3%. This is in agreement with a recent 
systematic review’s recommendation that a POD 3 - 5 CRP > 150mg/l merits 
close observation of the patient for signs of sepsis/AL (McDermott et al., 2015). 
However, the sensitivity of a POD 5 CRP > 153mg/l was only 37.5%. This 
highlights that whilst CRP may be a useful “rule out” test for complications/AL 
and may be a useful component of discharge criteria it is not a good marker of 
AL. 
 
In a previous study by Platt et al(Platt et al., 2012), WCC on POD 7 was found to 
be significantly higher in patients who developed an infective complication 
following elective colorectal surgery. In the context of AL typically being 
detected between POD 6 – 8 (Kanellos et al., 2004, Alves et al., 2002, Alves et 
al., 1999), and with the aim of early identification, the usefulness of a POD 7 
WCC as a marker of AL or infective complications is questionable. Other studies 
have not found WCC to be useful (Warschkow et al., 2011). Overall, a recent 
systematic review concluded that post-operative WCC was not a useful marker 
of AL(McDermott et al., 2015). This study confirms the lack of usefulness of WCC 
as a marker of complications in this group of patients.  
 
PCT was not found to be a useful predictor of complications. Given the sample 
size and specifically the number of infective complications this was unsurprising. 
PCT is marker of infection and has been found to out-perform CRP and other 
markers of inflammation such as interleukins and TNF-alpha in differentiating 
patients with sepsis from those with systemic inflammatory response syndrome 
(SIRS) (BalcI et al., 2002). As such PCT would not be expected to be significantly 
elevated in patients with non-infective complications. This was indeed the case 
in the present study. Of the 58 patients there were 21 complications but only 5 
of these were infective, with only 4 being within the timeframe in which PCT 
was being measured. Of the 5 patients with an infective complication, there 
should have been a total of 14 PCT samples (one patient was discharged on POD 
4) but only 9 were correctly collected, a further 2 were taken on POD 4 with 
only 2 patients having PCT taken on POD 1, 3 and 5 as per protocol.  Although 
the median POD 5 PCT was higher in the group with infective complications vs. 
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those with no complications (5.21ng/mL and 0.46ng/mL respectively), with such 
a small sample size it was not possible to determine if the difference was 
significant.  
 
Significant logistical challenges were the major limitations in the assessment of 
PCT as a marker of AL and post-operative complication. In our institution all 
post-operative blood tests are ordered via a computer system, the requests 
printed off by the phlebotomists and samples taken accordingly. As PCT was 
processed in a different lab there was no facility for online requesting and a 
paper request form had to be completed. The form was completed by the 
researcher and left on the phlebotomy trolley. The phlebotomy department 
were aware of the study and the arrangements for measurement of PCT but 
despite this a substantial number of PCT tests were missed. The PCT samples 
were analysed in batches so it was several weeks before the issues with missed 
samples became apparent.   
 
Overall, in the current study CRP was found to be the only useful biomarker of 
complications and out-performed lactate and pH from peritoneal drain fluid. 
Due to the small sample size and logistical difficulties encountered it would be 
useful to study PCT again in a larger cohort of patients to determine if it was a 
more sensitive marker of infective complications, including AL, than CRP in 
patients who have had colorectal surgery.  
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Chapter 8 – Discussion and 
conclusions  
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8 Chapter 8 – Discussion and conclusions  
 
Anastomotic leak (AL) following colorectal surgery remains a challenging 
problem. Recent work has illustrated that local biomarkers of infection, 
inflammation, bacteria and wound repair from the perianastomotic environment 
may have the ability to detect AL early and the potential of this technology has 
been highlighted as a target for further research (McDermott et al., 2015, Hirst 
et al., 2014). A literature review undertaken as part of this project identified 
lactate and pH as the biomarkers which had the most consistent and promising 
results for the early detection of AL. With the availability of biosensor 
technology that can measure samples as small as several microlitres 
development of a small, implantable and degradable or removable biosensor for 
AL represents an exciting possibility. As the first stage in the development of 
such a sensor this study aimed to further assess the usefulness of lactate and pH 
as a local biomarker of AL and other complications after colorectal surgery. In 
addition it aimed to address the issue of the stability of lactate and pH in 
peritoneal fluid to inform sensor design and also compare the performance of 
perianastomotic lactate and pH to commonly used, yet limited, blood 
biomarkers.  
 
This work has demonstrated that lactate and pH in peritoneal fluid can be easily 
measured using surgically placed intra-abdominal or pelvic drains with minimal 
upset to the patient. Analysis of these samples found both lactate and pH 
undergo clinically significant changes over time, supporting early analysis after 
sampling (within 2 hours). Whilst it was not possible to confirm the usefulness of 
perianastomotic lactate and pH as biomarkers of AL there was a trend towards 
an increasing pH level over PODs 1 – 3 being a marker of an uncomplicated 
recovery following colorectal surgery. The work in chapter 7 confirms the 
previously well documented finding that an elevated CRP from POD 3 onwards, 
and in this study particularly a CRP > 153mg/L on POD 5, can be an indication of 
the development of a complication following colorectal surgery, however it also 
highlights the poor sensitivity of CRP. WCC was found not be a useful marker of 
complications and the numbers were too small to comment on the usefulness of 
PCT as a marker of complications.  
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In the context of a small sample size and the limitations discussed in sections 
4.6, 5.7 and 6.5 it is felt that both perianastomotic lactate and pH merit further 
investigation in relation to their ability to predict AL early and the feasibility of 
constructing lactate and pH biosensors that can be used to monitor the 
perianastomotic environment. The major limitations of this work could be 
addressed by continuing the work in larger clinical cohorts. Ideally lactate and 
pH should be measured from a fresh sample of perianastomotic peritoneal fluid, 
or within 2 hours and should be measured on laboratory standard meters.  
 
Leading on from this project to further explore the utility of lactate and pH as 
biomarkers of AL one of the first issues to be addressed is to determine what 
affects the stability of lactate and pH in peritoneal fluid. Interrogation of 
cellular constituents of samples taken in a variety of settings – from those with 
non-infective ascites to those with blood-stained post-operative peritoneal fluid 
containing bacteria should be compared. Measurement of the concentration of 
RBCs, WBCs, osmolality, partial pressures of oxygen and carbon dioxide, number 
of bacteria present, the effect of temperature and of exposure of the sample to 
air should be explored. The results of this work would inform both measurement 
protocols in future studies and the design of lactate and pH sensors. It would 
also help to determine whether the variable lactate results obtained in chapter 
6 were due to inherent instability of lactate in post-operative peritoneal fluid or 
due to the LP2 meter cross reacting with other cellular constituents. 
 
Medical biosensor research and technology is a rapidly expanding field with over 
200 companies working in the area (Luong et al., 2008). The potential use of this 
technology is exciting. For example, a group at The University of Strathclyde is 
exploring the potential to incorporate biosensors into implantable technology to 
detect re-endothelisation of coronary stents. Current imaging techniques are 
insufficient to detect this re-endothelialisation at an early stage. Early, in-vitro 
work has shown that impedance spectroscopy measurement can be used 
characterise different vascular cell types (Holland et al., 2018). This has the 
potential to allow non-invasive monitoring of the arterial response to stent 
placement using the stent as an electrode. Specifically in relation to AL, in a 
thesis made available in 2018, Hirst et al (Hirst, 2014) developed a point-of-care 
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amperometric biosensor for lactate as a biomarker of AL and carried out a 
feasibility study using an animal model of AL and peritoneal drain fluid from a 
group of patients undergoing colorectal resections. Their results were promising 
and highlight the growing interest in lactate as a local biomarker of AL. 
Potentially aspects of the concept and design of the work in these two studies 
could be translated into the setting of non-invasive monitoring of a colorectal 
anastomosis. 
 
A key consideration in the development of a biosensor for AL is how to deploy 
the sensor into the perianastomotic environment, prevent it being dislodged and 
then safely remove it when it is no longer required. The option of incorporating 
a tiny real-time sensor into the tip of a drain could be explored, this would allow 
simple removal but ensuring it remained in the correct position intra-
abdominally would be more challenging. Exploration of the feasibility of 
inserting a sensor transanally would be another alternative. As described in 
section 1.8.2 transanal devices have previously been created that are either 
manually removed or naturally expelled after several days. Indeed, transanal 
devices such as the EndoSPONGE® (a foam sponge which applies controlled 
pressure) are already in use to manage low extra-peritoneal ALs (Riss et al., 
2010). Ultimately it may even be possible to harness current techniques for local 
management of AL with a biosensor to detect leak so that not only could a 
device detect a problem early it could also deliver local treatment such as the 
automatic release of antibiotics or the instigation of pressure therapy in real-
time in response to signs of a leak. 
 
Recently medical devices have come under increased scrutiny. An article 
published in December 2018 has highlighted that the number of reports of 
malfunctions and injuries sustained from medical devices is on the increase 
(Godlee, 2018). It is thought that one of the reasons for this may be the 
introduction of new devices after only testing in animals or very small numbers 
of humans. This highlights the importance of having a firm scientific basis prior 
to the development of any new technology. The work carried out in this project 
represents the first steps in gaining a better understanding of the 
perianastomotic environment which will provide the foundation for future work. 
In conjunction with this work a group of biomedical engineers at the University 
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of Strathclyde are exploring aspects of the modelling and design of an 
implantable device to detect AL (personal communication). Taking this approach 
and ensuring that there is thorough exploration of the biological and engineering 
considerations at any early stage will ensure that any device that is ultimately 
developed is safe and supported by clinical and scientific data. These important 
considerations underpin the approach taken in this thesis. 
 
Whilst pursuit of such technology is likely to be expensive and time consuming 
its potential to impact on patient orientated outcomes may help to drive 
research. Previously most research topics and studies were selected and 
designed by clinicians and scientists. More recently, with the knowledge that 
patients and clinicians often have differing priorities when it comes to research 
(Chalmers et al., 2014), there has been increasing recognition of the importance 
of involving patients in setting research priorities and designing new studies. In a 
recent patient and public consultation about research priorities in bowel disease 
carried out by the ACPGBI, 71% of patients considered exploring, “the impact of 
treatment for bowel and anal cancers on quality of life” to be of ‘high 
importance’ as a research topic (McNair et al., 2017). In a study of the impact of 
post-operative complications on long-term quality of life after colorectal cancer 
surgery, AL was found to adversely impact on quality of life at 3 years with 
patients reporting significantly poorer outcomes for physical and social 
functioning, body image, mobility, self care and pain/discomfort (Brown et al., 
2014). It is therefore likely that research to pursue a biosensor to detect/treat 
AL will be looked on favourably by patients and those making funding decisions. 
A further driver for research in this area is the potential applicability of the 
technology outwith the context of AL. For example, a lactate or pH sensor 
incorporated into the tip of a drain could be used in patients with a therapeutic 
ascitic drain to give early warning of the development of SBP by identifying a 
rising lactate and falling pH. Similarly incorporation into a chest drain would 
give warning as to the development of infection within the pleural cavity. 
Placement in a central venous access catheter may also provide real-time 
information as to the response to resuscitation of patients with a severe acidosis 
secondary to sepsis.  
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Overall, whilst in this work it was not possible to determine the clinical 
usefulness of perianastomotic lactate and pH as markers of AL, the stability of 
lactate and pH in peritoneal fluid over time has been characterised, trends 
identified in the pH of peritoneal fluid of patients making an uncomplicated 
recovery have been highlighted and the limits of blood biomarkers of AL have 
been demonstrated. In addition, it has provided insight into how further studies 
in the area should be conducted and which questions need to be addressed next 
in order to pursue the eventual aim of developing a biosensor to detect AL early. 
It is to be hoped that earlier detection of AL would allow prompt management 
ultimately reducing the morbidity and mortality currently associated with AL.  
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9.2 Appendix 2: NHS GGC Research & Development permission for the 
study – ‘The effect of time on pH and lactate in ascitic fluid 
 
 
 
Page 1 of 2 Board Approval GN16SG091   
 
Administrator: Mrs Elaine O’Neill R&D Management Office 
Telephone Number: 0141 232 1815 West Glasgow ACH 
E-Mail: elaine.o’neill2@ggc.scot.nhs.uk   Dalnair Street 
Website: www.nhsggc.org.uk/r&d Glasgow G3 8SW 
 
  
      
19 May 2016 
 
Ms Susan Moug 
Consultant Colorectal and General Surgeon 
Royal Alexandra Hospital 
Corsebar Road 
Paisley PA2 9PN 
 
NHS GG&C Board Approval 
Dear Ms Moug, 
 
 
Study Title:  Effects of time on pH and lactate levels in ascitic fluid 
Principal Investigator:   Ms Susan Moug 
GG&C HB site Royal Alexandra Hospital 
Sponsor NHS Greater Glasgow and Clyde 
R&D reference: GN16SG091 
REC reference: 16/WA/0142 
Protocol no: 
 
V6 18/05/16 
 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to grant Approval for the above 
study.   
 
Conditions of Approval 
1. For Clinical Trials as defined by the Medicines for Human Use Clinical Trial Regulations, 2004 
a. During the life span of the study GGHB requires the following information relating to this site 
i. Notification of any potential serious breaches. 
ii. Notification of any regulatory inspections. 
 
It is your responsibility to ensure that all staff involved in the study at this site have the appropriate GCP training 
according to the GGHB GCP policy (www.nhsggc.org.uk/content/default.asp?page=s1411), evidence of such 
training to be filed in the site file. 
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Page 2 of 2 Board Approval GN16SG091   
 
 
 
 
2. For all studies the following information is required during their lifespan. 
a. Recruitment Numbers on a monthly basis 
b. Any change of staff named on the original SSI form 
c. Any amendments – Substantial or Non Substantial 
d. Notification of Trial/study end including final recruitment figures 
e. Final Report & Copies of Publications/Abstracts 
 
Please add this approval to your study file as this letter may be subject to audit and monitoring. 
Your personal information will be held on a secure national web-based NHS database. 
I wish you every success with this research study 
 
 
Yours sincerely, 
 
 
 
Mrs Elaine O’Neill 
Senior Research Administrator 
 
 
Cc: Ms Emma Wright 
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9.3 Appendix 3: Study protocol for the study – ‘The effects of time on pH 
and lactate levels in ascitic fluid 
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Title:	 	
	
Effects	of	time	on	pH	and	lactate	levels	in	ascitic	fluid		
	
	
Introduction	
	
	
Anastomotic	leak	(AL)	is	the	most	dreaded	complication	in	colorectal	surgery.	It	leads	
to	significant	morbidity,	mortality	and	is	associated	with	a	poorer	oncological	
outcome	[1].	Pre-,	intra-	and	post-operative	risk	factors	have	been	identified	but	as	
yet	there	is	no	reliable	test	to	accurately	detect	or	predict	AL.	Previous	work	has	
shown	that	measurement	of	clinical	observations	such	as	heart	rate,	blood	pressure	
and	temperature	have	poor	specificity	for	detecting	AL	[2].	Blood	parameters	such	as	
CRP	and	Procalcitonin	have	been	shown	to	be	useful	markers	of	risk	of	anastomotic	
leak	but	again	they	lack	specificity	[3].	In	cases	of	a	suspected	leak	radiological	
studies,	most	often	a	computed	tomographic	(CT)	scan,	are	performed	in	an	attempt	
to	confirm	the	diagnosis.	Again,	this	modality	is	imperfect.	It	relies	upon	the	
experience	and	skill	of	the	reporting	radiologist.	In	addition,	in	the	early	stages	a	leak	
from	an	anastomosis	maybe	too	subtle	to	be	picked	up	on	CT.	Reports	on	the	
sensitivity	and	specificity	of	CT	are	variable	but	there	is	a	consensus	of	opinion	that	
CT	alone	is	not	a	reliable	test	for	AL	[3,4].	
	
Given	the	current	limitations	in	the	detection	of	AL	there	has	been	an	attempt	to	
identify	new	strategies.	Much	of	this	work	has	focused	on	so-called	“biomarkers”	for	
AL.	Biomarkers	are	substances	that	can	be	measured	locally	at	the	anastomotic	site	
and	may	give	information	about	the	health	of	the	anastomosis	[5].	To	date,	markers	
of	inflammation	(cytokines),	wound	repair	(matrix	metalloproteinases,	MMPs),	
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ischaemia	(lactate,	pH)	and	detection	of	the	presence	of	intra-abdominal	bacteria	
have	been	studied	[6,7,8,9].	These	parameters	have	been	analysed	via	microdialysis		
	
	
catheters	placed	close	to	the	anastomosis	and	via	peritoneal	drain	fluid.	Elevated	
lactate,	cytokines	and	reduced	pH	have	emerged	as	factors	which	may	help	to	
predict/detect	anastomotic	leak	several	days	prior	to	the	onset	of	clinical	symptoms.		
	
	
These	biomarkers	reflect	conditions	in	the	milieu	of	the	anastomosis	and	are	
therefore	more	specific	than	traditionally	measured	blood	parameters	which	are	not	
specific	to	the	anastomosis.	
	
Of	these	biomarkers,	pH	and	lactate	appear	to	show	the	most	promise.	They	are	
easy	and	inexpensive	to	measure	and	results	can	be	available	rapidly.	Different	
methods	have	been	used	to	measure	lactate	and	pH	–	intra-abdominal	microdialysis,	
intra-luminal	tonometry	and	analysis	of	peritoneal	drain	fluid.	The	simplest	method	
is	analysis	of	drain	fluid.	However,	as	drains	are	typically	emptied	once	a	day	the	
fluid	collected	for	analysis	may	have	been	out	with	the	abdominal	cavity	sitting	in	
the	drainage	bag	for	several	minutes	to	hours	before	lactate	and	pH	levels	are	
measured.	In	2009	Calatayud	et	al	[10]	took	a	sample	of	whole	blood	for	lactate	
analysis	and	measured	lactate	levels	at	various	time	points	over	a	two-hour	period.	
They	found	that	lactate	levels	increased	over	time.	This	could	have	important	
implications	for	the	analysis	of	peritoneal	drain	fluid.		
	
Aim	
	
Part	A	-	To	determine	the	effect	of	time	on	pH	and	lactate	levels	in	ascitic	fluid.		
Part	B	–	To	assess	the	validity	of	a	handheld	lactate	sensor	against	a	laboratory	gold	
standard	assay.	
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Patient	risks/benefits	
	
As	the	analysis	will	be	carried	out	on	surplus	ascitic	fluid	that	would	otherwise	be	
disposed	of	there	is	no	risk/potential	for	harm	to	patients	who	agree	to	participate	in	
the	study.	The	benefit	would	be	the	knowledge	that	results	obtained	may	ultimately	
help	to	reduce	morbidity	and	mortality	for	patients	undergoing	colorectal	surgery	in	
the	future.	
	
	
Methods	
	
All	patients	(approximately	20-30)	attending	the	gastroenterology	department	at	the	
Royal	Alexandra	Hospital	(RAH)	over	an	8-week	period	for	elective	drainage	of	ascitic	
fluid	will	be	eligible.	Patients	know	to	have	blood	borne	viruses	(HIV,	hepatitis	B,	
hepatitis	C)	will	be	excluded.	The	clinical	team	looking	after	the	patient	(liver	nurse	
specialist	and	doctors	from	the	gastroenterology	department)	will	inform	the	
researcher	about	potential	patients	for	the	study.	The	researcher	will	then	screen	
their	medical	record.	If	the	patient	is	eligible	for	the	study	they	will	be	given	an	
information	sheet	about	the	study	when	they	attend	for	their	ascitic	drainage.	They	
will	have	the	opportunity	to	ask	the	researcher	(or	other	suitably	qualified	member	
of	the	research	team)	questions	about	the	study.	If	they	are	willing	to	participate	
they	will	sign	a	consent	form.		
	
	The	patients’	community	health	index	(CHI)	number	will	be	stored	securely	to	allow	
patient	demographics,	underlying	diagnosis	and	recent	tests	to	be	included	in	the	
analysis.		
	
Part	A	–	Effects	of	time	on	pH	and	lactate	in	ascitic	fluid	
At	the	time	of	insertion	of	an	ascitic	drain	a	20ml	sample	of	fluid	will	be	collected	
into	a	white	top	container	and	stored	at	room	temperature	in	a	designated	area	in	
the	high	dependency	unit	(HDU).	Lactate	and	pH	will	be	measured	at	time	zero,	30	
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minutes,	60	minutes,	120	minutes	and	24	hours	after	collection.	At	the	end	of	the	24	
hour	period	the	sample	will	be	discarded.	Lactate	measurements	will	be	made	on	a	
”Lactate	Pro	2”	handheld	analyser	(Arkray	Global	Business,	Kyoto,	Japan)	and	pH	
measurements	on	a	PHH-7011	pocket	tester	(Omega	products,	UK).	
	
Part	B	–	Validation	of	handheld	lactate	sensor	
10	–	15	of	the	fluid	samples	will	have	10mls	of	fluid	taken	off	and	placed	in	a	fluoride	
oxalate	tube.	The	sample	will	then	be	taken	to	the	Department	of	Biomedical	
Engineering	at	Strathclyde	University	within	6	hours	where	the	lactate	level	will	be	
analysed	using	a	laboratory	colorimetric	assay	(gold	standard)	on	a	clinical	chemistry	
analyser.		
	
Data	handling/management	
The	patients’	details/CHI	number	will	be	recorded.	This	information,	along	with	the	
consent	form,	will	be	kept	in	a	locked	drawer	in	a	locked	office	in	the	Royal	
Alexandra	Hospital.	Patients’	will	be	assigned	a	unique	study	number.	This	will	then	
be	used	on	a	database	to	store	the	study	information	and	results,	this	will	ensure	
that	the	results	are	anonymised.	The	database	will	be	held	on	a	hospital	computer	
and	encrypted	memory	stick.		
	
Data	analysis	
Frequencies	will	be	recorded	and	a	students	t	test	used	to	look	for	significant	
differences	between	samples,	i.e.	to	test	whether	samples	taken	at	different	time	
points	are	significantly	different	from	the	baseline	measurement	taken	at	time	zero.	
	
Dissemination	of	results	
The	results	will	form	part	of	the	MD	thesis	for	the	researcher.	It	is	also	to	be	hoped	
that	they	will	be	accepted	for	publication	in	peer-reviewed	scientific	journals	and	
also	presented	at	relevant	scientific/medical	conferences.		
	
Notifying	participants	of	results	
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A	section	on	the	patient	information	sheet	will	invite	participants	to	contact	the	
researcher	to	find	out	the	results	of	the	study.	It	will	outline	that	the	study	forms	
part	of	a	larger	piece	of	work	towards	a	research	degree	and	the	results	will	be	
available	from	August	2017.	Patients	will	be	asked	to	use	the	contact	details	on	the	
patient	information	sheet	to	contact	the	researcher	after	August	2017.	
	
	
Ethics	
The	study	will	be	submitted	to	an	NHS	Research	Ethics	Committee	for	review.		No	
study	activity	will	take	place	before	a	REC	favourable	opinion	is	obtained.	
	
Finance	
	
This	work	is	being	supported	by	grants	awarded	to	the	investigator	from	“The	Royal	
College	of	Physicians	and	Surgeons	of	Glasgow”	(Aileen	Lynn	Bequest	Fund)	and	“The	
Ileostomy	Association”.	
	
Indemnity	
	
The	principal	investigator	is	an	employee	of	NHS	Greater	Glasgow	and	Clyde	and	will	
therefore	be	covered	by	them	for	indemnity.	
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Version 4 
April 12th 2016 
 
 
The effects of time on pH and lactate levels in ascitic fluid (abdominal fluid) 
 
Information Sheet 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take time to 
read the following information carefully. Talk to others about the study if you wish. Ask us if there 
is anything that is not clear or if you would like more information. 
 
Who is conducting the research? 
The research is being carried out by Miss Emma Wright (surgical registrar) and Ms Susan Moug 
(Consultant Surgeon) from the Department of General Surgery. The research will contribute to 
the submission of a thesis for a higher degree (an MD) at the University of Glasgow by Miss 
Wright. This degree is being carried out over a 2 year period commencing November 2015. 
 
What is the purpose of the study? 
There is some research to suggest that measuring pH and lactate levels in abdominal fluid after 
bowel surgery may help to predict the development of a specific complication of bowel surgery - 
an anastomotic leak (a leak from a surgically created join between two cut ends of bowel). Leaks 
can be hard to predict and there is often a delay in diagnosing them. The incidence of 
anastomotic leaks is reported to vary from 5-20%. The consequences can be very serious for the 
patient. They become very unwell and often require further surgery possibly resulting in the need 
for a permanent stoma (colostomy or “bag”) and admission to intensive care. Occasionally 
patients can die as a consequence of becoming very unwell after a leak. 
Our overall aim is to develop a sensor or device that measures pH and lactate which can be 
placed inside the abdomen after bowel surgery. This would help us to detect anastomotic leaks 
more quickly and therefore reduce the complications experienced by the patient.  
As part of further investigations in this area we need to find out whether a delay in analysing a 
fluid sample would affect the results, i.e. if a sample of abdominal fluid is taken but there is a 
delay of minutes to hours in analysing it will the pH and lactate levels be affected and therefore 
give a false result? 
In this study we plan to obtain samples of abdominal fluid and measure the change in pH and 
lactate levels over time when the sample is stored at room temperature. This will ultimately help 
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us with the design of a sensor or device to detect anastomotic leaks early. 
 
Why have I been invited? 
You have been invited to take part in this study because you are here today to have excess 
abdominal fluid drained. Normally the majority of this fluid would be discarded. We hope to be 
able to take a small sample of this excess fluid to help with our study.  
 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information sheet, which 
we will then give to you. You will be asked to sign a consent form to show you have agreed to 
take part. You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive or your future treatment. 
 
What does taking part involve? 
You do not have to actively do anything to take part. From the excess fluid that you are having 
drained we would simply take a 20ml sample which would otherwise be being discarded. This will 
not involve any additional time or discomfort to you.  
The sample will be stored for 24 hours. During this time the lactate and pH levels will be checked 
a various time points – within 5 mins, at 30 mins, 60 mins, 2 hours and 24 hours after the sample 
was first taken. After this time the sample will be discarded. Approximately half of the samples 
taken will be transported to Strathclyde University for additional tests – these are to check the 
performance of the lactate sensor we use in the hospital against a “gold standard” lactate 
analyser kept at the university. Once this test has been performed the sample will be disposed of 
at the university. The university has special facilities in place to safely dispose of clinical/human 
waste.  
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher and the people overseeing the research, who may need to look at it to make sure the 
study is being conducted properly. We will assign each participant a number and anonymously 
record underlying medical problems and blood test results from your medical records so that we 
can compare the results from patients with different medical conditions. The information obtained 
will stored securely – identifiable information will be kept in the hospital in a secure office. The 
anonymised information with a unique participation number will be included in a database which 
will be stored on a hospital computer and an encrypted memory stick. This will ensure that when 
the data is being analysed it is anonymous and individual patients will not be able to be identified 
from the database. 
 
What are the possible benefits of taking part? 
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By taking part in this research you may help to improve outcomes for patients undergoing bowel 
surgery in the future. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by the ‘Wales REC 7’ Research Ethics Committee. 
 
If you have any further questions? 
We will give you a copy of the information sheet and signed consent form to keep. If you would 
like more information about the study and wish to speak to someone you can contact the 
following people: 
Miss Emma Wright (Researcher) 
Ward 26 Day Room 
Royal Alexandra Hospital 
Corsebar Road 
Paisley 
PA2 9PN 
Email: Emmawright8@nhs.net 
Phone: 0141 887 9111 
 
Ms Susan Moug (Consultant Colorectal & General Surgeon and Research Supervisor of 
Miss Wright) 
Ward 26 Day Room 
Royal Alexandra Hospital 
Corsebar Road 
Paisley 
PA2 9PN 
Email: Susanmoug@nhs.net 
Phone: 0141 887 9111 
 
Or alternatively if you would like to speak to someone not closely linked to the study, please 
contact: 
Mr Mark Vella (Consultant Colorectal & General Surgeon) 
Ward 26 Day Room 
Royal Alexandra Hospital 
Corsebar Road 
Paisley 
PA2 9PN 
Email: Mark.Vella@ggc.scot.nhs.uk 
Phone: 0141 887 9111 
 
Another useful source of information about research activity within the NHS is the ‘Patient Advice 
and Support Service’. This can be accessed via any Citizens Advice Bureau (CAB) in Scotland. 
Their contact details are as follows: 
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Website: www.patientadvicescotland.org.uk 
Phone: 0141 375 7328 (local CAB service for Renfrewshire) 
 
If you would like to know the results of the study? 
As previously outlined this study will form part of a larger research project which will be submitted as a 
thesis by the researcher to the University of Glasgow for a higher degree (an MD). It is anticipated that 
results will be available from August 2017. Should you wish to find out the results you are welcome to 
contact the researcher using the contact details provided above from August 2017 onwards.  
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact 
the researcher in the first instance but the normal NHS complaint mechanism is also available to 
you. 
 
Thank-you for your time  
 
 
Version 4 April 12th 2016 
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Version	5	April	20th	2016	
	
 
The effects of time on pH and lactate levels in 
ascitic fluid (abdominal fluid) 
 
 
 
I confirm that I have read and understand the information 
sheet dated 20/04/16 (version 5) for the above study and 
have had the opportunity to ask questions 
 
I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason, without my medical care or legal rights being 
affected.  
 
I understand that sections of my medical notes may be 
looked at by the research team and the regulatory 
authorities where it is relevant to my taking part in the 
research. I give my permission for these people to have 
access to my records. 
 
I agree to take part in the above study. 
 
-------------------------  ------------------  ----------------------------
Name of participant  Date    Signature 
 
-------------------------  ------------------  ----------------------------
Name of researcher  Date    Signature  
 
1 copy to patient, 1 copy to researcher, 1 copy to notes 
Please	initial	the	
boxes	
 	
 	
 	
 	
Consent form 
	 	
Department	of	General	Surgery,		
Royal	Alexandra	Hospital,	
Paisley	
A	 	 a 	
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9.7 Appendix 7: NHS GGC Research & Development approval for the study - 
‘Can serial measurement of pH and lactate in peritoneal drain fluid 
predict anastomotic leak after colorectal surgery?’ 
 
 
 
 
Page 1 of 2 R&D Management Approval Letter GN16GA471  
 
 
Senior Research Administrator: Kayleigh Pender 
Telephone Number: 0141 232 1826 
E-Mail: Kayleigh.pender@ggc.scot.nhs.uk  
website www.nhsggc.org.uk/r&d 
Clinical Research & Development 
West Glasgow ACH 
Dalnair Street 
Glasgow G3 8SJ 
Scotland, UK 
 
29/09/2016 
 
 
Ms Emma Wright 
NHS Greater Glasgow and Clyde 
Ward 26 Day Room 
Royal Alexandra Hospital 
Paisley 
PA2 9PN 
 
 
 
NHS GG&C Board Approval 
Dear Ms Wright, 
 
Study Title:  Can the serial measurement of pH and lactate in peritoneal drain fluid predict anastomotic 
leak after colorectal surgery?  
Principal Investigator:   Ms Emma Wright 
GG&C HB site Royal Alexandra Hospital 
Sponsor NHS Greater Glasgow & Clyde 
R&D reference: GN16GA471 
REC reference: 16/EM/0394 
Protocol no: 
(including version and 
date) 
V2.0 09.08.16 
 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to grant Approval for the above study. 
 
Conditions of Approval 
1. For Clinical Trials as defined by the Medicines for Human Use Clinical Trial Regulations, 2004 
a. During the life span of the study GGHB requires the following information relating to this site 
i. Notification of any potential serious breaches. 
ii. Notification of any regulatory inspections. 
 
It is your responsibility to ensure that all staff involved in the study at this site have the appropriate GCP training according 
to the GGHB GCP policy (www.nhsggc.org.uk/content/default.asp?page=s1411), evidence of such training to be filed in the 
site file. 
 
2. For all studies the following information is required during their lifespan. 
a. Recruitment Numbers on a quarterly basis 
b. Any change of staff named on the original SSI form 
c. Any amendments – Substantial or Non Substantial 
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Page 2 of 2 R&D Management Approval Letter GN16GA471  
 
 
d. Notification of Trial/study end including final recruitment figures 
e. Final Report & Copies of Publications/Abstracts 
 
Please add this approval to your study file as this letter may be subject to audit and monitoring. 
Your personal information will be held on a secure national web-based NHS database. 
I wish you every success with this research study 
 
 
Yours sincerely, 
 
 
 
Kayleigh Pender 
Senior Research Administrator 
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lactate in peritoneal drain fluid predict anastomotic leak after colorectal 
surgery?’ 
 
 
 
Version	2						
August	9th	2016	
	
	
Title:	 	
	
Can	the	serial	measurement	of	pH	and	lactate	in	
peritoneal	drain	fluid	predict	anastomotic	leak	after	
colorectal	surgery?		
	
	
Introduction	
	
	
Anastomotic	leak	(AL)	is	the	most	dreaded	complication	in	colorectal	surgery.	It	leads	
to	significant	morbidity,	mortality	and	is	associated	with	a	poorer	oncological	
outcome	((1).	Pre-,	intra-	and	post-operative	risk	factors	have	been	identified	but	as	
yet	there	is	no	reliable	test	to	accurately	detect	or	predict	AL.	Previous	work	has	
shown	that	measurement	of	clinical	observations	such	as	heart	rate,	blood	pressure	
and	temperature	have	poor	specificity	for	detecting	AL	Erb,	Hyman	(2).	Blood	
parameters	such	as	CRP	and	Procalcitonin	have	been	shown	to	be	useful	markers	of	
risk	of	anastomotic	leak	but	again	they	lack	specificity	McDermott,	Heeney	(3).	In	
cases	of	a	suspected	leak	radiological	studies,	most	often	a	computed	tomographic	
(CT)	scan,	are	performed	in	an	attempt	to	confirm	the	diagnosis.	Again,	this	modality	
is	imperfect.	It	relies	upon	the	experience	and	skill	of	the	reporting	radiologist.	In	
addition,	in	the	early	stages	a	leak	from	an	anastomosis	maybe	too	subtle	to	be	
picked	up	on	CT.	Reports	on	the	sensitivity	and	specificity	of	CT	are	variable	but	
there	is	a	consensus	of	opinion	that	CT	alone	is	not	a	reliable	test	for	AL	McDermott,	
Heeney	(3)	Hirst,	Tiernan	(4).	
	
Given	the	current	limitations	in	the	detection	of	AL	there	has	been	an	attempt	to	
identify	new	strategies.	Much	of	this	work	has	focused	on	so-called	“biomarkers”	for	
AL.	Biomarkers	are	substances	that	can	be	measured	locally	at	the	anastomotic	site	
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and	may	give	information	about	the	health	of	the	anastomosis	Komen,	de	Bruin	(5).	
To	 date,	 markers	 of	 inflammation	 (cytokines),	 wound	 repair	 (matrix	
metalloproteinases,	MMPs),	ischaemia	(lactate,	pH)	and	detection	of	the	presence	of	
intra-abdominal	bacteria	have	been	studied	Cini,	Wolthuis	(6),	Matthiessen,	Strand	
(7),	Millan,	Garcia-Granero	(8),	Komen,	Slieker	(9).	Elevated	lactate,	cytokines	and	
reduced	pH	have	emerged	as	factors	which	may	help	to	predict/detect	anastomotic	
leak	several	days	prior	to	the	onset	of	clinical	symptoms.		
	
These	biomarkers	reflect	conditions	in	the	milieu	of	the	anastomosis	and	are	
therefore	more	specific	than	traditionally	measured	blood	parameters	which	are	not	
specific	to	the	anastomosis.	
	
Of	these	biomarkers,	pH	and	lactate	appear	to	show	the	most	promise.	In	most	of	
the	existing	research	lactate	has	been	measured	via	microdialysis	(Matthiessen,	
Strand	(7),	Horer,	Norgren	(10),	Daams,	Wu	(11),	Pedersen,	Qvist	(12)).	This	involves	
inserting	very	small	probes	with	dialysis	membranes	into	the	operative	field	at	the	
end	of	a	procedure.	Fluid	then	flows	through	the	circuit	constantly	allowing	
measurement	of	various	analytes	including	lactate.	It	is	expensive,	technically	
challenging	and	technical	failures	are	common	(Daams,	Wu	(11)).	One	study	has	
looked	at	measurement	of	lactate	from	peritoneal	drains	(Bini,	Ferrari	(13)).	They	
studied	lactate	in	relation	to	“major	complications	requiring	reintervention”	which	
included	anastomotic	leaks.	They	found	that	raised	lactate	levels	were	predictive	of	
complications	including	AL.	Of	the	two	studies	looking	at	pH	(Millan,	Garcia-Granero	
(8),	Yang,	Huang	(14))	only	one	used	peritoneal	drain	fluid	(Yang,	Huang	(14)).	They	
found	that	a	low	pH	on	post-operative	day	3	was	predictive	of	AL	which	occurred	
several	days	later.	In	the	other	study	a	catheter	was	sited	intraluminally	just	
proximal	to	the	anastomosis	and	pH	measured	via	tonometry	(Millan,	Garcia-
Granero	(8)).	Measurement	of	lactate	and	pH	via	peritoneal	drain	fluid	analysis	is	
quick,	easy	and	inexpensive,	it	is	therefore	an	attractive	alternative	to	microdialysis	
and	intraluminal	tonometry.	
	
 213 
 
 
 
Version	2						
August	9th	2016	
This	study	will	measure	peritoneal	drain	fluid	pH	and	lactate	levels	following	
colorectal	surgery.	We	aim	to	determine	if	the	finding	of	Yang	et	al	regarding	the	
ability	of	day	3	pH	to	predict	anastomotic	leak	can	be	replicated	and	we	will	be	the	
first	group	to	look	at	specifically	at	peritoneal	drain	fluid	lactate	in	relation	to	
prediction	of	anastomotic	leak.		
	
Aim	
	
Part	A	-	To	determine	if	measurement	of	peritoneal	drain	fluid	pH	can	predict	
colorectal	anastomotic	leak		
Part	B	–	To	determine	if	measurement	of	peritoneal	drain	fluid	lactate	can	predict	
colorectal	anastomotic	leak	
	
Patient	risks/benefits	
	
As	the	analysis	will	be	carried	out	on	surplus	ascitic	fluid	that	would	otherwise	be	
disposed	of	there	is	no	risk/potential	for	harm	to	patients	who	agree	to	participate	in	
the	study.	The	benefit	would	be	the	knowledge	that	results	obtained	may	ultimately	
help	to	reduce	morbidity	and	mortality	for	patients	undergoing	colorectal	surgery	in	
the	future.	
	
	
Methods	
	
All	patients	attending	the	Royal	Alexandra	Hospital	(RAH)	over	a	9-month	period	for	
elective	colorectal	resection	will	be	eligible.	The	placement	of	a	peritoneal	drain	and	
the	timing	of	its	removal	following	elective	colorectal	surgery	is	at	the	discretion	of	
the	operating	surgeon,	typically	they	are	removed	around	post-operative	day	5.	
	
There	are	approximately	3-4	colorectal	resections	per	week	in	the	department	but	it	
is	anticipated	that	not	all	will	meet	inclusion	criteria/give	consent	to	participate.	The	
aim	would	be	to	have	80	patients	in	the	study	with	samples	taken	daily	for	3-5	days	
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following	surgery.	Little	work	has	been	done	in	this	area	so	a	power	calculation	is	
difficult.	
	
Inclusion	criteria:	
· Age	18-100	
· Attending	for	elective	colorectal	surgery	
· Placement	of	a	peritoneal	drain	during	surgery	
Exclusion	criteria:	
· Known	to	have	blood	bourne	virus(HIV,	hepatitis	B,	hepatitis	C).		
	
The	patients’	community	health	index	(CHI)	number	will	be	stored	securely	to	allow	
patient	demographics,	underlying	diagnosis	and	recent	tests	to	be	included	in	the	
analysis.	The	following	information	will	be	obtained:	age,	sex,	ASA	grade,	smoking	
status,	alcohol	intake,	body	mass	index	(BMI),	neoadjuvant	chemotherapy	status,	
mechanical	bowel	preparation	received,	type	of	operation,	duration	of	operation,	
blood	loss,	requirement	for	blood	transfusion,	the	anastomosis	technique	used,	
presence/absence	of	covering	stoma	and	placement	of	peritoneal	drain.	The	results	
of	the	patients	routine	daily	blood	tests	taken	during	their	admission	including:	
albumin,	white-cell	count	(WCC),	C-reactive	protein	(CRP)	and	procalcitonin	will	be	
recorded.	The	patients’	notes	will	be	reviewed	to	determine	the	post-operative	
course	–	presence/absence	of	anastomotic	leak	or	other	complication	during	their	
admission.	The	case	notes	will	be	looked	at	again	30	days	following	discharge	to	
determine	if	pre-admission	for	any	complication	including	the	late	detection	of	AL	
has	occurred.	
	
Each	morning	a	fresh	(within	2	hours	of	emptying	the	drain)	sample	of	fluid	(10-
20mls)	from	the	peritoneal	drain	will	be	tested	for	lactate	and	pH	levels.	Lactate	
measurements	will	be	made	on	a	”Lactate	Pro	2”	handheld	analyser	(Arkray	Global	
Business,	Kyoto,	Japan)	and	pH	measurements	on	a	PHH-7011	pocket	tester	(Omega	
products,	UK).	This	will	be	done	daily	until	the	drain	is	removed	or	the	patient	is	
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discharged.	After	measurement	of	lactate	and	pH	levels	the	fluid	will	then	be	
discarded	via	the	standard	hospital	clinical	waste	stream.	
	
	In	order	to	validate	the	use	of	the	lactate	and	pH	sensors	10-15	of	the	samples	will	
have	10mls	of	fluid	taken	and	placed	in	a	universal	container	and	transferred	to	the	
Department	of	Biomedical	Engineering	at	Strathclyde	University	within	6	hours.	At	
the	university,	lactate	levels	will	be	measured	using	a	laboratory	colorimetric	assay	
(gold	standard)	and	pH	also	measured	using	gold	standard	laboratory	protocol.	After	
testing	the	samples	will	be	disposed	of	immediately	via	the	universities	clinical	waste	
service.	
	
Data	handling/management	
The	patients’	details/CHI	number	will	be	recorded.	This	information,	along	with	the	
consent	form,	will	be	kept	in	a	locked	drawer	in	a	locked	office	in	the	Royal	
Alexandra	Hospital.	Patients’	will	be	assigned	a	unique	study	number.	This	will	then	
be	used	on	a	database	to	store	the	study	information	and	results,	this	will	ensure	
that	the	results	are	anonymised.	The	database	will	be	held	on	a	hospital	computer	
and	encrypted	memory	stick.		
	
Data	analysis	
The	Mann-Whitney	test	will	be	used	to	look	for	significant	differences	between	the	
samples	for	patients	with	AL	versus	those	without	AL.	For	lactate	and	pH	the	area	
under	the	curve	(AUC)	will	be	calculated	for	each	post-operative	day	to	assess	
whether	lactate	and	pH	can	predict	AL.		
	
Dissemination	of	results	
The	results	will	form	part	of	the	MD	thesis	for	the	researcher.	It	is	also	to	be	hoped	
that	they	will	be	accepted	for	publication	in	peer-reviewed	scientific	journals	and	
also	presented	at	relevant	scientific/medical	conferences.		
	
Notifying	participants	of	results	
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A	section	on	the	patient	information	sheet	will	invite	participants	to	contact	the	
researcher	to	find	out	the	results	of	the	study.	It	will	outline	that	the	study	forms	
part	of	a	larger	piece	of	work	towards	a	research	degree	and	the	results	will	be	
available	from	November	2017.	Patients	will	be	asked	to	use	the	contact	details	on	
the	patient	information	sheet	to	contact	the	researcher	after	November	2017.	
	
	
Ethics	
	
The	study	will	be	submitted	to	an	NHS	Research	Ethics	Committee	for	review.		No	
study	activity	will	take	place	before	a	REC	favourable	opinion	is	obtained.	
	
	
Finance	
	
This	work	is	being	supported	by	grants	awarded	to	the	investigator	from	“The	Royal	
College	of	Physicians	and	Surgeons	of	Glasgow”	(Aileen	Lynn	Bequest	Fund)	and	“The	
Ileostomy	Association”.	
	
Indemnity	
	
The	principal	investigator	is	an	employee	of	NHS	Greater	Glasgow	and	Clyde	and	will	
therefore	be	covered	by	them	for	indemnity.	
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Can	 the	 serial	 measurement	 of	 pH	 and	 lactate	 in	
peritoneal	drain	 fluid	predict	anastomotic	 leak	after	
colorectal	surgery?		
 
Information	Sheet	
We	would	like	to	invite	you	to	take	part	in	a	research	study.	Before	you	
decide	you	need	to	understand	why	the	research	is	being	done	and	what	it	
would	involve	for	you.	Please	take	time	to	read	the	following	information	
carefully.	Talk	to	others	about	the	study	if	you	wish.	Ask	us	if	there	is	
anything	that	is	not	clear	or	if	you	would	like	more	information.	
	
Who	is	conducting	the	research?	
The	research	is	being	carried	out	by	Miss	Emma	Wright	(Surgical	Registrar)	
and	Ms	Susan	Moug	(Consultant	Surgeon)	from	the	Department	of	General	
Surgery.	The	research	will	contribute	to	the	submission	of	a	thesis	for	a	
higher	degree	(an	MD)	at	the	University	of	Glasgow	by	Miss	Wright.	This	
degree	is	being	carried	out	over	a	2	year	period	commencing	November	
2015.	
	
What	is	the	purpose	of	the	study?	
There	is	some	research	to	suggest	that	measuring	pH	and	lactate	levels	in	
abdominal	fluid	after	bowel	surgery	may	help	to	predict	the	development	
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of	a	specific	complication	of	bowel	surgery	-	an	anastomotic	leak	(a	leak	
from	a	surgically	created	join	between	two	cut	ends	of	bowel).	Leaks	can	be	
hard	to	predict	and	there	is	often	a	delay	in	diagnosing	them.	The	incidence	
of	anastomotic	leaks	is	reported	to	vary	from	5-20%.	The	consequences	can	
be	very	serious	for	the	patient.	They	can	become	very	unwell	and	often	
require	further	surgery	possibly	resulting	in	the	need	for	a	permanent	
stoma	(colostomy	or	“bag”)	and	admission	to	intensive	care.	Occasionally	
patients	can	die	as	a	consequence	of	becoming	very	unwell	after	a	leak.	
Following	colorectal	surgery	the	surgeon	often	(but	not	always)	leaves	a	
drain	in	the	abdomen.	This	helps	them	to	monitor	the	patients	progress	
after	the	operation	and	may	help	to	detect	complications.	In	previous	
studies	researchers	have	measured	various	substances	from	fluid	in	the	
drain	to	see	if	they	can	help	to	detect	an	anastomotic	leak	at	an	early	stage.	
Lactate	and	pH	have	emerged	as	the	most	promising	candidates.	
Our	overall	aim	is	to	develop	a	sensor	or	device	which	can	be	placed	inside	
the	abdomen	after	bowel	surgery	which	will	monitor	the	environment	
around	the	anastomosis	and	provide	an	early	warning	of	any	adverse	
changes	which	may	 indicate	a	 leak.		This	would	help	us	to	detect	
anastomotic	leaks	more	quickly	and	therefore	reduce	the	complications	
experienced	by	the	patient.		
In	trying	to	develop	a	sensor	we	have	to	decide	which	substances	it	should	
measure.	In	view	of	previous	research	in	this	area	we	think	lactate	and	pH	
might	be	the	best	substances	to	measure.	However,	the	studies	that	have	
previously	been	done	are	small.	In	order	to	help	us	to	decide	how	to	
develop	our	sensor	we	need	to	carry	out	a	further	study	to	attempt	to	
confirm	or	refute	the	previous	finding	that	lactate	and	pH	are	helpful	in	
detecting	anastomotic	leaks.	
In	this	study	we	plan	to	measure	the	lactate	and	pH	levels	of	fluid	in	the	
abdominal	drain	each	day	following	colorectal	surgery.	The	placement	of	a	
drain	is	at	the	discretion	of	the	operating	surgeon	at	the	time	of	surgery.	
Those	who	have	a	drain	placed	will	have	the	lactate	and	pH	level	of	the	
drain	fluid	measured	each	day	until	the	drain	is	removed,	the	timing	of	
removal	of	the	drain	will	be	decided	by	the	operating	surgeon.		
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Why	have	I	been	invited?	
You	have	been	invited	to	take	part	in	this	study	because	you	are	having	
colorectal	surgery	that	will	involve	the	creation	of	an	anastomosis	and	as	
part	of	the	procedure	your	surgeon	may	choose	to	leave	an	abdominal	
drain	in	place	at	the	end	of	your	operation.	If	you	consent	to	participate	but	
your	surgeon	decides	not	to	place	a	peritoneal	drain	then	you	will	not	enter	
the	study.	
Do	I	have	to	take	part?	
It	is	up	to	you	to	decide.	We	will	describe	the	study	and	go	through	this	
information	sheet,	which	we	will	then	give	to	you.	You	will	be	asked	to	sign	
a	consent	form	to	show	you	have	agreed	to	take	part.	You	are	free	to	
withdraw	at	any	time,	without	giving	a	reason.	This	would	not	affect	the	
standard	of	care	you	receive	or	your	future	treatment.	
	
What	does	taking	part	involve?	
You	do	not	have	to	actively	do	anything	to	take	part.	When	a	drain	is	left	in	
your	abdomen	the	fluid	collected	in	it	is	measured	each	day	and	then	
discarded.	Prior	to	it	being	discarded	we	would	measure	the	lactate	and	pH	
levels	and	then	it	would	be	disposed	of	via	the	normal	procedure	on	the	
ward.	Having	the	lactate	and	pH	levels	tested	will	not	involve	any	additional	
time	or	discomfort	to	you.	Approximately	10-15	of	the	samples	taken	in	the	
study	will	be	transported	to	Strathclyde	University	for	additional	tests	–	
these	are	to	check	the	performance	of	the	lactate	and	pH	sensors	we	use	in	
the	hospital	against	a	“gold	standard”	analysers	kept	at	the	university.	Once	
this	test	has	been	performed	the	samples	will	be	disposed	of	at	the	
university.	The	university	has	special	facilities	in	place	to	safely	dispose	of	
clinical/human	waste.	
	
What	happens	to	the	information?	
Your	identity	and	personal	information	will	be	completely	confidential	and	
known	only	to	the	researcher	and	the	people	overseeing	the	research,	who	
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may	need	to	look	at	it	to	make	sure	the	study	is	being	conducted	properly.	
We	will	assign	each	participant	a	number	and	anonymously	record	the	
lactate	and	pH	levels	of	the	drain	fluid	each	day	along	with	the	following	
information:	age,	sex,	ASA	grade	(fitness	grading	used	by	anesthetists),	
smoking	 status,	 alcohol	 intake,	body	mass	 index	 (BMI),	 neoadjuvant	
chemotherapy	status,	mechanical	bowel	preparation	received,	type	of	
operation,	 duration	 of	 operation,	 blood	 loss,	 requirement	 for	 blood	
transfusion,	 the	 anastomosis	 technique	 used,	 presence/absence	 of	
covering	stoma	and	placement	of	peritoneal	drain	and	the	results	of	
routine	post-operative	daily	blood	tests.	Your	medical	record	will	be	
checked	again	at	30	days	after	discharge	to	see	if	you	have	subsequently	
been	re-admitted	with	a	complication	such	as	an	anastomotic	leak.	The	
information	obtained	will	stored	securely	–	identifiable	information	will	be	
kept	in	the	hospital	in	a	secure	office.	The	anonymised	information	with	a	
unique	participation	number	will	be	included	in	a	database	which	will	be	
stored	on	a	hospital	computer	and	an	encrypted	memory	stick.	This	will	
ensure	that	when	the	data	is	being	analysed	it	is	anonymous	and	individual	
patients	will	not	be	able	to	be	identified	from	the	database.	
	
What	are	the	possible	benefits	of	taking	part?	
By	taking	part	in	this	research	you	may	help	to	improve	outcomes	for	
patients	undergoing	bowel	surgery	in	the	future.	
	
Who	has	reviewed	the	study?	
All	research	in	the	NHS	is	looked	at	by	an	independent	group	of	people,	
called	a	Research	Ethics	Committee,	to	protect	your	interests.	This	study	
has	been	reviewed	and	given	favourable	opinion	by	the	BLANK	Research	
Ethics	Committee.	
	
If	you	have	any	further	questions?	
We	will	give	you	a	copy	of	the	information	sheet	and	signed	consent	form	
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to	keep.	If	you	would	like	more	information	about	the	study	and	wish	to	
speak	to	someone	you	can	contact	the	following	people:	
Miss	Emma	Wright	(Researcher)	
Ward	26	Day	Room	
Royal	Alexandra	Hospital	
Corsebar	Road	
Paisley	
PA2	9PN	
Email:	Emmawright8@nhs.net	
Phone:	0141	887	9111	
	
Ms	Susan	Moug	(Consultant	Colorectal	&	General	Surgeon	and	Research	
Supervisor	of	Miss	Wright)	
Ward	26	Day	Room	
Royal	Alexandra	Hospital	
Corsebar	Road	
Paisley	
PA2	9PN	
Email:	Susanmoug@nhs.net	
Phone:	0141	887	9111	
	
Or	alternatively	if	you	would	like	to	speak	to	someone	not	closely	linked	to	
the	study,	please	contact:	
Mr	Mark	Vella	(Consultant	Colorectal	&	General	Surgeon)	
Ward	26	Day	Room	
Royal	Alexandra	Hospital	
Corsebar	Road	
Paisley	
PA2	9PN	
Email:	Mark.Vella@ggc.scot.nhs.uk	
Phone:	0141	887	9111	
	
Another	useful	source	of	information	about	research	activity	within	the	
NHS	is	the	‘Patient	Advice	and	Support	Service’.	This	can	be	accessed	via	
any	Citizens	Advice	Bureau	(CAB)	in	Scotland.	Their	contact	details	are	as	
 223 
 
 
  
Version	3	
August	22nd	2016	
follows:	
Website:	www.patientadvicescotland.org.uk	
Phone:	0141	375	7328	(local	CAB	service	for	Renfrewshire)	
	
If	you	would	like	to	know	the	results	of	the	study?	
As	previously	outlined	this	study	will	form	part	of	a	larger	research	project	
which	will	be	submitted	as	a	thesis	by	the	researcher	to	the	University	of	
Glasgow	for	a	higher	degree	(an	MD).	It	is	anticipated	that	results	will	be	
available	from	November	2017.	Should	you	wish	to	find	out	the	results	you	
are	welcome	to	contact	the	researcher	using	the	contact	details	provided	
above	from	November	2017	onwards.		
	
If	you	have	a	complaint	about	any	aspect	of	the	study?	
If	you	are	unhappy	about	any	aspect	of	the	study	and	wish	to	make	a	
complaint,	please	contact	the	researcher	in	the	first	instance	but	the	
normal	NHS	complaint	mechanism	is	also	available	to	you.	
	
Thank-you	for	your	time		
	
	
Version	3	August	22nd	2016	
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	Can	the	serial	measurement	of	pH	and	lactate	in	
peritoneal	drain	fluid	predict	anastomotic	leak	after	
colorectal	surgery?		
 
 
 
 
I confirm that I have read and understand the information 
sheet dated 05/09/16 (version 4) for the above study and 
have had the opportunity to ask questions 
 
I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason, without my medical care or legal rights being 
affected.  
 
I understand that sections of my medical notes may be 
looked at by the research team and the regulatory 
authorities where it is relevant to my taking part in the 
research. I give my permission for these people to have 
access to my records. 
 
I agree to take part in the above study. 
 
-------------------------  ------------------  ----------------------------
Name of participant  Date    Signature 
 
-------------------------  ------------------  ----------------------------
Name of researcher  Date    Signature  
Please	initial	the	
boxes	
 	
 	
 	
 	
Consent form 
	 	
Department	of	General	Surgery,		
Royal	Alexandra	Hospital,	
Paisley	
A	 	 a 	
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Lactate	assay	for	Peritoneal	Fluid	Samples	
Revision	 Author	 Description	 Date	
1.0	 Joshua	Paulinus	
(Strathclyde)	
Original	document		 28/10/16	
1.1	 Emma	Wright	
(Strathclyde)	
Amended	version	 07/02/17	
	
1.	Introduction	
This	procedure	details	the	method	for	determining	lactate	concentration	(up	to	20mM)	in	
fluid	samples	using	the	Randox	Lactate	assay	(LC2389)	in	a	96	well	plate.	
2.	Equipment	
1000µL	pipette	and	tips	
2.5µL	pipette	and	tips	
Computer	controlled	Labsystems	Multiskan	Ascent	
Eppendorff	tubes	
50ml	plastic	tube	
	
3.	Materials	
Randox	Lactate	Assay	Kit	(LC2389)	
Sodium	L-Lactate	
Deionised	water	
Samples	(peritoneal	fluid)	
PPE	consisting	of:	blue	nitrile	gloves,	face	shield,	lab	coat	
	
4.	Methodology	
4.1	Creating	calibration	solutions	
a)		 Add	0.1221g	of	Sodium	Lactate	to	50mL	of	water	in	a	50mL	plastic	container	to	
create	a	20mM	solution.	
b)		 Serially	dilute	the	20mM	of	sodium	lactate	to	make	10mM,	5mM,	2.5mM	and	
1.25mM	concentrations	in	separate	Eppendorf	tubes	using	1000µL	pipette.	(Table	below	to	
help)	
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Lactate	 solution	
concentration	
	
20mM	:	 Add	2mL	of	20mM	to	Eppendorf	tube	made	from	previous	
step		
10mM	:	 1mL	20mM	lactate	solution	+	1mL	dH2O	
5mM	:	 1mL	10mM	lactate	solution	+	1mL	dH2O	
2.5mM	:	 1mL	5mM	lactate	solution	+	1mL	dH2O	
1.25mM	:	 1mL	2.5mM	lactate	solution	+	1mL	dH2O	
	
4.2	Equipment	and	Materials	Preparation	
a)	 Prior	to	setting	up	plate,	make	up	the	enzyme	reagent	found	in	the	Randox	lactate	
assay	kit	by	adding	6mL	of	the	buffer	found	in	the	kit.	For	this	method,	each	bottle	is	enough	
for	24	samples	so	make	up	enough	for	your	purpose	(enzyme	is	stable	for	approximately	2	
weeks	in	the	fridge	once	buffer	is	added).	Additionally,	switch	on	the	Multiskan	plate	reader	
and	set	up	the	experiment	on	the	Skanit	software	found	on	the	connected	PC.	Use	the	
following	settings:	
-	Incubation	temperature	at	37°C		
-	Add	shaking	at	low	speed	for	5	mins	
-	Add	single	absorbance	measurement	at	550nm	(ensure	shaking	happens	before	this	step)	
Remember	to	add	save	results	to	an	Excel	file.	
	
4.3	96	Well	Plate	set	up		
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Key:	B=Blank	Sample,	S=Sample	Repeat	(e.g.	S1=Sample	1	repeat),	Purple	wells=	calibration	
solutions		
a)	 For	each	well,	add	2.5µL	of	calibration	solution	first	into	the	96	well	plate	as	shown	
above	using	a	pipette.	For	the	blank	wells,	add	2.5µL	deionised	water.	More	repeats	can	be	
added	as	required.	Should	you	wish	to	check	the	accuracy	of	the	calibration	curve,	you	may	
add	the	standard	solution	found	in	the	lactate	assay	kit	for	comparison.	The	concentration	
of	the	standard	will	be	found	in	the	box	of	the	kit.	
b)	 The	sample	of	peritoneal	fluid	will	be	kept	in	a	demarcated	“biohazard”	area	of	the	
lab.	The	96	well	plate	should	be	brought	to	this	area	for	the	samples	of	peritoneal	fluid	to	be	
added.		
c)	 Once	done,	check	the	Multiskan	Plate	reader	is	at	37°C	and	then	add	250µL	of	the	
enzyme	reagent	into	all	wells	containing	a	sample/calibration	solution	using	a	pipette.	Do	
this	part	quickly	so	all	samples	react	at	approximately	the	same	time.	It	might	be	advisable	
to	use	a	multi-pipette	instead.		
d)	 Place	a	cover	over	the	96	well	plate	and	transfer	it	to	the	Multiskan	and	run	the	
method	programed	earlier.		
e)	 When	the	programme	is	complete	the	96	well	plate	reader	will	be	removed	from	the	
Multiskan	and	taken	back	to	the	demarcated	“biohazard”	area	of	the	lab.	The	plate,	and	its	
contents,	should	be	placed	in	Virkon	solution.	Thereafter	samples	and	materials	should	be	
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disposed	of	as	per	the	protocol	outlined	in	the	COOSH	form	for	the	handling	of	peritoneal	
fluid.	
5.	Analysis	
Below	is	a	sample	calibration	curve	example	(Table	below).	(0	is	the	blank	reference)	
Firstly,	we	will	take	an	average	(mean)	of	the	absorbance	values	for	each	concentration	
(Column	Mean	(Y)).	Standard	deviation	was	also	calculated	to	check	how	the	range	of	data	
points	for	each	reference	(Column	Standard	Deviation	(Y)).	We	then	subtract	the	blank	
reference	to	get	the	correct	absorbance	value	(seen	in	figure	below	in	column	F(Y)).	
	
	
Column	A(X)	and	then	column	F(Y)	are	then	plotted	to	get	the	calibration	curve	shown	
below.	
0 10 20
0
1
2
A
b
s
o
rb
a
n
c
e
Lactate Concentration (mM)
Equation y = a + b*x
Weight No Weighting
Residual Sum of 
Squares
0.00798
Pearson's r 0.99936
Adj. R-Square 0.99846
Value Standard Error
Absorbance
Intercept 0 --
Slope 0.1079 0.00173
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Excel	and	origin	(in	this	case)	can	be	used	to	get	a	linear	fit	curve	for	which	an	equation	can	
be	developed.	In	this	case,	the	y-intercept	was	set	at	0	so	the	equation	of	the	line	is	
y=0.1079x.	This	relationship	can	be	used	to	find	the	concentrations	of	lactate	in	samples.	
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9.12 Appendix 12: Laboratory protocol for measuring pH 
 
 
 
 
1	
	
pH	testing	of	peritoneal	drain	fluid	samples	-	Protocol	
Revision	 Author	 Description	 Date	
1.0	 Joshua	 Paulinus	
(Strathclyde)	
Original	document		 17/11/16	
1.1	 Emma	Wright	 Revised	&	amended	 13/04/17	
	
1.	Introduction	
This	 procedure	 details	 the	 method	 for	 attaining	 pH	 measurements	 of	 peritoneal	 drain	 fluid	
samples	 using	 either	 Mettler	 Toledo	 InLab®	 Expert	 Pro-ISM	 or	 InLab®	 Micro	 with	 Mettler	
Toledo	 SevenCompact	 pH	 reader.	 It	 is	 advisable	 to	 use	 InLab®	 Expert	 Pro-ISM	 as	 it	 has	
temperature	compensation.		
2.	Equipment	
Description	 Qty	
pH	 probe	 (Either	 InLab®	 Expert	 Pro-ISM	 or	
InLab®	Micro)	
1	
pH	probe	reader	(SevenCompact	pH	reader)	 1	
Glass	beakers	 	
Squeeze	bottle	containing	deionised	water		 	
	
3.	Materials	
Description	 Supplier	 Qty	
Ethanol	 (required	 for	
biological	testing)	
Sigma	32221	 	
Deionised	Water	 	 	
pH4	buffer	solution	tablets	 Fisher	Scientific	B/4765/77	 	
pH7	buffer	solution	tablets	 Fisher	Scientific	B/4760/77	 	
pH10	buffer	solution	 Acros	Organics	258600010	 	
Virkon	(For	biological	testing)	 	 	
	
4.	Methodology	
4.1	Preparation	
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2	
	
4.1.1	Creating	buffer	solutions	
pH4	buffer	solution:	Add	one	pH4	buffer	solution	tablet	to	100mL	of	dH2O	
pH7	buffer	solution:	Add	one	pH7	buffer	solution	tablet	to	100mL	of	dH2O	
4.2	Calibration	of	pH	probe	
Prior	 to	 experimentation,	 the	 pH	 probe	 requires	 calibration.	 Pour	 calibration	 solutions	 into	
separate	 glass	 beakers	 (enough	 to	 cover	 glass	 bulb)	 and	 enter	 calibration	 mode	 and	 calibrate	
according	the	manufacturer	instructions.	It	is	advisable	to	check	calibration	occasionally	during	
experiments	to	check	the	probe	is	still	reading	correctly.	Rinse	probe	with	deionised	water	(use	
squeeze	bottle	over	a	beaker)	prior	to	testing	a	different	solution.		
4.3	Preparation	of	the	sample	of	peritoneal	drain	fluid	
The	 sample	 will	 be	 handled	 as	 per	 the	 instructions	 in	 the	 COSHH	 form	 (Working with human 
peritoneal fluid (hazard group 2))	within	the	designated	 ‘biohazard	area’’	of	lab	4.09.	It	will	be	
removed	from	the	outer	transport	packaging	and	kept	in	the	universal	white	top	container	that	
it	was	collected	in.	
4.4	Testing	the	peritoneal	drain	fluid	sample		
Prior	to	testing	a	sample	rinse	the	probe	with	dH2O	(use	squeeze	bottle	over	a	beaker)	and	then	
dip	it	in	ethanol	before	thoroughly	rinsing	in	dH2O	.To	test	a	sample,	simply	place	the	pH	probe	
into	the	solution.	Use	a	pH	probe	stand	to	hold	the	pH	probe	in	place	and	leave	the	probe	until	
the	reading	given	out	stabilises	and	notes	the	value.	The	pH	level	will	be	measured	3	times	to	
obtain	 an	 average	reading.	Rinse	 the	pH	probe	with	 water	(use	squeeze	bottle	over	a	beaker)	
between	taking	each	reading.	
Once	testing	is	complete,	make	up	a	1%	w/v	Virkon	solution	and	place	the	probe	in	this	solution	
for	10-15mins	before	storing	the	pH	probe	in	a	solution	of	pH	4	buffer	solution.				
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9.13 Appendix 13: COSHH form covering the handling of peritoneal fluid 
samples in the laboratory 
 
 
 
 
 1 
 
 
CONTROL OF SUBSTANCES HAZARDOUS TO HEALTH 
RISK ASSESSMENT FORM  S21 
 
 
Before completing this form, please read the University’s COSHH Local Rules and Guidance Notes 
provided as separate documents in order to ensure the form is completed properly. 
 
This form MUST BE COMPLETED prior to the commencement of any work involving hazardous 
substances, so that a suitable and sufficient assessment of any potential health risks can be made. 
 
Individuals working under this risk assessment have a legal responsibility under the Health and Safety at 
Work Act, 1974 to ensure they are aware of the hazards associated with the work activities they are 
undertaking and that they follow the control measures stipulated to safeguard the health and safety of 
themselves and others. 
 
SECTION 1 
 
1.1     OPERATION / ACTIVITY                                                 Complete the relevant details of the activity being assessed. 
 
Title: 
 
     Working with human peritoneal fluid (hazard group 2) 
 
Location(s) of work  
 
     Biomedical Engineering Lab, Wolfson 
Building 
 
Ref. No. 
 
      
 
Brief description:        
 Permission has been obtained from the NHS Greater Glasgow and Clyde Research and Development 
(R&D) department to test the lactate and pH levels of peritoneal fluid obtained from patients undergoing 
ascitic drainage and those who have a peritoneal drain in-situ following colorectal surgery. Collection of 
samples from the first group has been approved by the Wales REC 7 NHS Ethics committee (reference 
no. 16/WA/0142) and for the post-operative patients by the Leicester Central NHS Ethics committee 
(reference no. 16/EM/0394). 10-15ml samples of peritoneal fluid will be obtained from patients at the Royal 
Alexandra Hospital in Paisley via normal clinical protocols. The samples will be collected into universal 
white-topped containers. These samples will be obtained and handled in the hospital as per the usual 
hospital standards.  
 
When consulting the University guidelines on the transport of infectious substances and biological 
specimens’, human ascitic fluid falls under the classification ‘Category B biological substance (UN 3373)’. 
In accordance with the guidelines the specimen will be triple packed in a container which meets the 
requirements for transfer of a UN3373 substance. Briefly, the universal white top container will be placed in 
a secondary pack and a rigid outer pack. Between the specimen and secondary pack there will be 
absorbance pads. On the outside of the container a hazard label (UN 3373) will be displayed. Alongside 
this it will say ‘Biological Substance, Category B’. The name/address of the person dispatching the 
specimen and the name/address of the person receiving the specimen will also be displayed. The 
researcher’s name and contact number will be displayed as an emergency contact. The hospital has a 
contract with a taxi firm for the transport of clinical substances. They will be used to transport the sample 
from the hospital to the Wolfson Centre. 
 
Transfer of the samples from the RAH to University of Strathclyde is covered by the generic material 
transfer agreement (MTA) that is in place between “Glasgow Biomedicine and The University of 
Strathclyde”. This has been confirmed with Jane Hair from Biorepository and Paul Dearie from NHS GGC 
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R&D department. A copy of the generic MTA is attached to this form. 
 
Samples will taken to lab 4.09. An area of the lab with be clearly demarcated with biohazard tape and 
signage. The samples will be placed in this area. Signs will be present on the door into the lab indicating 
the presence of potentially hazardous biological material. Experimental work will take place in the 
demarcated are of the lab. The lab is secure as access to the Wolfson building is restricted and requires a 
swipe card for entry. All persons with swipe card access are aware that biologically hazardous substances 
may be present and are alert to signs indicating where this is the case.  
 
The samples will have their lactate and pH levels measured. These experiments will be carried out as per 
the attached protocols. Following use the samples will be disposed of through clinical waste in accordance 
with university policy and specific disposal instructions (see section 7). 
 
 
 
 
1.2 PERSON RESPONSIBLE FOR THIS WORK 
 
Name: 
 
     Prof Patricia Connolly 
 
Position: 
 
      
 
Department: 
  
Signature: 
 
      
 
 
 
1.3     PERSON CONDUCTING THIS ASSESSMENT 
 
Name: 
 
     Emma Wright 
 
Position: 
 
Visiting Researcher      
 
Date risk assessment undertaken:  
 
     19/01/17 
 
Signature: 
 
      
 
 
 
1.4      ASSESSMENT REVIEW HISTORY 
This assessment should be reviewed immediately if there is any reason to suppose that the original assessment is no longer valid.  Otherwise, the 
assessment should be reviewed annually.  The responsible person must ensure that this risk assessment remains valid during use. 
REVIEW HISTORY  
 Review 1 Review 2 Review 3 Review 4 
Due date                         
Date conducted                         
Conducted by                         
 
 
A SIGNED COPY OF THIS ASSESSMENT MUST BE RETAINED BY THE DEPARTMENT 
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SECTION 2 
2.1:     SUMMARY CLASSIFICATION OF HAZARDOUS SUBSTANCES 
Substances can be regarded as hazardous not just in the form in which they occur in the work activity but also in by-products and as intermediate substances in processes and waste residues. 
 
CHEMICAL V. Toxic  Toxic   Corrosive   Harmful   Mutagenic Category      1    2   3  
Irritant  
 
Cytotoxic        
Flammable  Oxidising  
Explosive  
Carcinogenic Category: 1    2   3  
Toxic to reproductive system  
Environment  Respiratory sensitiser   
 
Biological Hazard Group         1    2 x  3  
 
2.2:     HAZARDS 
List all the details of the hazardous substance  used in the appropriate columns.  Name of the substance including the chemical name where known.  Quantity used in the process.  Form of substance in use (e.g. 
liquid, powder, dust etc).  The nature of the hazard should state whether the substance is very toxic, toxic, corrosive, harmful or irritant etc.  For biological substances this should include the Hazard Grouping.  If the 
substance has a Workplace Exposure Limit (WEL) it should be entered here.  State whether a Material Safety Datasheet (MSDS) is available for the substance. 
 
Substance 
 
Quantity 
To be used 
 
Form of 
Substance 
Nature of Hazard or 
Biological Hazard 
Grouping 
WEL 
(ppm or mg/m3) 
15 min or 8 hr 
 
MSDS 
Available? 
 
     Human peritoneal (ascitic) 
fluid 
10-15mls 
 
Liquid 
Biological hazard group 2  Yes             No x 
      
 
Yes    No  
      
 
      Sodium Hydroxide 
 
 Max. 100mL 
 
Liquid 
(0.7%) 
H319:Causes serious eye damage 
H315:Cause skin irritation 
Yes             No x 
      
 
Yes    No  
      
 
      Virkon 
 
     500mL 
 
Powder/Liqu
id (2%w/v) 
      H271:May cause fire or 
explosion; strong oxidiser 
H315: Cause skin irritation 
H318: Cause serious eye damage 
H335: May cause respiratory 
irritation 
Yes             No x 
      
 
Yes     No  
      
 
               Ethanol 
 
     10ml 
 
Liquid 
      H225: Highly flammable 
liquid and vapour 
H319: Causes serious eye damage 
Yes             No x 
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
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      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
2.2:     HAZARDS 
List all the details of the hazardous substance(s) used in the appropriate columns.  Name of the substance including the chemical name where known.  Quantity used in the process.  Form of substance in use (e.g. 
liquid, powder, dust etc).  The nature of the hazard should state whether the substance is very toxic, toxic, corrosive, harmful or irritant etc.  For biological substances this should include the Hazard Grouping.  If the 
substance has a Workplace Exposure Limit (WEL) it should be entered here.  State whether a Material Safety Datasheet (MSDS) is available for the substance. 
 
Substance 
 
Quantity 
To be used 
 
Form of 
Substance 
Nature of Hazard or 
Biological Hazard 
Grouping 
WEL 
(ppm or mg/m3) 
15 min or 8 hr 
 
MSDS 
Available? 
 
      
 
      
 
  
      Yes             No  
      
 
Yes    No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes    No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
      
 
      
 
      
 
  
      Yes             No  
      
 
Yes     No  
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2.3:     ROUTE(S) BY WHICH THE SUBSTANCES ARE HAZARDOUS                   Complete  all boxes that may apply 
Inhalation 
X 
Direct contact: skin, eyes 
x 
Skin absorption 
  
Injection (via sharps) 
x 
Ingestion 
x 
 
 
 
2.4:     PROCESS FACTORS INFLUENCING THE RISK OF EXPOSURE 
 
 Weighing 
 
 
x Pipetting 
 
 
 Filtering 
 
 
X Shaking / Mixing 
 
 
 Centrifugation 
 
 Use of sharps 
 
 Elevated temperatures 
 
 High pressure 
 
 Sonication  
 
 Other (specify):        
 
 
 
2.5:     COMMENTS ON THE HAZARDS ASSOCIATED WITH THE SUBSTANCES 
List any known or suspected health hazards associated with potential exposures to the substances used or generated in the operation or activity.   
 
Normally within the peritoneal cavity there is up to 25ml of fluid present (peritoneal fluid). In a range of disease states, 
e.g. liver cirrhosis and heart failure, excess fluid can be created and accumulates in the peritoneal cavity. This excess 
peritoneal fluid generated by the body is often called ‘ascites’. A sample of this fluid is often obtained sent for 
biochemical and microbiological analysis to help diagnose the underlying condition.  
 
Following colorectal surgery there can also be increased levels of peritoneal fluid in the abdomen. This is due to 
tissue reaction to the surgery. In addition, the abdominal cavity is irrigated at the end of an operation with saline 
solution and the majority of this is removed via suction. However, inevitably some wash fluid remains so some of the 
additional fluid found in the peritoneal cavity may be residual saline wash. If a complication occurs, e.g. an 
anastomotic leak, then bowel content will leak into the peritoneal cavity and be present in the peritoneal fluid. The 
most common bacteria cultured from peritoneal fluid following colorectal surgery are e coli and e faecalis (Komen et 
al 2013). Transmission of these bacteria is by the faecal-oral route. These organisms are classified as hazard group 2 
in the HSE approved list of biological agents.  
 
Like any bodily fluid, peritoneal fluid has the potential to contain blood borne viruses (BBV) but infection is unlikely 
when diagnostic tests are being performed rather than cell/viral culture. In particular, the HSE guidelines state in 
paragraph 184 that work such as clinical chemistry on body fluid substances that contain or may contain BBVs can 
be carried out at containment level 2 (see attached HSE document). Taking this into consideration, ascites/peritoneal 
fluid, is considered to be a hazard group 2 substance. It is listed on the University of Strathclyde list of ‘Chemicals 
and Biological Substances’ as a hazard group 2 substance. In accordance with the university ‘Guidance on the 
handling of blood and blood products’, bodily fluids, where the screening status for BBVs is unknown, can be handled 
at category 2 containment. Use of a Microbiological Safety Cabinet is not specifically required.  
 
 
The samples have the potential to cause laboratory acquired infection if they are ingested, inhaled or come into 
contact with open cuts/wounds or mucous membranes. Aerosol production is expected to be minimal. People working 
with peritoneal fluid samples should wear personal protective equipment (PPE) in the form of a laboratory coat, face 
shield and disposable nitrile gloves. Spillages should be cleared up using the disinfectant virkon. The laboratory 
standard operating procedures that will be used to ensure safe handling of samples are outlined below in section 11, 
experimental protocols are attached to the COSHH form.  
 
 
 
Reference: 
Komen N, Morsink MC, Beiboer S, Miggelbrink A, Willemsen P, van der Harst E, Lange JF and van 
Leeuwen WB (2009) Detection of colon flora in peritoneal drain fluid after colorectal surgery: can RT-PCR 
play a role in diagnosing anastomotic leakage? J Microbiol Methods 79 (1):67-70. 
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SECTION 3.0 
 
3.0:    IDENTIFICATION OF THOSE AT RISK OF EXPOSURE 
Identify all categories of individuals who may be affected either directly or indirectly through the work activity. 
 
x Dept. Staff 
 
 Estates/Cleaning staff 
 
x Pregnant Women or Women of reproductive age 
 
x Postgraduate Students 
 
 Undergraduate students 
 
 Young Workers 
 
 Inexperienced Workers 
 
 Immuno-compromised  
     Individuals 
 
 Contractors 
 
 Visitors  
 
 Other       
 
 
SECTION 4.0  
List the  control measures taken to reduce risks.  Can any substances be eliminated, or substituted with a less hazardous one?  Are there any physical controls such 
as enclosure, local exhaust ventilation and PPE etc.  Do not forget other controls including safe working procedures, information, instruction, training and 
supervision.  Include details of maintenance and test schedules for physical controls. 
 
4.1:     CONTROL MEASURES – ELIMINATION / SUBSITUTION  
 
Can any of the hazardous substances identified or the procedures required for this activity be 
eliminated or substituted with a less hazardous substance or procedure (e.g. by changing from a 
fine powder to a liquid form of the chemical)?  If possible, please give details below: 
 
Yes  
 
No x 
 
For research purposes, the fluid has in the same condition as it is taken from patients in order to properly determine 
lactate and pH levels. 
 
 
 
 
4.2:     CONTROL MEASURES – ENGINEERING & DESIGN  
 
  
 
Work can be carried out on the open bench without the use of control measures.   
 
  
 
Local Exhaust Ventilation - Fume cupboard (FC) 
 
FC No.       
 
Location:        
 
  
 
Local Exhaust Ventilation (Other Partial Enclosure) 
 
Specify:       
 
  
 
Local Exhaust Ventilation (Full Enclosure) 
 
Specify:       
 
  
 
Microbiological Safety Cabinet 
 
Class:   
 
Cabinet No.       
 
Location:        
 
x  
 
Biological Laboratory Containment Level: 
 
2 
 
  
 
Laminar Flow Cabinet 
 
Specify:       
 
x  
 
Other: please specify Work will be carried out in lab 4.09. It will take place in a clearly designated area of the 
lab. The bench top area will be marked off with tape and hazard signs will be displayed in the lab and on 
doors leading into the lab to alert staff/students to the hazard. Work will only be undertaken by those who 
have read, understood and signed this risk assessment. 
 
 
 
4.3:     ADMINISTRATIVE CONTROLS  e.g. Risk  assessments, SOPs, signage 
Entry to lab 4.09 where the work is undertaken is restricted through signage on door.   
 
All staff and students conducting work on this project must have read and signed this risk assessment prior to 
commencing work. 
 
Staff and students working with biological material must ensure that they have completed the BP2 biological safety 
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form on Pegasus.  The BP2 form must be completed annually. 
 
 
      
 
 
 
4.4:     INSTRUCTION AND TRAINING 
The following online University of Strathclyde biological safety modules must be completed by all staff and students 
who carry out work on peritoneal fluid: 
- Module 1 Basic Biological Information 
- Module 2 Controlling the Risk of Exposure to Infectious Agents 
- Module 3 Safe working with Infectious Agents 
 
These modules are available online under the University of Strathclyde Health and Safety webpage: 
http://www.strath.ac.uk/wellbeing/safetyhealthandwellbeing/healthandsafetytraining/ 
Any problems accessing the training should be referred to the departmental safety convener. 
 
Only the researcher, or other suitably qualified postgraduate students/members of staff who have read, signed and 
understood the relevant COSHH and risk assessments will work with peritoneal fluid samples. The researcher will 
demonstrate the protocols on a substitute (model) fluid for pipetting, experiment and disposal before the work starts.  
 
      
 
 
 
4.5:     SUPERVISION AND LONE WORKING 
 
x  
 
The supervisor will approve straightforward routine work in progress. 
 
  
 
The supervisor will specifically approve the safe system of work. 
 
  
 
The supervisor will provide supervision personally to control the work. 
 
             Is lone working permitted for this activity? 
A key aspect of our research is looking at lactate and pH levels in peritoneal drain fluid 
collected from patients on post-operative days 1, 2 and 3. The samples need to be tested 
shortly after collection from the drain. In the RAH there are 2 operating lists on a Thursday and 
2 on a Friday. This means that post-operative days 1-3 fall over the weekend. For this reason 
lone working at the weekend is required so that these samples can be analysed in a timely 
manner following collection. The experiments being undertaken in the lab are low risk and 
therefore Prof Connolly feels that lone working is appropriate. However, when possible 2 
people will work in the lab together testing the samples. 
 
Yes x 
 
 
 
 
 
4.6:     CONTROL MEASURES – PERSONAL PROTECTIVE EQUIPMENT 
 
Eyes / Face 
 
x Safety spectacles 
 
 Goggles  
 
X Face shield 
 
(specify) :  General lab 
 
Hand 
 
x Gloves 
 
(specify): Disposable nitrile gloves EN374 
 
Respiratory 
 
 Disposable respirator  
     Type       
 
 Full-face respirator  
     Type       
 
 Reusable half-face respirator 
     Type       
  
 Powered hood  
     Type       
 
 Breathing apparatus 
     Type       
 
 Other  (specify)       
 
Clothing 
 
 Coverall  
Specify:       
 
x Laboratory coat 
Specify: Blue side 
fastening Howie style 
 
 Side –fastening coat 
Specify:       
 
 Apron / Gown 
Specify:       
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coat 
  
Other   (specify)       
 
 
 
4.7:     MONITORING AND HEALTH SURVIELLANCE 
If monitoring or health surveillance is required for any of the hazardous substances relating to this assessment specify how this will be carried out. 
 
Will monitoring for airborne contaminants be required?  If “yes”, give details below: 
 
Yes  
 
No x 
 
      
 
Will health surveillance for workers be required?  If “yes”, give details below: 
 
Yes  
 
No x 
 
      
 
 
 
SECTION 5.0:     RISK EVALUATION RATING 
Use the information above, and the guidance from the Hazard Identification and Risk Assessment section, taking into account the control measures in operation, 
decide the applicable SEVERITY and LIKELIHOOD, and ESTIMATE the risk rating 
SEVERITY 
1.  Negligible injury or illness. 
2.  Minor injury or illness. 
3.  Moderate injury or illness. 
4.  Major injury or illness. 
5.  Extreme loss, fatality, disaster. 
LIKELIHOOD 
1.  Very Unlikely - Rarely happens 
2.  Unlikely to occur. 
3.  Possibly can occur. 
4.  Likely to occur. 
5.  Very Likely to occur. 
RATING 
 
Rating =  
Severity x Likelihood 
 
4 2 8 
 
 
 
SECTION 6.0:     STORAGE, TRANSPORT, HANDLING AND USE 
Highlight any special circumstances relating to the safe method of storing, handling and using the substances.  If there are any special requirements highlight 
them here. 
 
Samples taken at RAH will be in universal white top containers. For transport, samples will be boxed and labelled as 
a ‘Category B biological substance (UN 3373)’ as outlined in section 1. Sample will be dispatched from the RAH 
to the Wolfson Centre in an authorised account taxi. On arrival at the Wolfson Centre samples will be taken to lab 
4.09 and placed in the designated area. The samples will be handled and tested as per the protocol/SOP outlined in 
section 11.  
 
During the work a container of Virkon solution will be in the designated area of the lab. All materials such as pipette 
tips and plate readers will be placed in the solution after being used. Used peritoneal fluid will also be poured into the 
Virkon solution. They will remain in the solution for 24 hours after which the liquid will be poured down the sink and 
plastic material will be autoclaved before disposal in the clinical waste stream.  
 
Ethanol stock solution must be stored in the safety cabinet in W402. Lactate assay kit must be stored in fridge.  
 
 
 
 
 
SECTION 7.0:     WASTE DISPOSAL ROUTES 
State how the substances or any excess or waste will be disposed of.  If there are any special requirements due to the nature of the material, or if it should be 
treated as special waste, identify what procedures will be used for safe disposal. 
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In-house to Council waste collection, after rendering safe. 
 
  
 
In-house to drain, after rendering safe. 
 
  
 
Solid chemical waste (disposed via Hazardous Waste Service) 
 
  
 
Liquid chemical waste (disposed via Hazardous Waste Service) 
 
  
 
Solvent waste (disposed via Hazardous Waste Service) 
 
x 
 
Biological Waste (disposed via Clinical Waste Service) 
 
x  
 
Other: please specify: During the work a container with Virkon solution will be in the designated area of the 
lab. All materials such as pipette tips and plate readers will be placed in the solution after being used. Used 
peritoneal fluid will also be poured into the Virkon solution. They will remain in the solution for 24 hours after 
which the liquid will be poured down the sink and plastic material will be autoclaved before disposal in the 
clinical waste stream.  
      
 
 
 
SECTION 8.0:     SPILLAGE / EMERGENCY PROCEDURES 
Identify any specific instructions or requirements in the event of a spillage or emergency. 
 
  
 
Written emergency instructions will be provided to workers and others who might be affected. 
 
Specify:       
 
x  
 
First Aid Provisions (for example, eye wash station, body shower, antidote, specialist hospital etc.) 
 
Specify: An eye wash and first aid kit is located within the laboratory. If fluid gets in a persons eye they 
should immediately was the eye out and then seek medical assistance. 
 
 
 
x  
 
Specific Spillage Procedures (such as neutralisation procedures, absorption granules disinfectants etc.) 
 
Specify: Virkon will be available at all times in the lab. In the event of a spillage the virkon should be poured 
over the fluid, left for 3 minutes then mopped up with a tissue. The contaminated tissues should be placed in 
a sterile bag for autoclaving. PPE should be worn when this is undertaken. 
 
  
 
Other Specify:       
 
 
 
SECTION 9.0:    SUBSTANCES / ACTIVITY SUBJECT TO OTHER LEGISLATION 
Refer to the Guidance Note to complete this section for any chemical substances / biological agents or activity which may be subject to other 
legislation.  Where other legislation is applicable, please cross-reference with the appropriate details  
 
 Anti-Terrorism, Crime and Security Act 2001 (ATCSA) 
 
      
 
 Specified Animal Pathogens Order 1998 (SAPO) 
 
      
 
 Home Office Drug Precursors or Controlled Drugs 
 
      
 
 Dangerous Substances and Explosive Atmospheres Regulations (DSEAR) 
 
      
 
 Risk Assessments 
 
      
 
x Other (specify):  Register as a biological worker with safety services using 
BP2 online form. 
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SECTION 10.0:    SUMMARY OF ASSESSMENT RECOMMENDATIONS 
Complete this section after the assessment.  Include brief details of the assessment findings.  Include details on all control measures e.g. monitoring, training, 
PPE, spillage procedures, health surveillance or any other relevant details. 
 
1. Only fully trained staff will work with ascitic fluid 
2. PPE consisting of labcoat, face shield, and gloves should be worn. 
3. Any cuts/open wounds should be covered with a dressing. 
4. All spillages should be disinfected in accordance with the specified spillage procedure. 
5. Peritoneal fluid samples should be clearly labelled and kept in a sealed container in a designated area of lab 4.09. 
Samples should be on the bench for the duration of the experiment only. At the end of the experiment the samples 
must be disposed of as described in section 7.  
6. Hands should be washed with soap and water upon entry and exit of the lab. 
7.  Only the Standard procedures (section 11) for handling peritoneal fluid and protocols for testing lactate and pH 
(see attachments) should be followed to reduced the likelihood of spillage or contamination and these are the only 
procedures authorised for these samples by this COSHH form 
8. University ethical approval must be granted before any work can start. 
 
 
 
 
 
 
 
 
SECTION 11.0:    SAFE SYSTEM OF WORK (SOW) / STANDARD OPERATING PROCEDURE (SOP)                                          
Specify if a SOW or SOP is required for the work activity and if so complete or attach the details of this. 
 
Is a safe system of work or standard operating procedure deemed necessary for this work? 
 
Yes x 
 
No  
 
If yes, please give details:   
 
11.1 Hazards and Risks 
 
Ascitic Fluid 
Ascitic fluid that is going be used in this work will be contaminated with blood and bacteria. Though it is possible to 
become infected by the fluid, it is unlikely to do so as long as good laboratory practice is followed. The route by which 
ascitic fluid is hazardous to your health is through ingestion, inhalation by direct contact with broken skin. The aerosol 
production is expected to be minimal.  
 
Chemical Hazards and Risks 
Ethanol is classified as harmful, flammable and an irritant. Use only in small amounts and store the stock solution in 
the fire cabinet in W4.02. 
 
Virkon and Sodium Hydroxide are classified as Irritants. 
 
11.2 Actions to be taken before commencing work 
 
Training 
Complete the online biological safety modules 1-3 provided by Safety Services. Additionally, if you are involved in the 
transport of biological fluid from the hospital to the university, also complete Biological Safety Module 6. More 
information can be found at:  
 
http://www.strath.ac.uk/wellbeing/safetyhealthandwellbeing/healthandsafetytraining/ 
 
Complete lab safety induction with the departmental safety convener and training on machinery to be used for the 
experiment.  
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Equipment/Materials Required 
Prepare 70% Ethanol Solution and keep blue roll nearby for spillages. 
 
PPE Required 
Face sheild and Nitrile gloves (EN374-2) to be used when handling chemicals and biological fluid. Use of a Howie 
style lab coat is also recommended. 
 
11.3 Transport and Storage 
 
Peritoneal fluid must be transported and stored in a triple packaging system in accordance with UN3373. The first 
layer being the bag containing the ascitic fluid. The secondary layer of an airtight bag large enough to hold layer the 
first layer. Being the first layer and second, there must be absorbent material that is capable of holding all the ascitic 
fluid should the first layer break. The third (outer) layer that allows transit of the fluid (airtight). This outer container 
must state “BIOLOGICAL SUBSTANCE, CATEGORY B”. Additionally, a diamond (2mm thick) with “UN3373” stated 
in the middle (at least 6mm high) must be put on this outer surface. Researcher details must be attached to the 
container including a phone number and from and to addresses. Hospital approved taxi service must be used and the 
driver must be told before transport occurs. Peritoneal fluid can be stored at room temperature, in the fridge or freezer 
as long as the triple packing system is used.  
 
Ethanol must be stored in the fire cabinet in room W4.02. The lactate assay kit (containing sodium hydroxide) must 
be stored in the fridge.  
 
11.4 Areas where work can be performed 
 
Work will be performed in a designated area of lab 4.09. The area will be marked off with biohazard tape and signs 
nearby to indicate that a biological substance is being handled in this area. If machinery outside this area is required 
then as much of the experiment as possible will be prepared in the designated area prior to transfer to the relevant 
area of the lab e.g. plate reader. Before and after work is carried out the bench top should be wiped down with 70% 
ethanol. Any spillages will be dealt with as outlined below. 
 
 
11.5 Step by Step Procedure 
 
1) Wear lab coat, face shield and gloves when in labs 
 
2) Avoid hand to mouth contact when in labs. Eating, drinking and use of mobile phones and headphone are not 
allowed. 
 
3) Prepare 70% ethanol solution in a spray bottle and keep nearby working area. Additionally keep absorbent tissue 
and Virkon nearby. This is in preparation in case of spills. Additionally, if work is needs to be done in another lab, 
place plastic sheet (wipe down with Trigene prior to use) in appropriate area and mark area as a biohazard area. 
Prepare machinery needed to minimise the amount of time samples are outside the demarcated area.  
 
4) Remove peritoneal fluid from triple packing only within the designated area of lab 4.09.  
 
6) Prepare the sample for the experiment within the designated area. Carry out the experiment within the designated 
area if possible. If not then place a cover over the prepared sample for transfer to another area of the lab. Pre-
prepare machines needed for the experiment and wipe them down with ethanol before and after use. Spillages in the 
plate reader are dealt with as per section 11.8. 
 
7) At end of experiments, dispose of peritoneal fluid (see 11.8). Wipe down the bench with Trigene. 
 
8) Wash hands thoroughly when leaving labs.    
 
11.6 Spillages 
 
Small spillages: Must be cleaned with 2%w/v Virkon or 70% ethanol solution and absorbent tissue. 
Large spillages: Use of a spill kit (found in W4.05) or cover with Virkon powder and then clean with 2% w/v Virkon. 
Spillages in the plate reader: if this occurs Brian Cartilage (lab technician) is to be contacted and he will ensure the 
machine is adequately cleaned and disinfected. 
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Ensure that spillage area has been fully disinfected.  
 
11.7 First Aid Procedure 
 
Peritoneal Fluid 
 
Skin Contact: Wash hands immediately with soap and warm water. Remove and autoclave contaminated clothing. 
Ingestion: Seek medical attention 
Eyes: Rinse with water using eye washing station and seek medical attention. 
 
Ethanol, Sodium Hydroxide and Virkon 
 
Skin Contact: Wash off immediately with soap and warm water. Remove contaminated clothing 
Inhalation: Move to well ventilated area and seek medical attention. 
Ingestion: Seek medical attention immediately. 
Eye: Rinse with water using eye washing station (for at least 15 mins) and seek medical attention. 
 
First Aid can be received by calling extension 2222 
 
11.8 Disposal Procedures 
 
Peritoneal fluid can be poured into 2% w/v Virkon solution (volume of Virkon must be greater than the amount of 
biological fluid) for inactivation. All contaminated solid items (including gloves) must also be placed in the solution of 
2% w/v Virkon solution as well. Leave for 24 hours and dispose of the fluid down the sink. All solid items should be 
placed in autoclave bags and be autoclaved (W4.05) at 126°C.  
 
For equipment that cannot be autoclaved or reusable equipment: these items can be placed in 1% w/v Virkon solution 
for at least 15 mins before being stored away. 
 
 
SECTION 12.0:    RECEIPT AND AGREEMENT OF ASSESSMENT    (Reference No.      ) 
 
All individuals who are working to this risk assessment must sign and date to acknowledge that they have read and are aware of this risk 
assessment and the measures taken to safeguard the health of them and others.  If this assessment is modified in any way, all current 
signatories must sign again to show they are aware of the modifications made. 
 
 Version 1  Version 2 Version 3 
 
NAME 
 
SIGNATURE 
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Date of Revision Next review date 
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